[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"American Surgical Company\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":407},{"warningLetters":4,"total":406},[5,31,53,73,96,118,137,159,180,198,220,240,260,277,298,317,335,352,368,390],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},746,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-21T04:00:00Z\">07\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025\">Onkos Surgical, Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick J. Treacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Onkos Surgical, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>77 E Halsey Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ptreacy@onkossurgical.com\"> ptreacy@onkossurgical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 712573\u003C\u002Fp>\u003Cp>July 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patrick J. Treacy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “\u003Cem>ensure compliance to ISO 13485\u003C\u002Fem>” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier \u003Cstrong>(b)(4)\u003C\u002Fstrong> Final Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>i. You approved the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***\u003Cem>The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts\u003C\u002Fem> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)***.”\u003C\u002Fp>\u003Cp>Similarly, you approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***\u003Cem>To validate the cleaning process, parts shall be cleaned using\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>over\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>runs***To create a\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>batch of product***Clean what is expected to be a\u003C\u002Fem> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” load in \u003Cstrong>(b)(4)\u003C\u002Fstrong>***\u003Cem>A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “\u003Cem>Assessment of Product Change or New Product Adoption for Cleaning Processes\u003C\u002Fem>” reports. For example:\u003C\u002Fp>\u003Cp> The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have a similar or less complex design?\u003C\u002Fem>” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\u003C\u002Fp>\u003Cp> The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?\u003C\u002Fem>” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and comparison devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), which contain no holes.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>Although requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In reviewing the “Process Validation of***\u003Cstrong>(b)(4)\u003C\u002Fstrong> Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\u003C\u002Fp>\u003Cp>i. The rationale in the PQ report to accept deviations from the nominal operating range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F and control charts indicated a lower control limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (Deviation 3) does not take into account the vast differences in sample sizes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and acceptance criterion (Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\u003C\u002Fp>\u003Cp>ii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “\u003Cem>mass recovered from gravimetric\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> and corrected “\u003Cem>mass recovered from\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> to 0.00 mg in the “\u003Cem>Gravimetric Extraction Summary\u003C\u002Fem>” table during gravimetric testing, thereby passing the acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fcm\u003Csup>2\u003C\u002Fsup> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). For example, during OQ, an \u003Cstrong>(b)(4)\u003C\u002Fstrong> value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\u003C\u002Fp>\u003Cp>c. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices &amp; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Instruments\u003C\u002Fp>\u003Cp>You approved the adoption of new products into this supplier’s existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\u003C\u002Fp>\u003Cp>i. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> or broken up into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>ii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 1\u002F15\u002F26, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (target date not provided), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 3\u002F1\u002F26 at the latest.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification by family was completed to establish new limits placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to \u003Cstrong>(b)(4)\u003C\u002Fstrong> internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to conduct an assessment for worst-case part challenge per part family by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and will fall under controls established for therein.\u003C\u002Fp>\u003Cp>Corrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\u003C\u002Fp>\u003Cp>However, no target date was provided for the new cleaning validation planned for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis of infection complaints “***\u003Cem>is more than\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>above the literature rate or\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>are above the literature rate\u003C\u002Fem>***” for a given procedure type. For example, you did not initiate CAPAs when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis for infection complaints exceeded the rates of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for the distal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for proximal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for total femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) established in the journal article by Henderson et. al “\u003Cem>Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review\u003C\u002Fem>” (Journal Bone and Joint Surgery 2011) by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection rates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reporting for infections and \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***\u003Cem>for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated\u003C\u002Fem>***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), PCR 05132024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and PCR 10172024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% through \u003Cstrong>(b)(4)\u003C\u002Fstrong>% since April 1, 2019.\u003C\u002Fp>\u003Cp>An update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by a revision of the corresponding risk tables by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***\u003Cem>identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data\u003C\u002Fem>***” of ELEOS Implant Devices received from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\u003C\u002Fp>\u003Cp>a. You reviewed and approved incoming DHRs for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each were inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each was inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. You reviewed and approved incoming DHRs (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) where sampling plans utilized an AQL (acceptable quality limit) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was inspected at an AQL level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> during final inspection on 1\u002F23\u002F24.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>a. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>b. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>c. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Len Tokish\u003Cbr>VP of Quality Assurance &amp; Regulatory Affairs\u003Cbr>ltokish@onkossurgical.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick J. Treacy\n\nRecipient Title\n\nPresident and CEO\n\nOnkos Surgical, Inc.\n\n77 E Halsey Rd\n\nParsippany, NJ 07054\n\nUnited States\n\nptreacy@onkossurgical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712573\nJuly 21, 2025\nDear Mr. Patrick J. Treacy:\nDuring an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\nSpecifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “ensure compliance to ISO 13485” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\na. (b)(4) – Tier (b)(4) Final Cleaner of ELEOS Implant Devices\ni. You approved the (b)(4) cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts ((b)(4))***.”\nSimilarly, you approved (b)(4) cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of (b)(4) and (b)(4) per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***To validate the cleaning process, parts shall be cleaned using (b)(4) over (b)(4) runs***To create a (b)(4) batch of product***Clean what is expected to be a “(b)(4)” load in (b)(4)***A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production***.”\nii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing (b)(4) cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “Assessment of Product Change or New Product Adoption for Cleaning Processes” reports. For example:\n The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have a similar or less complex design?” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\n The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the (b)(4) device ((b)(4)) and comparison devices ((b)(4)), which contain no holes.\nb. (b)(4) – Tier 1 (b)(4) Cleaner of ELEOS Implant Devices\nAlthough requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, (b)(4). In reviewing the “Process Validation of***(b)(4) Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\ni. The rationale in the PQ report to accept deviations from the nominal operating range of (b)(4)°F ((b)(4), and (b)(4)°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as (b)(4)°F and control charts indicated a lower control limit of (b)(4)°F (Deviation 3) does not take into account the vast differences in sample sizes ((b)(4) vs. (b)(4)) and acceptance criterion (Ppk (b)(4) vs. Ppk (b)(4)) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\nii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “mass recovered from gravimetric (b)(4) and corrected “mass recovered from (b)(4) to 0.00 mg in the “Gravimetric Extraction Summary” table during gravimetric testing, thereby passing the acceptance criteria of (b)(4) mg\u002Fcm2 ((b)(4)). For example, during OQ, an (b)(4) value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\nc. (b)(4) – (b)(4) Cleaner of ELEOS Implant Devices & (b)(4) Cleaner of ELEOS Instruments\nYou approved the adoption of new products into this supplier’s existing (b)(4) cleaning validations titled “(b)(4) Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “(b)(4) Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\ni. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a (b)(4) or broken up into (b)(4).\nii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was (b)(4) and (b)(4) respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was (b)(4) and (b)(4), respectively.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for (b)(4) by 1\u002F15\u002F26, (b)(4) (target date not provided), and (b)(4) by 3\u002F1\u002F26 at the latest.\nFor (b)(4), an assessment of worst-case part justification by family was completed to establish new limits placed on (b)(4), and (b)(4). You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to (b)(4) internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by (b)(4).\nFor (b)(4), an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a (b)(4) basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\nFor (b)(4), you plan to conduct an assessment for worst-case part challenge per part family by (b)(4). For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to (b)(4) for (b)(4) cleaning and will fall under controls established for therein.\nCorrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes ((b)(4)) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\nHowever, no target date was provided for the new cleaning validation planned for (b)(4). Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the (b)(4) analysis of infection complaints “***is more than (b)(4) above the literature rate or (b)(4) are above the literature rate***” for a given procedure type. For example, you did not initiate CAPAs when the (b)(4) analysis for infection complaints exceeded the rates of (b)(4)% for the distal femur ((b)(4)); (b)(4)% for proximal femur ((b)(4) and (b)(4)); and (b)(4)% for total femur ((b)(4) and (b)(4)) established in the journal article by Henderson et. al “Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review” (Journal Bone and Joint Surgery 2011) by (b)(4).\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of (b)(4) infection rates from (b)(4) to (b)(4) (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform (b)(4) trend reporting for infections and (b)(4) or (b)(4) trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\nSpecifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 ((b)(4)), PCR 05132024-1 ((b)(4)), and PCR 10172024-1 ((b)(4)) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at (b)(4)% through (b)(4)% since April 1, 2019.\nAn update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by (b)(4) followed by a revision of the corresponding risk tables by (b)(4). As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by (b)(4). Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\nSpecifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data***” of ELEOS Implant Devices received from (b)(4). during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the (b)(4) sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\na. You reviewed and approved incoming DHRs for Lot # (b)(4) and Lot # (b)(4) on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of (b)(4) was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of (b)(4) ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for (b)(4) each were inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4). Similarly, out of (b)(4) ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for (b)(4) each was inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4).\nb. You reviewed and approved incoming DHRs (Lot #: (b)(4)) where sampling plans utilized an AQL (acceptable quality limit) of (b)(4) or (b)(4) to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of (b)(4) ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of (b)(4) was inspected at an AQL level of (b)(4) for Lot # (b)(4) during final inspection on 1\u002F23\u002F24.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by (b)(4); and develop (b)(4) inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on (b)(4) by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the (b)(4) devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\na. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nb. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nc. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nThe adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Len Tokish\nVP of Quality Assurance & Regulatory Affairs\nltokish@onkossurgical.com","Onkos Surgical, Inc.","onkos-surgical-inc-712573-07212025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025","2026-10-26T08:09:38.140644+00:00","Warning Letter","Issued","2025-07-29","712573","Medical Devices","Patrick J. Treacy","2026-08-19T16:32:45.913+00:00","VIA Electronic Mail","2025-07-21",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2333,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2022-11-21T18:00:00Z\">11\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-16T05:00:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcbd-american-shaman-llc-628753-11162022\">CBD American Shaman, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Unapproved New Drugs\u002FMisbranded\u002FCannabidiol (CBD) Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Stephen Vincent Sanders II\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CBD American Shaman, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2405 Southwest Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kansas City\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>64108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@cbdamericanshaman.com\"> support@cbdamericanshaman.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Drug Evaluation and Research\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Veterinary Medicine\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 16, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 628753\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sanders:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address CBDAmericanShaman.com in October 2022 and has determined that you take orders there for various human and animal products which you promote as products containing cannabidiol (CBD). We also reviewed your social media websites at www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, which link to your website cbdamericanshaman.com, to purchase your products. FDA has determined that your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)], because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products into interstate commerce under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)].\u003C\u002Fp>\n\n\u003Cp>FDA is particularly concerned that some of your products are in forms that are appealing to children. For example, your CBD Suckers, CBD Hard Candies, various Cookies [with] 10mg CBD per Serving, and various CBD Gummies products are all in forms that would be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children. Furthermore, your products have not been evaluated by the Agency for safety, effectiveness, and quality. As discussed below, CBD has been studied as a drug, and it is the active ingredient in the approved drug product Epidiolex. The use of untested drugs can have unpredictable and unintended consequences, especially in vulnerable populations, such as children. For example, children may be at greater risk for adverse reactions associated with certain drug products due to differences in the ability of children to absorb, metabolize, distribute, or excrete such drug products or their metabolites.\u003C\u002Fp>\n\n\u003Cp>You also market other products that consumers may confuse with traditional foods for humans, including CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey; therefore, with these products there is a risk of unintended consumption of the CBD ingredient by consumers.\u003C\u002Fp>\n\n\u003Cp>In addition, “CBD + ZINC OXIDE Sunscreen” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act [21 U.S.C. 355(a)], and is misbranded under section 502(ee) of the FD&amp;C Act [21 U.S.C. 352(ee)]. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act [21 U.S.C. 331(d) and (a)]. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>Further, the claims on your website and social media websites establish that your Canine 300 Tincture, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs products, which you promote as products containing CBD for use in pets, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&amp;C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. 351(a)(5)].\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods and 301(ll)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are foods to which CBD has been added. We analyzed a sample of your Grandma’s Raisin &amp; Pecan Hermit Cookies and confirmed that the product contains CBD. We also note that you may intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products. Specifically, you describe these gummy products as “adult gummy candy” and\u002For “the perfect way to satisfy your sweet tooth,” and the web pages for three of the products bear Nutrition Facts information.\u003Cbr>\n\u003Cbr>\nAs defined in section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)], the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act [21 U.S.C. 348(a)], and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. The available data raise serious concerns about potential harm from CBD added to conventional food. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)] and is subject to the provisions of section 409 of the FD&amp;C Act [21 U.S.C. 348]. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)] because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)]. To the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, they would be adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)] for the same reason.\u003C\u002Fp>\n\n\u003Cp>Further, in regard to your Cookies [with] 10mg CBD per Serving, CBD Suckers, CBD Hard Candies, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey, and, to the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, you should be aware that it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)], prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Human Drug and Misbranded Human Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“CBD + ZINC OXIDE Sunscreen” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(C)], because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as sunscreen.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the product’s labeling, including the claims observed on your website, www.cbdamericanshaman.com, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product includes, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“CBD + ZINC OXIDE Sunscreen . . . BROAD SPECTRUM SPF 35+ UVA • UVB” [from the label on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\u003C\u002Fp>\n\n\u003Cp>“Drug Facts . . . Active Ingredients [s] . . . Cannabidiol (Hemp Exract [sic] (Aerial Parts), Cannabidiol) 0.072% . . . Purpose . . . Sunscreen . . .” [from the label on your website, website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\u003C\u002Fp>\n\n\u003Cp>“This all natural CBD sunscreen lotion is a natural way to protect yourself from harmful UV rays while using an all-natural product that won’t harm you or our planet! This cbd infused sunscreen is 35+ SPF (broad spectrum) and is rated to block UVA and UVB rays. We use Zinc Oxide which is rated safe by EWG on their Skin Deep website and isn't hazardous for the environment like oxybenzone or octinoxate. There is 60mg of nano full-spectrum CBD oil per container.” [from the product information on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, “CBD + ZINC OXIDE Sunscreen” is a topical product intended for use as a sunscreen drug. As described below, this sunscreen drug is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)], if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. 355(a)]. No FDA-approved application pursuant to section 505 of the FD&amp;C Act [21 U.S.C. 355], is in effect for this drug product.\u003C\u002Fp>\n\n\u003Cp>“CBD + ZINC OXIDE Sunscreen” is a sunscreen drug subject to section 505G of the FD&amp;C Act [21 U.S.C. 355h], which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, sunscreen drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, this sunscreen drug product does not conform to the conditions of use specified in M020 because the product’s labeling lists CBD as an active ingredient in the Drug Facts panel. CBD is not an active ingredient allowed in any applicable final monograph. Thus, your “CBD + ZINC OXIDE Sunscreen” product does not meet the requirements under section 505G of the FD&amp;C Act, under which it would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>Furthermore, even if CBD could be considered an inactive ingredient in “CBD + ZINC OXIDE Sunscreen,” this product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&amp;C Act. In particular, such a product would not meet the conditions under section 505G(a)(1) or (2), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD has no known functional role as an inactive ingredient in a finished drug product.\u003C\u002Fp>\n\n\u003Cp>Additionally, an inactive ingredient should not exert pharmacological effects\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and must be safe when used at the intended dosage.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD, however, has a known pharmacological activity with demonstrated risks.\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> It is unknown whether the level of CBD used in your “CBD + ZINC OXIDE Sunscreen” drug product has pharmacological activity or poses any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Consequently, if CBD is intended to be an inactive ingredient in your “CBD + ZINC OXIDE Sunscreen” product, that product would not meet the general requirements for legal marketing of nonprescription drugs under sections 505G(a)(1) or (2) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “CBD + ZINC OXIDE Sunscreen” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) of the FD&amp;C Act. Introduction or delivery for introduction of such product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act [21 U.S.C. 331(d)].\u003C\u002Fp>\n\n\u003Cp>In addition, “CBD + ZINC OXIDE Sunscreen” is misbranded under section 502(ee) of the FD&amp;C Act [21 U.S.C. 352(ee)] because it is a nonprescription drug subject to section 505G of the FD&amp;C Act [21 U.S.C. 355h], is not the subject of an application approved under section 505 of the FD&amp;C Act [21 U.S.C. 355], and does not comply with the requirements under section 505G of the FD&amp;C Act [21 U.S.C. 355h]. Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act [21 U.S.C. 331(a) and (d)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our review of your firm’s website cbdamericanshaman.com and your social media websites, www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, FDA determined that your firm is marketing the unapproved new animal drugs Canine 300 Tincture, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs. Based on our review of your website and social media websites, these products are drugs under section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• On your webpage titled “CBD Dog Treats” under the header “How do CBD dog treats help your pup?”:\u003Cbr>\n&nbsp; o “You can use CBD American Shaman dog treats to relieve your furry friends with high levels of stress. We include CBD oil for dogs in each treat to help calm pets during a storm, firework show, loud party or any other situation that puts them in a state of panic.”\u003Cbr>\n&nbsp; o “They [CBD dog treats] may also help regulate heartbeat and blood pressure”\u003C\u002Fp>\n\n\u003Cp>• On your webpage titled “How To Choose A CBD Oil Product” under the header “Dogs”:\u003Cbr>\n&nbsp; o “If you would like to give your dog CBD every once in a while, like before the vet, for 4th of July fireworks, or when your dog may be extra anxious, we recommend any of our Dog CBD oils (https:\u002F\u002Fcbdamericanshaman.com\u002Fpets) and Soft CBD Dog Treats (https:\u002F\u002Fcbdamericanshaman.com\u002Fsoft-cbd-dog-treats).”\u003Cbr>\n\u003Cbr>\n• On your webpage titled “How To Choose A CBD Oil Product” under the header “Cats”:\u003Cbr>\no “Our feline CBD (https:\u002F\u002Fcbdamericanshaman.com\u002Ffeline-cbd-hemp-oil-tincture) oils are also great for when your cat needs help calming down or relaxing before a triggering event.”\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your social media websites that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• On your October 13, 2021 Instagram and Facebook posts: “Does your dog need support for #jointhealth or experience storm stress? Our unique recipe of high-quality CBD oil dog treats taste like peanut butter and will leave your pet wanting more.”\u003Cbr>\n• On your February 23, 2018 Facebook post: A photo of a dog is posted by CBD American Shaman with the caption “#funfactfriday: CBD Oil is becoming more and more available for use on pets! In FACT, veterinarians are finding #cbdoil useful in arthritis, stress, digestive issues, and much more.”\u003Cbr>\n&nbsp; o A comment on this post and response from CBD American Shaman:\u003Cbr>\n&nbsp; &nbsp;  Comment from follower: “I am considering trying this for our dog who had seizures.”\u003Cbr>\n&nbsp; &nbsp;  Response from CBD American Shaman: “A lot of people are having success with their dogs [sic] seizures using CBD.”\u003C\u002Fp>\n\n\u003Cp>• On your October 16, 2017 Facebook video post:\u003Cbr>\n&nbsp; o At the 20 second mark in the video a graphic states, “From arthritic canines to anxiety filled equines, CBD Oil is changing the way veterinarians and pet owners treat their furry family members.”\u003Cbr>\n&nbsp; o At the 28 second mark in the video a graphic with the heading “CBD Hemp Oil” states, “Whether a dog has cancer, seizures, or anxiety, cannabis oil can serve as an alternative medication to help treat symptoms.”\u003C\u002Fp>\n\n\u003Cp>• On your September 27, 2017 Facebook post: “Animals have anxiety, joint discomfort, and many of the same disorders as humans. So, just as with our human line of products, we use the best of ingredients for our canine, feline, or equine customers.”\u003C\u002Fp>\n\n\u003Cp>Your CBD-containing products for animals are “new animal drugs” under section 201(v) of the FD&amp;C Act [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\n\n\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. 360b, 360ccc, and 360ccc-1]. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&amp;C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. 351(a)(5)]. Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>301(ll) and Adulterated Animal Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Furthermore, it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD, as described above.\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are animal food to which CBD has been added. Specifically, the product labeling depicted on your website, cbdamericanshaman.com, refers to your Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, and Horsey Chews, as a “treats.” Additionally, your Doggy Nugs and Kitty Nugs are referred to as food, for example, on your webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Doggy Nugs and states, “If you are seeking CBD benefits for your dog on a daily basis, we recommend our CBD Dog Food, which is made with real chicken and is bowl-licking good.” On the same webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Kitty Nugs and states, “If you are seeking an easy way to give your cat CBD on a daily basis, try our CBD cat food made with real chicken.” Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should also be aware that, as defined in section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)], the term “food additive” refers to any substance the intended use of which results in its becoming a component of any animal food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in animal food is deemed to be unsafe under section 409(a) of the FD&amp;C Act [21 U.S.C. 348(a)], and causes the animal food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of CBD in animal food. Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in animal food. FDA’s regulations in 21 CFR 570.30(a)-(c) describe the criteria for eligibility for classification of an animal food ingredient as GRAS. The use of an animal food substance may be GRAS based on either scientific procedures or, for a substance used in animal food before 1958, through experience based on common use in animal food (see 21 CFR 570.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in animal food prior to January 1, 1958. Based on our review of the publicly available literature, the data and information necessary to support the safe use of CBD in animal food are lacking. In fact, literature reports have raised safety concerns for animals consuming CBD, including, but not limited to, male reproductive toxicity and liver toxicity. Therefore, based on our review, the use of CBD in animal products does not satisfy the criteria for GRAS status under 21 CFR 570.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in animal food. Therefore, CBD added to animal food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act [21 U.S.C. 348]. Under section 409 of the FD&amp;C Act [21 U.S.C. 348], an animal food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any animal food. Animal food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Introduction of this adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>* * *\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>We have the following additional comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to the label of your Grandma’s Raisin &amp; Pecan Hermit Cookies [with] 10mg CBD per Serving, the product contains 10 mg CBD per one cookie serving. We collected a sample and analyzed this product and confirmed that the product contains CBD. However, FDA analysis found significantly higher levels of CBD than declared on the label, at 19.3 mg CBD per serving and 17.6 mg CBD per serving in our original and check analyses, respectively. As stated above, failure to accurately list the amount of CBD in the product further increases the risk associated with consumption of the product. We have significant concerns about products marketed with incorrect statements about the amount of CBD, particularly those that contain higher amounts of CBD than labeled because consumers may be consuming more CBD than intended. Nevertheless, even if the product labels were accurate regarding the level of CBD in the product, the product would still be adulterated because it bears or contains an unsafe food additive, as discussed above.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement Labeling\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Information on your website indicates that you intend to market some of your CBD products as dietary supplements. For example, the images of the labels on the product pages of your Rapid Dissolve CBD Tablets, CBD Capsules, VG Cloud Tinctures, Water Soluble Hemp Oil Extract, Gourmet Gummies Hemp Oil Isolate, Gourmet Gummies Energy, CBD Gummies, and Sugar Free Gourmet Gummies all bear the term “dietary supplement.” Your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act [21 U.S.C. 321(ff)]. FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]. Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&amp;C Act [21 U.S.C. 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.\u003Csup>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, but you may present FDA with any evidence that has bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 628753” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance &amp; Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)], the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See \u003Cstrong>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome\u003C\u002Fstrong>). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330, prior to enactment of the CARES Act. In the case of OTC sunscreen drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use. (See Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F\u003C\u002Fa>.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 330.1(e) requires that “the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 330.1(e).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s)(5) of the FD&amp;C Act [21 U.S.C. 321(s)(5)], new animal drugs are excluded from the food additive definition. If a new animal drug is unsafe within the meaning of section 512 because it is not approved for use in animal food, then the animal food is adulterated under section 402(a)(2)(C)(ii) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> As noted above, CBD is the active ingredient in the approved drug product Epidiolex and the existence of substantial clinical investigations regarding CBD has been made public.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nAnimal & Veterinary\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nStephen Vincent Sanders II\n\nRecipient Title\n\nCEO\n\nCBD American Shaman, LLC\n\n2405 Southwest Blvd.\n\nKansas City, MO 64108\n\nUnited States\n\nsupport@cbdamericanshaman.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nCenter for Drug Evaluation and Research\n\nCenter for Veterinary Medicine\n\nWARNING LETTER\n\nNovember 16, 2022\n\nRE: 628753\n\nDear Mr. Sanders:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address CBDAmericanShaman.com in October 2022 and has determined that you take orders there for various human and animal products which you promote as products containing cannabidiol (CBD). We also reviewed your social media websites at www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, which link to your website cbdamericanshaman.com, to purchase your products. FDA has determined that your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)], because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products into interstate commerce under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)].\n\nFDA is particularly concerned that some of your products are in forms that are appealing to children. For example, your CBD Suckers, CBD Hard Candies, various Cookies [with] 10mg CBD per Serving, and various CBD Gummies products are all in forms that would be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children. Furthermore, your products have not been evaluated by the Agency for safety, effectiveness, and quality. As discussed below, CBD has been studied as a drug, and it is the active ingredient in the approved drug product Epidiolex. The use of untested drugs can have unpredictable and unintended consequences, especially in vulnerable populations, such as children. For example, children may be at greater risk for adverse reactions associated with certain drug products due to differences in the ability of children to absorb, metabolize, distribute, or excrete such drug products or their metabolites.\n\nYou also market other products that consumers may confuse with traditional foods for humans, including CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey; therefore, with these products there is a risk of unintended consumption of the CBD ingredient by consumers.\n\nIn addition, “CBD + ZINC OXIDE Sunscreen” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act [21 U.S.C. 355(a)], and is misbranded under section 502(ee) of the FD&C Act [21 U.S.C. 352(ee)]. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act [21 U.S.C. 331(d) and (a)]. These violations are described in more detail below.\n\nFurther, the claims on your website and social media websites establish that your Canine 300 Tincture, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs products, which you promote as products containing CBD for use in pets, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. 351(a)(5)].\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nAdulterated Human Foods and 301(ll)\n\nAccording to your product labeling, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are foods to which CBD has been added. We analyzed a sample of your Grandma’s Raisin & Pecan Hermit Cookies and confirmed that the product contains CBD. We also note that you may intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products. Specifically, you describe these gummy products as “adult gummy candy” and\u002For “the perfect way to satisfy your sweet tooth,” and the web pages for three of the products bear Nutrition Facts information.\n\nAs defined in section 201(s) of the FD&C Act [21 U.S.C. 321(s)], the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.1\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act [21 U.S.C. 348(a)], and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nThere is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. The available data raise serious concerns about potential harm from CBD added to conventional food. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act [21 U.S.C. 321(s)] and is subject to the provisions of section 409 of the FD&C Act [21 U.S.C. 348]. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)] because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)]. To the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, they would be adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)] for the same reason.\n\nFurther, in regard to your Cookies [with] 10mg CBD per Serving, CBD Suckers, CBD Hard Candies, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey, and, to the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, you should be aware that it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.2 There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)], prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nUnapproved New Human Drug and Misbranded Human Drug\n\n“CBD + ZINC OXIDE Sunscreen” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act [21 U.S.C. 321(g)(1)(C)], because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as sunscreen.\n\nExamples of claims from the product’s labeling, including the claims observed on your website, www.cbdamericanshaman.com, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product includes, but may not be limited to, the following:\n\n“CBD + ZINC OXIDE Sunscreen . . . BROAD SPECTRUM SPF 35+ UVA • UVB” [from the label on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\n\n“Drug Facts . . . Active Ingredients [s] . . . Cannabidiol (Hemp Exract [sic] (Aerial Parts), Cannabidiol) 0.072% . . . Purpose . . . Sunscreen . . .” [from the label on your website, website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\n\n“This all natural CBD sunscreen lotion is a natural way to protect yourself from harmful UV rays while using an all-natural product that won’t harm you or our planet! This cbd infused sunscreen is 35+ SPF (broad spectrum) and is rated to block UVA and UVB rays. We use Zinc Oxide which is rated safe by EWG on their Skin Deep website and isn't hazardous for the environment like oxybenzone or octinoxate. There is 60mg of nano full-spectrum CBD oil per container.” [from the product information on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\n\nBased on the above labeling claims, “CBD + ZINC OXIDE Sunscreen” is a topical product intended for use as a sunscreen drug. As described below, this sunscreen drug is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. 321(p)], if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act [21 U.S.C. 355(a)]. No FDA-approved application pursuant to section 505 of the FD&C Act [21 U.S.C. 355], is in effect for this drug product.\n\n“CBD + ZINC OXIDE Sunscreen” is a sunscreen drug subject to section 505G of the FD&C Act [21 U.S.C. 355h], which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, sunscreen drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020).3 However, this sunscreen drug product does not conform to the conditions of use specified in M020 because the product’s labeling lists CBD as an active ingredient in the Drug Facts panel. CBD is not an active ingredient allowed in any applicable final monograph. Thus, your “CBD + ZINC OXIDE Sunscreen” product does not meet the requirements under section 505G of the FD&C Act, under which it would be deemed to be GRASE and not a new drug.\n\nFurthermore, even if CBD could be considered an inactive ingredient in “CBD + ZINC OXIDE Sunscreen,” this product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&C Act. In particular, such a product would not meet the conditions under section 505G(a)(1) or (2), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.4 A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).5 CBD has no known functional role as an inactive ingredient in a finished drug product.\n\nAdditionally, an inactive ingredient should not exert pharmacological effects6 and must be safe when used at the intended dosage.7 CBD, however, has a known pharmacological activity with demonstrated risks.8 It is unknown whether the level of CBD used in your “CBD + ZINC OXIDE Sunscreen” drug product has pharmacological activity or poses any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Consequently, if CBD is intended to be an inactive ingredient in your “CBD + ZINC OXIDE Sunscreen” product, that product would not meet the general requirements for legal marketing of nonprescription drugs under sections 505G(a)(1) or (2) of the FD&C Act.\n\nIn addition, FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “CBD + ZINC OXIDE Sunscreen” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) of the FD&C Act. Introduction or delivery for introduction of such product into interstate commerce is prohibited under section 301(d) of the FD&C Act [21 U.S.C. 331(d)].\n\nIn addition, “CBD + ZINC OXIDE Sunscreen” is misbranded under section 502(ee) of the FD&C Act [21 U.S.C. 352(ee)] because it is a nonprescription drug subject to section 505G of the FD&C Act [21 U.S.C. 355h], is not the subject of an application approved under section 505 of the FD&C Act [21 U.S.C. 355], and does not comply with the requirements under section 505G of the FD&C Act [21 U.S.C. 355h]. Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act [21 U.S.C. 331(a) and (d)].\n\nUnapproved New Animal Drugs\n\nDuring our review of your firm’s website cbdamericanshaman.com and your social media websites, www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, FDA determined that your firm is marketing the unapproved new animal drugs Canine 300 Tincture, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs. Based on our review of your website and social media websites, these products are drugs under section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&C Act.\n\nExamples of claims observed on your website that show the intended use of your products as drugs include, but are not limited to, the following:\n\n• On your webpage titled “CBD Dog Treats” under the header “How do CBD dog treats help your pup?”:\n\no “You can use CBD American Shaman dog treats to relieve your furry friends with high levels of stress. We include CBD oil for dogs in each treat to help calm pets during a storm, firework show, loud party or any other situation that puts them in a state of panic.”\n\no “They [CBD dog treats] may also help regulate heartbeat and blood pressure”\n\n• On your webpage titled “How To Choose A CBD Oil Product” under the header “Dogs”:\n\no “If you would like to give your dog CBD every once in a while, like before the vet, for 4th of July fireworks, or when your dog may be extra anxious, we recommend any of our Dog CBD oils (https:\u002F\u002Fcbdamericanshaman.com\u002Fpets) and Soft CBD Dog Treats (https:\u002F\u002Fcbdamericanshaman.com\u002Fsoft-cbd-dog-treats).”\n\n• On your webpage titled “How To Choose A CBD Oil Product” under the header “Cats”:\n\no “Our feline CBD (https:\u002F\u002Fcbdamericanshaman.com\u002Ffeline-cbd-hemp-oil-tincture) oils are also great for when your cat needs help calming down or relaxing before a triggering event.”\n\nExamples of claims observed on your social media websites that show the intended use of your products as drugs include, but are not limited to, the following:\n\n• On your October 13, 2021 Instagram and Facebook posts: “Does your dog need support for #jointhealth or experience storm stress? Our unique recipe of high-quality CBD oil dog treats taste like peanut butter and will leave your pet wanting more.”\n\n• On your February 23, 2018 Facebook post: A photo of a dog is posted by CBD American Shaman with the caption “#funfactfriday: CBD Oil is becoming more and more available for use on pets! In FACT, veterinarians are finding #cbdoil useful in arthritis, stress, digestive issues, and much more.”\n\no A comment on this post and response from CBD American Shaman:\n\n Comment from follower: “I am considering trying this for our dog who had seizures.”\n\n Response from CBD American Shaman: “A lot of people are having success with their dogs [sic] seizures using CBD.”\n\n• On your October 16, 2017 Facebook video post:\n\no At the 20 second mark in the video a graphic states, “From arthritic canines to anxiety filled equines, CBD Oil is changing the way veterinarians and pet owners treat their furry family members.”\n\no At the 28 second mark in the video a graphic with the heading “CBD Hemp Oil” states, “Whether a dog has cancer, seizures, or anxiety, cannabis oil can serve as an alternative medication to help treat symptoms.”\n\n• On your September 27, 2017 Facebook post: “Animals have anxiety, joint discomfort, and many of the same disorders as humans. So, just as with our human line of products, we use the best of ingredients for our canine, feline, or equine customers.”\n\nYour CBD-containing products for animals are “new animal drugs” under section 201(v) of the FD&C Act [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\n\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. 360b, 360ccc, and 360ccc-1]. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. 351(a)(5)]. Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\n301(ll) and Adulterated Animal Foods\n\nFurthermore, it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD, as described above.\n\nAccording to your product labeling, your Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are animal food to which CBD has been added. Specifically, the product labeling depicted on your website, cbdamericanshaman.com, refers to your Doggy Chews (all flavors), Soft & Tender Doggy Chews, and Horsey Chews, as a “treats.” Additionally, your Doggy Nugs and Kitty Nugs are referred to as food, for example, on your webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Doggy Nugs and states, “If you are seeking CBD benefits for your dog on a daily basis, we recommend our CBD Dog Food, which is made with real chicken and is bowl-licking good.” On the same webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Kitty Nugs and states, “If you are seeking an easy way to give your cat CBD on a daily basis, try our CBD cat food made with real chicken.” Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&C Act.\n\nYou should also be aware that, as defined in section 201(s) of the FD&C Act [21 U.S.C. 321(s)], the term “food additive” refers to any substance the intended use of which results in its becoming a component of any animal food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.9\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in animal food is deemed to be unsafe under section 409(a) of the FD&C Act [21 U.S.C. 348(a)], and causes the animal food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nThere is no food additive regulation that authorizes the use of CBD in animal food. Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in animal food. FDA’s regulations in 21 CFR 570.30(a)-(c) describe the criteria for eligibility for classification of an animal food ingredient as GRAS. The use of an animal food substance may be GRAS based on either scientific procedures or, for a substance used in animal food before 1958, through experience based on common use in animal food (see 21 CFR 570.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in animal food prior to January 1, 1958. Based on our review of the publicly available literature, the data and information necessary to support the safe use of CBD in animal food are lacking. In fact, literature reports have raised safety concerns for animals consuming CBD, including, but not limited to, male reproductive toxicity and liver toxicity. Therefore, based on our review, the use of CBD in animal products does not satisfy the criteria for GRAS status under 21 CFR 570.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in animal food. Therefore, CBD added to animal food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act [21 U.S.C. 348]. Under section 409 of the FD&C Act [21 U.S.C. 348], an animal food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any animal food. Animal food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Introduction of this adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe have the following additional comments:\n\nAccording to the label of your Grandma’s Raisin & Pecan Hermit Cookies [with] 10mg CBD per Serving, the product contains 10 mg CBD per one cookie serving. We collected a sample and analyzed this product and confirmed that the product contains CBD. However, FDA analysis found significantly higher levels of CBD than declared on the label, at 19.3 mg CBD per serving and 17.6 mg CBD per serving in our original and check analyses, respectively. As stated above, failure to accurately list the amount of CBD in the product further increases the risk associated with consumption of the product. We have significant concerns about products marketed with incorrect statements about the amount of CBD, particularly those that contain higher amounts of CBD than labeled because consumers may be consuming more CBD than intended. Nevertheless, even if the product labels were accurate regarding the level of CBD in the product, the product would still be adulterated because it bears or contains an unsafe food additive, as discussed above.\n\nDietary Supplement Labeling\n\nInformation on your website indicates that you intend to market some of your CBD products as dietary supplements. For example, the images of the labels on the product pages of your Rapid Dissolve CBD Tablets, CBD Capsules, VG Cloud Tinctures, Water Soluble Hemp Oil Extract, Gourmet Gummies Hemp Oil Isolate, Gourmet Gummies Energy, CBD Gummies, and Sugar Free Gourmet Gummies all bear the term “dietary supplement.” Your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act [21 U.S.C. 321(ff)]. FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]. Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act [21 U.S.C. 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.10 There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 628753” in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nNeal Bataller\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine\n\nFood and Drug Administration\n\n_____________________\n\n1 Under section 201(s) of the FD&C Act [21 U.S.C. 321(s)], the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\n\n2 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n3 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330, prior to enactment of the CARES Act. In the case of OTC sunscreen drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use. (See Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\n\n4 21 CFR 330.1(e) requires that “the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.”\n\n5 See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload.\n\n6 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\n\n7 See 21 CFR 330.1(e).\n\n8 For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf.\n\n9 Under section 201(s)(5) of the FD&C Act [21 U.S.C. 321(s)(5)], new animal drugs are excluded from the food additive definition. If a new animal drug is unsafe within the meaning of section 512 because it is not approved for use in animal food, then the animal food is adulterated under section 402(a)(2)(C)(ii) of the FD&C Act.\n\n10 As noted above, CBD is the active ingredient in the approved drug product Epidiolex and the existence of substantial clinical investigations regarding CBD has been made public.","CBD American Shaman, LLC","cbd-american-shaman-llc-628753-11162022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcbd-american-shaman-llc-628753-11162022","2026-10-26T08:08:12.074684+00:00","2022-11-21","628753","Animal & VeterinaryDrugsFood & Beverages","Stephen Vincent Sanders II","2026-08-20T01:25:12.266+00:00","Via Overnight Delivery","2022-11-16",{"id":54,"raw":55,"subject":12,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":26,"closeout_date":19,"issuing_office":59,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},2923,[56,57,58,59,12,13,13,13],"\u003Ctime datetime=\"2022-01-18T14:20:00Z\">01\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-21T05:00:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsunstar-americas-inc-614058-12212021\">Sunstar Americas, Inc.\u003C\u002Fa>","Office of Medical Devices and Radiological Health Operations Div. 2 Central","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard McMahon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sunstar Americas, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 E. Central Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Schaumburg\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60195\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health Operations Div. 2 Central\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter # 614058\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 21, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McMahon:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Sunstar Americas, Inc., FEI 1413787, at 301 E. Central Rd., Schaumburg, Illinois, from January 12 to February 18, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the FD&amp;C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&amp;C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 11, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of its written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our investigators documented deficiencies in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;system) validation protocol and deviations during its execution. For example:\u003C\u002Fp>\n\n\u003Cp>• Excursions in the performance parameters of your water system occurred while the system was being validated. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration, which impacts the ability of the system to maintain microbiological control, was recorded at \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the system storage tank. \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurements were below the limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> days in January 2018. These occurrences were not documented in the validation report as deviations and reviewed before you deemed the water system validated.\u003C\u002Fp>\n\n\u003Cp>• The water system validation study did not provide scientific data supporting the type and frequency of chemical sanitization performed in addition to the routine \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization. Your protocol also lacked provisions for evaluating these parameters of your water system sanitization program. Your current practice is to conduct chemical sanitization \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>• The protocol allowed for reduced sampling and testing if results were considered acceptable but you did not define what an acceptable standard would be. Although you had results as high as \u003Cstrong>(b)(4)\u003C\u002Fstrong> at your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you still reduced sampling and testing to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequency.\u003C\u002Fp>\n\n\u003Cp>You have not shown that your water system can consistently produce water suitable for drug manufacturing and meets, at a minimum, the USP purified water monograph and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>It is essential that you design your water system to ensure consistently high purity water that is suitable for its intended use. High bioburden or objectionable microbes in the water used as an ingredient in your drugs may pose significant risk to consumers.\u003C\u002Fp>\n\n\u003Cp>In your response, you committed to reassessing your water system followed by revalidation. You also committed to conducting a gap assessment of your validation program and performing comprehensive CGMP and quality systems training for all personnel.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent assessment of your water system design, control, and maintenance, and corresponding corrective actions and preventative actions (CAPA).\u003C\u002Fp>\n\n\u003Cp>• A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\u003C\u002Fp>\n\n\u003Cp>• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your water system was subject to microbiological contamination and numerous deviations from operating parameters since validation. Many of these deviations were either not investigated or did not result in implementation of CAPA.\u003C\u002Fp>\n\n\u003Cp>• No investigations were conducted in response to identification of \u003Cem>Burkholderia contaminans\u003C\u002Fem> in seven samples taken from your water system ports \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, between January 1, 2020, and June 30, 2020. \u003Cem>Burkholderia contaminans\u003C\u002Fem> was not identified as an objectionable organism in your procedures or your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water specifications. The presence of objectionable microorganisms in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system can adversely affect the quality of your drug products.\u003C\u002Fp>\n\n\u003Cp>• You opened a CAPA during the validation of your water system due to findings of \u003Cem>Burkholderia cepacia\u003C\u002Fem> in three samples collected at ports \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These ports supply water for manufacturing. The CAPA investigation identified a possible root cause of a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> supply port to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample port and your firm proposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the CAPA was closed approximately a year and a half later without addition of the filter or explanation why corrective action was not taken. You subsequently identified \u003Cem>Burkholderia contaminans\u003C\u002Fem> at port \u003Cstrong>(b)(4)\u003C\u002Fstrong> multiple times in 2020.\u003C\u002Fp>\n\n\u003Cp>• During the validation of your water system, a third-party service technician observed staining inside the water tank and noted you were investigating the cause. You lacked documentation of the cause or CAPA addressing the service technician’s finding.\u003C\u002Fp>\n\n\u003Cp>• Deviations in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization process were not logged in accordance with your deviation procedure. We found a pattern of failure to conduct investigations or implement CAPA following deviations in the operating parameters during ozone sanitization when the minimum level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not met in the storage tank, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and loop supply.\u003C\u002Fp>\n\n\u003Cp>In your response, you committed to hire a third-party expert and to perform training on investigations. You also committed to performing a review of all CAPA, out-of-specification (OOS), out-of-trend (OOT), and invalidated quality control data initiated from January 1, 2019, to present. You also revised your purified water specifications to include Burkholderia cepacia complex (BCC) as an objectionable organism as of January 11, 2021.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to accurately categorize some OOS and OOT results, deviations, and unexpected discrepancies.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS (including in-process, release, and stability testing) results for US products irrespective of whether the batch was ultimately distributed in the US and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>\n&nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; o For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive retrospective review of all GMP documentation associated with distributed finished drug product batches that remain within expiry and the equipment and systems used in their manufacture to ensure all OOS results, OOT results, deviations, and unexpected discrepancies were categorized and appropriately investigated.\u003C\u002Fp>\n\n\u003Cp>• Explain whether you have reconsidered the sequence of the water system components in your current design. You currently have \u003Cstrong>(b)(4)\u003C\u002Fstrong> system although the latter represents the best means of microbial reduction.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fp>\n\n\u003Cp>• A detailed description of all CAPA that have been identified to address this violation, with timeframes for CAPA activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to&nbsp;assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Before beginning distribution, you did not adequately study antimicrobial effectiveness in your finished drugs products to evaluate the ability of the preservative system to inhibit the growth of certain objectionable organisms including BCC.\u003C\u002Fp>\n\n\u003Cp>For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> studies for 0.12% chlorhexidine gluconate oral rinse (Paroex) using \u003Cem>Burkholderia cepacia\u003C\u002Fem> were not performed until July 2020. Notably, BCC was found to proliferate to excessive levels in your product over its shelf life for several batches including too numerous to count (TNTC) levels. Numerous lots of this product were recalled from the market because of excessive microbiological contamination. Paroex is produced by a contract manufacturer under your ANDA 076434.\u003C\u002Fp>\n\n\u003Cp>In your response, you committed to assessing your procedure titled “U.S. Regulatory Information Concerning SAI Products” to determine its adequacy in establishing and maintaining product-specific information and meeting regulatory requirements.\u003C\u002Fp>\n\n\u003Cp>You committed to adding BCC to microbiological tests for products manufactured at and for your firm. You also committed to developing and implementing a procedure to establish steps to follow when a new microorganism is identified in the manufacturing facility to ensure the adequacy of controls, including addressing potentially objectionable microorganisms.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, describe how your product and process development programs will build quality into your products, including conducting appropriate studies to support each new product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately exercise your responsibility to ensure all drug products manufactured by and for your firm possessed appropriate quality attributes, antimicrobial properties, or preservative systems to ensure their microbiological quality and safety. For example, your non-sterile aqueous-based drug product specifications did not include \u003Cem>Burkholderia cepacia\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>Your drugs are often used in hospitals or clinical settings in which patients may have a higher vulnerability to infection with \u003Cem>Burkholderia cepacia\u003C\u002Fem> and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\u003C\u002Fp>\n\n\u003Cp>The agreement between your firm and your contract manufacturer (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) specifically identified your responsibilities with respect to the manufacture of your drug products. Your responsibilities include the provision of support regarding technical and regulatory issues to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the products’ manufacture. You are also responsible for overseeing the CGMP compliance of your contract manufacturer through mechanisms including the review of procedures and records associated with the manufacture of your products.\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you initially recalled batches of Paroex bearing an expiration date from June 30, 2022, to September 30, 2022, because of the presence of objectionable microbiological contamination or substantial risk of contamination. We also acknowledge your expansion of the recall to include all potentially affected lots of Paroex following further discussions with FDA. We also acknowledge your subsequent recalls of Hydral Dry Mouth Relief, Butler Clear Dip, and Perioshield Oral Health Rinse, medical devices, because of potential contamination with objectionable organisms.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of whether you manufacture them, or a contract facility manufactures them for you on your behalf. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide your updated procedures that ensure all activities performed by you and your contract manufacturers are adequate and approved by your quality unit.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Quality System Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to adequately validate a process whose results cannot be fully verified by subsequent inspection and test through established procedures (21 CFR 820.75(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer above to the discussion of 21 CFR 211.100(a) and (b) violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Your failed to adequately establish procedures for corrective and preventive action to include the documentation of such activities (21 CFR 820.100(a) &amp; (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer above to the discussion of 21 CFR 211.192 violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish schedules for the adjustment, cleaning, and other maintenance of equipment (21 CFR 820.70(g)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitization system of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system was not part of a maintenance schedule. The system included three gauges that measure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the system to verify that the sanitization process and the storage tank control are acceptable. There was no documentation that gauges (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) had been calibrated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to adequately establish procedures for design input (21 CFR 820.30(c)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, the design for Hydral Spray failed to include \u003Cem>Burkholderia cepacia\u003C\u002Fem> as a challenge in \u003Cstrong>(b)(4)\u003C\u002Fstrong> although \u003Cem>Burkholderia cepacia\u003C\u002Fem> was included in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> challenge for other products to include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> toothpaste in June 2017. The risk management file of the Hydral Spray was not updated to include these objectionable organisms and any controls necessary to mitigate the risks as part of Hydral spray design verification and validation. The risk management file was updated on January 18, 2021, after the start of the FDA inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload\u003C\u002Fa>, \u003Cem>Q9 Quality Risk Management\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71543\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71543\u002Fdownload\u003C\u002Fa> and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\">https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend production of drugs at this facility.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume manufacturing drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility and in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (614058). Please address your reply via email to: oradevices2firmresponse@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Rafael Padilla. Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Rafael Padilla at (312) 596-4212.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey Meng\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Richard McMahon\n\nRecipient Title\n\nManaging Director\n\nSunstar Americas, Inc.\n\n301 E. Central Rd.\n\nSchaumburg, IL 60195\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\n\nUnited States\n\nWarning Letter # 614058\n\nDecember 21, 2021\n\nDear Mr. McMahon:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Sunstar Americas, Inc., FEI 1413787, at 301 E. Central Rd., Schaumburg, Illinois, from January 12 to February 18, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nUnder section 201(h) of the FD&C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\n\nThis inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\n\nWe reviewed your March 11, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nDrug CGMP Violations\n\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of its written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nOur investigators documented deficiencies in the “(b)(4) system) validation protocol and deviations during its execution. For example:\n\n• Excursions in the performance parameters of your water system occurred while the system was being validated. For example, the (b)(4) concentration, which impacts the ability of the system to maintain microbiological control, was recorded at (b)(4) in the system storage tank. (b)(4) measurements were below the limit of (b)(4) for (b)(4) out of (b)(4) days in January 2018. These occurrences were not documented in the validation report as deviations and reviewed before you deemed the water system validated.\n\n• The water system validation study did not provide scientific data supporting the type and frequency of chemical sanitization performed in addition to the routine (b)(4) sanitization. Your protocol also lacked provisions for evaluating these parameters of your water system sanitization program. Your current practice is to conduct chemical sanitization (b)(4).\n\n• The protocol allowed for reduced sampling and testing if results were considered acceptable but you did not define what an acceptable standard would be. Although you had results as high as (b)(4) at your (b)(4), you still reduced sampling and testing to a (b)(4) frequency.\n\nYou have not shown that your water system can consistently produce water suitable for drug manufacturing and meets, at a minimum, the USP purified water monograph and appropriate microbial limits.\n\nIt is essential that you design your water system to ensure consistently high purity water that is suitable for its intended use. High bioburden or objectionable microbes in the water used as an ingredient in your drugs may pose significant risk to consumers.\n\nIn your response, you committed to reassessing your water system followed by revalidation. You also committed to conducting a gap assessment of your validation program and performing comprehensive CGMP and quality systems training for all personnel.\n\nIn response to this letter provide:\n\n• A comprehensive independent assessment of your water system design, control, and maintenance, and corresponding corrective actions and preventative actions (CAPA).\n\n• A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\n\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour water system was subject to microbiological contamination and numerous deviations from operating parameters since validation. Many of these deviations were either not investigated or did not result in implementation of CAPA.\n\n• No investigations were conducted in response to identification of Burkholderia contaminans in seven samples taken from your water system ports (b)(4), and (b)(4), between January 1, 2020, and June 30, 2020. Burkholderia contaminans was not identified as an objectionable organism in your procedures or your (b)(4) water specifications. The presence of objectionable microorganisms in your (b)(4) water system can adversely affect the quality of your drug products.\n\n• You opened a CAPA during the validation of your water system due to findings of Burkholderia cepacia in three samples collected at ports (b)(4) and (b)(4). These ports supply water for manufacturing. The CAPA investigation identified a possible root cause of a “(b)(4)” from the (b)(4) supply port to the (b)(4) sample port and your firm proposed (b)(4). However, the CAPA was closed approximately a year and a half later without addition of the filter or explanation why corrective action was not taken. You subsequently identified Burkholderia contaminans at port (b)(4) multiple times in 2020.\n\n• During the validation of your water system, a third-party service technician observed staining inside the water tank and noted you were investigating the cause. You lacked documentation of the cause or CAPA addressing the service technician’s finding.\n\n• Deviations in the (b)(4) sanitization process were not logged in accordance with your deviation procedure. We found a pattern of failure to conduct investigations or implement CAPA following deviations in the operating parameters during ozone sanitization when the minimum level of (b)(4) was not met in the storage tank, (b)(4), and loop supply.\n\nIn your response, you committed to hire a third-party expert and to perform training on investigations. You also committed to performing a review of all CAPA, out-of-specification (OOS), out-of-trend (OOT), and invalidated quality control data initiated from January 1, 2019, to present. You also revised your purified water specifications to include Burkholderia cepacia complex (BCC) as an objectionable organism as of January 11, 2021.\n\nYour response is inadequate because you failed to accurately categorize some OOS and OOT results, deviations, and unexpected discrepancies.\n\nIn response to this letter, provide:\n\n• A retrospective, independent review of all invalidated OOS (including in-process, release, and stability testing) results for US products irrespective of whether the batch was ultimately distributed in the US and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\n• A comprehensive retrospective review of all GMP documentation associated with distributed finished drug product batches that remain within expiry and the equipment and systems used in their manufacture to ensure all OOS results, OOT results, deviations, and unexpected discrepancies were categorized and appropriately investigated.\n\n• Explain whether you have reconsidered the sequence of the water system components in your current design. You currently have (b)(4) system although the latter represents the best means of microbial reduction.\n\n• A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n• A detailed description of all CAPA that have been identified to address this violation, with timeframes for CAPA activities.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nBefore beginning distribution, you did not adequately study antimicrobial effectiveness in your finished drugs products to evaluate the ability of the preservative system to inhibit the growth of certain objectionable organisms including BCC.\n\nFor example, (b)(4) studies for 0.12% chlorhexidine gluconate oral rinse (Paroex) using Burkholderia cepacia were not performed until July 2020. Notably, BCC was found to proliferate to excessive levels in your product over its shelf life for several batches including too numerous to count (TNTC) levels. Numerous lots of this product were recalled from the market because of excessive microbiological contamination. Paroex is produced by a contract manufacturer under your ANDA 076434.\n\nIn your response, you committed to assessing your procedure titled “U.S. Regulatory Information Concerning SAI Products” to determine its adequacy in establishing and maintaining product-specific information and meeting regulatory requirements.\n\nYou committed to adding BCC to microbiological tests for products manufactured at and for your firm. You also committed to developing and implementing a procedure to establish steps to follow when a new microorganism is identified in the manufacturing facility to ensure the adequacy of controls, including addressing potentially objectionable microorganisms.\n\nIn response to this letter, describe how your product and process development programs will build quality into your products, including conducting appropriate studies to support each new product.\n\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nYou did not adequately exercise your responsibility to ensure all drug products manufactured by and for your firm possessed appropriate quality attributes, antimicrobial properties, or preservative systems to ensure their microbiological quality and safety. For example, your non-sterile aqueous-based drug product specifications did not include Burkholderia cepacia.\n\nYour drugs are often used in hospitals or clinical settings in which patients may have a higher vulnerability to infection with Burkholderia cepacia and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\n\nThe agreement between your firm and your contract manufacturer ((b)(4)) specifically identified your responsibilities with respect to the manufacture of your drug products. Your responsibilities include the provision of support regarding technical and regulatory issues to (b)(4) for the products’ manufacture. You are also responsible for overseeing the CGMP compliance of your contract manufacturer through mechanisms including the review of procedures and records associated with the manufacture of your products.\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nWe acknowledge that you initially recalled batches of Paroex bearing an expiration date from June 30, 2022, to September 30, 2022, because of the presence of objectionable microbiological contamination or substantial risk of contamination. We also acknowledge your expansion of the recall to include all potentially affected lots of Paroex following further discussions with FDA. We also acknowledge your subsequent recalls of Hydral Dry Mouth Relief, Butler Clear Dip, and Perioshield Oral Health Rinse, medical devices, because of potential contamination with objectionable organisms.\n\nYou are responsible for the quality of your drugs regardless of whether you manufacture them, or a contract facility manufactures them for you on your behalf. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity.\n\nIn response to this letter, provide your updated procedures that ensure all activities performed by you and your contract manufacturers are adequate and approved by your quality unit.\n\nMedical Device Quality System Violations\n\n5. Your firm failed to adequately validate a process whose results cannot be fully verified by subsequent inspection and test through established procedures (21 CFR 820.75(a)).\n\nRefer above to the discussion of 21 CFR 211.100(a) and (b) violations.\n\n6. Your failed to adequately establish procedures for corrective and preventive action to include the documentation of such activities (21 CFR 820.100(a) & (b)).\n\nRefer above to the discussion of 21 CFR 211.192 violations.\n\n7. Failure to adequately establish schedules for the adjustment, cleaning, and other maintenance of equipment (21 CFR 820.70(g)).\n\nSpecifically, the (b)(4) Sanitization system of the (b)(4) water system was not part of a maintenance schedule. The system included three gauges that measure the (b)(4) in the system to verify that the sanitization process and the storage tank control are acceptable. There was no documentation that gauges ((b)(4)) had been calibrated.\n\n8. Failure to adequately establish procedures for design input (21 CFR 820.30(c)).\n\nSpecifically, the design for Hydral Spray failed to include Burkholderia cepacia as a challenge in (b)(4) although Burkholderia cepacia was included in the (b)(4) challenge for other products to include the (b)(4) toothpaste in June 2017. The risk management file of the Hydral Spray was not updated to include these objectionable organisms and any controls necessary to mitigate the risks as part of Hydral spray design verification and validation. The risk management file was updated on January 18, 2021, after the start of the FDA inspection.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71543\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nObjectionable Organisms\n\nFor further information regarding the significance of Burkholderia cepacia complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend production of drugs at this facility.\n\nIf you plan to resume manufacturing drugs, notify this office before resuming your operations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility and in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (614058). Please address your reply via email to: oradevices2firmresponse@fda.hhs.gov\n\nAttention: Rafael Padilla. Compliance Officer\n\nU.S. Food and Drug Administration\n\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\n\nIf you have questions regarding the contents of this letter, please contact Rafael Padilla at (312) 596-4212.\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey Meng\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III","Sunstar Americas, Inc.","sunstar-americas-inc-614058-12212021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsunstar-americas-inc-614058-12212021","2026-10-26T08:10:07.599719+00:00","2022-01-18","614058","Mr. Richard McMahon","2026-08-20T02:16:16.278+00:00","UPS","2021-12-21",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":94,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},139,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-14T04:00:00Z\">05\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026\">GC America, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-76\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph T. Talanges\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GC America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3737 West 127th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Talanges:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including those for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to ensure components were suitable for use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum, meets specifications in the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system records show that you only performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling requirements and acceptance criteria. According to your management, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug batches with inadequately tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> from 2023 through 2025.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for \u003C\u002Fem>\u003Cstrong>(b)(4) \u003C\u002Fstrong>\u003Cem>Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination before using them to manufacture your drug products. This includes, but is not limited to, testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its appropriate identity prior to use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not perform all testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per USP, and you commit to sending a sample of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on drug products released from 2023 to 2025 and to establishing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing SOP.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a detailed procedure explaining how you will assess your \u003Cstrong>(b)(4)\u003C\u002Fstrong> against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fp>\u003Cp>• The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fp>\u003Cp>• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>• A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fp>\u003Cp>• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fp>\u003Cp>• Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system qualification report.\u003C\u002Fp>\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the USP monograph.\u003C\u002Fp>\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\u003Cp>• A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\u003Cbr>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for \u003Cstrong>(b)(4)\u003C\u002Fstrong> consisted of a single batch tested for \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter affixed to a laptop by a sticker used for processing \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter test results. In addition, the data from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\u003C\u002Fp>\u003Cp>Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\u003C\u002Fp>\u003Cp>In your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\u003Cbr>• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003Cbr>\u003Cbr>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>Kennerly K. Chapman -S\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Digitally signed by Kennerly K. Chapman -S\u003Cbr>Date: 2026.05.14 15:58:58 -04'00'\u003Cbr>Office of Manufacturing Quality Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-76\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph T. Talanges\n\nRecipient Title\n\nPresident & Chief Operating Officer\n\nGC America, Inc.\n\n3737 West 127th Street\n\nAlsip, IL 60803\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 14, 2026\nWARNING LETTER\n\nDear Mr. Talanges:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products, including those for (b)(4). Your firm failed to ensure components were suitable for use in manufacturing your drug products.\n(b)(4) Used as a Component in Drug Products\nYou did not adequately demonstrate your (b)(4), at a minimum, meets specifications in the United States Pharmacopeia (USP) (b)(4) monograph. For example, your (b)(4) system records show that you only performed (b)(4) testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing (b)(4) sampling requirements and acceptance criteria. According to your management, you manufactured approximately (b)(4) finished drug batches with inadequately tested (b)(4) from 2023 through 2025.\nProducts Containing Ingredients at Risk for (b)(4) Contamination\nYou also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of (b)(4) contamination before using them to manufacture your drug products. This includes, but is not limited to, testing (b)(4) to determine its appropriate identity prior to use in manufacturing your drug products.\nIdentity testing for (b)(4) and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nIn your response, you acknowledge you do not perform all testing of (b)(4) per USP, and you commit to sending a sample of your (b)(4) to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient (b)(4) testing on drug products released from 2023 to 2025 and to establishing a (b)(4) testing SOP.\nYour response is inadequate. You do not provide a detailed procedure explaining how you will assess your (b)(4) against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\nWithout adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\nIn response to this letter, provide:\n• A procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\n• The current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n• A comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\n• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\n• Your (b)(4) system qualification report.\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of (b)(4) of the USP monograph.\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n• A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\nYour firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for (b)(4) consisted of a single batch tested for (b)(4) at (b)(4) degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\nWithout an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\nSee FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\nIn your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\nYour response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\nIn response to this letter, provide:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYour quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the (b)(4) meter affixed to a laptop by a sticker used for processing (b)(4) meter test results. In addition, the data from the (b)(4) meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\nYour QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\nIn your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\nYour response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\n\nSincerely,\nKennerly K. Chapman -S\nFrancis Godwin\nDirector\nDigitally signed by Kennerly K. Chapman -S\nDate: 2026.05.14 15:58:58 -04'00'\nOffice of Manufacturing Quality Office of Compliance\nCenter for Drug Evaluation and Research","GC America, Inc.","gc-america-inc-727602-05142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026","2026-10-26T08:08:44.827832+00:00","2026-05-26","727602","Drugs Over-the-Counter Drugs","Mr. Joseph T. Talanges","2026-08-19T04:39:48.869+00:00","Via Email Return Receipt Requested","320-26-76","2026-05-14",{"id":97,"raw":98,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":112,"product_type":113,"closeout_date":19,"issuing_office":102,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":117,"medical_device_id":19,"response_letter_date":19},21709,[99,100,101,102,103,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-pharma-mfg-inc-728227-08042026\">American Pharma Mfg. Inc. \u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vishal D. Savalia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Pharma Mfg. Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1845 S. Vineyard Ave Ste 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ontario\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91761-7762\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 4, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #728227\u003C\u002Fp>\u003Cp>Dear Mr. Savalia:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1845 S. Vineyard Ave, Ste 5, Ontario, CA, from March 16-27, 2026. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on March 27, 2026, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 14 and 17, 2026, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from March 16-27, 2026, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to ensure that each person who is identified to perform quality control operations is qualified to do so, as required by 21 CFR 111.12(b). Specifically, neither your Operations Manager nor your Production Manager, who are performing the responsibilities of quality control, is qualified to do so, as neither is knowledgeable about the applicable requirements.\u003C\u002Fp>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you identified an employee to lead your quality control unit; however, you provided no information demonstrating that this person is qualified.\u003C\u002Fp>\u003Cp>2. You failed to meet sanitation requirements that apply to your physical plant and grounds, as required by 21 CFR 111.15. Specifically, during the inspection, our investigator observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>You failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> pipes \u003Cstrong>(b)(4)\u003C\u002Fstrong> had powder build up and residue different than the color from the product being run in the machines; and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> rooms had unknown residue\u002Fbuildup on the floors and walls. Additionally, the corners of your walls in the blending room have holes, and there were temporary patches in place made with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> corners were \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and where \u003Cstrong>(b)(4)\u003C\u002Fstrong> was broken it revealed the damaged wall underneath.\u003C\u002Fli>\u003Cli>You failed to identify and hold cleaning compounds, sanitizing agents, pesticides, pesticide chemicals, or other toxic materials in a manner that protects against contamination of components, dietary supplements, or contact surfaces, as required by 21 CFR 111.15(c)(3). During the walk-through on March 17, 2026, our investigator observed a can of \u003Cstrong>(b)(4)\u003C\u002Fstrong> stored under a table that was adjacent to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line. Containers of ingredients, in-process products, and finished products of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were held adjacent or in the same area.\u003C\u002Fli>\u003Cli>You failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). Specifically, we observed a gap at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> tall at the bottom of an exit door in your warehouse, which does not prevent entry by pests.\u003C\u002Fli>\u003Cli>You failed to establish plumbing in your physical plant that is of an adequate size and design and that is adequately installed and maintained to properly convey sewage and liquid disposable waste from your physical plant, as required by 21 CFR 111.15(f)(2). Specifically, your firm is currently not allowed to discharge wastewater and is storing all liquid waste in a container located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room. Adjacent to the enclosed container is an uncovered container with a pump inside filled with liquid of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We noted the uncovered container, and its immediate surroundings, were not maintained in a sanitary manner, with apparent splash marks and other unidentifiable substances on and around containers and along the wall. The wastewater containers were a few feet away from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> ladders.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you were going to ensure that all doors are sealed or fitted with pest-proof sweeps, that you have moved all cleaning agents to a designated location, and that you have moved the containers of liquid waste to a designated area. However, you have not provided any photos or documentation of evidence to confirm corrective action has taken place.\u003C\u002Fp>\u003Cp>3. You failed to establish the following specifications, as required by 21 CFR 111.70:\u003C\u002Fp>\u003Cul>\u003Cli>For components used in the manufacture of a dietary supplement, you did not establish identity specifications; specifications necessary to ensure the specifications for purity, strength, and composition of the dietary supplement are met; and limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b). For example, you failed to establish specifications for the identity or limits of contaminates for the components \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture the dietary supplement product \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you failed to establish specifications for the identity or limits of contaminants for the components \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture the dietary supplement product \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>For each dietary supplement that you manufacture, you did not establish product specifications for the identity, purity, strength, and composition of the finished batches of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). You have not established specifications for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you will establish component and dietary supplement specifications; however, you have not submitted any further evidence of this corrective action to date.\u003C\u002Fp>\u003Cp>4. You failed to prepare a batch production record (BPR) every time you manufactured a batch of a dietary supplement, as required by 21 CFR 111.255(a). Specifically, during the inspection you were unable to provide our investigator with a batch production record for your packaging operations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement product, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, for other dietary supplements you failed to prepare a BPR that includes all information required under 21 CFR 111.260. For example, your batch production records for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) dietary supplement products that you manufacture failed to include:\u003C\u002Fp>\u003Cul>\u003Cli>A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (21 CFR 111.260(f));\u003C\u002Fli>\u003Cli>Documentation, at the time of performance, of the manufacture of the batch (21 CFR 111.260(j)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you retroactively created a BPR for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and placed lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on hold pending full quality review and release. For other products you stated that you created new master BPR templates and were planning to implement an \u003Cstrong>(b)(4)\u003C\u002Fstrong> record system in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you have not provided any evidence of these corrective actions.\u003C\u002Fp>\u003Cp>5. You failed to take all the necessary precautions during the manufacture of a dietary supplement to prevent contamination of components or dietary supplements by failing to use effective measures to protect against the inclusion of metal or other foreign material in components or dietary supplements, as required by 21 CFR 111.365(i). Specifically, on March 16, 2026, your metal detector was not properly connected while filling and packaging a dietary supplement product. On March 17, 2026, our investigator observed the metal detector check failing to detect the metal test pieces. On March 23, 2026, our investigator observed that the employee using the metal detector was not performing the metal detector check properly and was not documenting the actual time of performance.\u003C\u002Fp>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you have recalibrated your metal detector. Calibrating your metal detector will not address the root causes of this violation in full.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #728227 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Vishal D. Savalia\n\nRecipient Title\n\nChief Operating Officer\n\nAmerican Pharma Mfg. Inc.\n\n1845 S. Vineyard Ave Ste 5\n\nOntario, CA 91761-7762\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nAugust 4, 2026\nWARNING LETTER\nCMS #728227\nDear Mr. Savalia:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1845 S. Vineyard Ave, Ste 5, Ontario, CA, from March 16-27, 2026. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on March 27, 2026, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 14 and 17, 2026, and we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility from March 16-27, 2026, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to ensure that each person who is identified to perform quality control operations is qualified to do so, as required by 21 CFR 111.12(b). Specifically, neither your Operations Manager nor your Production Manager, who are performing the responsibilities of quality control, is qualified to do so, as neither is knowledgeable about the applicable requirements.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you identified an employee to lead your quality control unit; however, you provided no information demonstrating that this person is qualified.\n2. You failed to meet sanitation requirements that apply to your physical plant and grounds, as required by 21 CFR 111.15. Specifically, during the inspection, our investigator observed the following:\nYou failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). Specifically, the (b)(4) pipes (b)(4) had powder build up and residue different than the color from the product being run in the machines; and the (b)(4) rooms had unknown residue\u002Fbuildup on the floors and walls. Additionally, the corners of your walls in the blending room have holes, and there were temporary patches in place made with (b)(4) and (b)(4). At least (b)(4) corners were (b)(4), and where (b)(4) was broken it revealed the damaged wall underneath.\nYou failed to identify and hold cleaning compounds, sanitizing agents, pesticides, pesticide chemicals, or other toxic materials in a manner that protects against contamination of components, dietary supplements, or contact surfaces, as required by 21 CFR 111.15(c)(3). During the walk-through on March 17, 2026, our investigator observed a can of (b)(4) stored under a table that was adjacent to the (b)(4) filling line. Containers of ingredients, in-process products, and finished products of (b)(4), Lot (b)(4), were held adjacent or in the same area.\nYou failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). Specifically, we observed a gap at least (b)(4) tall at the bottom of an exit door in your warehouse, which does not prevent entry by pests.\nYou failed to establish plumbing in your physical plant that is of an adequate size and design and that is adequately installed and maintained to properly convey sewage and liquid disposable waste from your physical plant, as required by 21 CFR 111.15(f)(2). Specifically, your firm is currently not allowed to discharge wastewater and is storing all liquid waste in a container located in the (b)(4) room. Adjacent to the enclosed container is an uncovered container with a pump inside filled with liquid of (b)(4). We noted the uncovered container, and its immediate surroundings, were not maintained in a sanitary manner, with apparent splash marks and other unidentifiable substances on and around containers and along the wall. The wastewater containers were a few feet away from the (b)(4) and (b)(4) ladders.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you were going to ensure that all doors are sealed or fitted with pest-proof sweeps, that you have moved all cleaning agents to a designated location, and that you have moved the containers of liquid waste to a designated area. However, you have not provided any photos or documentation of evidence to confirm corrective action has taken place.\n3. You failed to establish the following specifications, as required by 21 CFR 111.70:\nFor components used in the manufacture of a dietary supplement, you did not establish identity specifications; specifications necessary to ensure the specifications for purity, strength, and composition of the dietary supplement are met; and limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b). For example, you failed to establish specifications for the identity or limits of contaminates for the components (b)(4) and (b)(4) used to manufacture the dietary supplement product (b)(4). In addition, you failed to establish specifications for the identity or limits of contaminants for the components (b)(4) and (b)(4) used to manufacture the dietary supplement product (b)(4).\nFor each dietary supplement that you manufacture, you did not establish product specifications for the identity, purity, strength, and composition of the finished batches of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). You have not established specifications for your (b)(4) and (b)(4) dietary supplement products.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you will establish component and dietary supplement specifications; however, you have not submitted any further evidence of this corrective action to date.\n4. You failed to prepare a batch production record (BPR) every time you manufactured a batch of a dietary supplement, as required by 21 CFR 111.255(a). Specifically, during the inspection you were unable to provide our investigator with a batch production record for your packaging operations for your (b)(4) dietary supplement product, lot (b)(4). Additionally, for other dietary supplements you failed to prepare a BPR that includes all information required under 21 CFR 111.260. For example, your batch production records for the (b)(4) (lot (b)(4)) and (b)(4) (lot (b)(4)) dietary supplement products that you manufacture failed to include:\nA statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (21 CFR 111.260(f));\nDocumentation, at the time of performance, of the manufacture of the batch (21 CFR 111.260(j)).\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you retroactively created a BPR for the (b)(4) product and placed lot (b)(4) on hold pending full quality review and release. For other products you stated that you created new master BPR templates and were planning to implement an (b)(4) record system in (b)(4). However, you have not provided any evidence of these corrective actions.\n5. You failed to take all the necessary precautions during the manufacture of a dietary supplement to prevent contamination of components or dietary supplements by failing to use effective measures to protect against the inclusion of metal or other foreign material in components or dietary supplements, as required by 21 CFR 111.365(i). Specifically, on March 16, 2026, your metal detector was not properly connected while filling and packaging a dietary supplement product. On March 17, 2026, our investigator observed the metal detector check failing to detect the metal test pieces. On March 23, 2026, our investigator observed that the employee using the metal detector was not performing the metal detector check properly and was not documenting the actual time of performance.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you have recalibrated your metal detector. Calibrating your metal detector will not address the root causes of this violation in full.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #728227 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","American Pharma Mfg. Inc.","american-pharma-mfg-inc-728227-08042026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-pharma-mfg-inc-728227-08042026","2026-11-10T01:02:16.121874+00:00","2026-09-29","728227","Dietary Supplements","Mr. Vishal D. Savalia","2026-10-14T12:34:14.48+00:00","Via Email","2026-08-04",{"id":119,"raw":120,"subject":124,"body_html":125,"body_text":126,"firm_name":127,"letter_id":128,"created_at":18,"fei_number":19,"letter_url":129,"updated_at":130,"action_type":22,"case_status":23,"posted_date":131,"marcs_cms_no":132,"product_type":133,"closeout_date":19,"issuing_office":79,"recipient_name":19,"body_fetched_at":134,"delivery_method":135,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},651,[121,122,123,79,124,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fall-american-wellness-715991-09092025\">All American Wellness\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>All American Wellness\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:https:\u002F\u002Fall-american-wellness.com\"> https:\u002F\u002Fall-american-wellness.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:zak@allamericangroups.com\"> zak@allamericangroups.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>All American Wellness:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fall-american-wellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.\u003Ca id=\"footnoteref1_it46bgf\" href=\"#footnote1_it46bgf\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cp>• &nbsp;“Mounjaro’s compounded version- Tirzepatide Prescription”\u003Cbr>• &nbsp;“Ozempic’s compounded version- Semaglutide”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_tj9ejkx\" href=\"#footnote2_tj9ejkx\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_it46bgf\">\u003Ca href=\"#footnoteref1_it46bgf\">1\u003C\u002Fa>The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_tj9ejkx\">\u003Ca href=\"#footnoteref2_tj9ejkx\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nAll American Wellness\n\nUnited States\n\nhttps:\u002F\u002Fall-american-wellness.com\n\nzak@allamericangroups.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nAll American Wellness:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fall-american-wellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.1 As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n• “Mounjaro’s compounded version- Tirzepatide Prescription”\n• “Ozempic’s compounded version- Semaglutide”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","All American Wellness","all-american-wellness-715991-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fall-american-wellness-715991-09092025","2026-10-26T08:07:52.391249+00:00","2025-09-16","715991","Drugs","2026-08-19T16:18:39.287+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":138,"raw":139,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":43,"fei_number":19,"letter_url":149,"updated_at":150,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":152,"product_type":153,"closeout_date":19,"issuing_office":154,"recipient_name":155,"body_fetched_at":156,"delivery_method":157,"recipient_title":19,"reference_number":19,"action_taken_date":158,"medical_device_id":19,"response_letter_date":19},2206,[140,141,142,143,144,13,13,13],"\u003Ctime datetime=\"2023-02-14T14:20:00Z\">02\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-24T05:00:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cruise-lines-641736-01242023\">American Cruise Lines\u003C\u002Fa>"," Division of Human and Animal Food Operations East V ","Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Paul E. Taiclet\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Cruise Lines\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>741 Boston Post Road, Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guilford\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06437\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Taiclet@americancruiselines.com\"> Taiclet@americancruiselines.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 24, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter 641736\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Taiclet:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your American Star and American Heritage vessels from April 30, 2022, through June 17, 2022, and from June 15, 2022, through August 15, 2022, respectively. FDA also conducted an investigation of the American Star and American Heritage vessels in December 2021. The investigation and inspections were initiated by FDA after three of your passengers who traveled in April 2021, September 2021, and September-October 2021 aboard these vessels were diagnosed with Legionnaires’ disease. American Cruise Lines and FDA were notified by the Centers for Disease Control and Prevention (CDC) of the first confirmed case of Legionnaires’ disease at the end of April 2021 (American Heritage), the second at the beginning of November 2021 (American Star), and the third at the end of November 2021 (American Heritage).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>During our inspections, FDA investigators collected biofilm swabs and potable water samples from your American Star and American Heritage vessels. Laboratory Analysis of those samples identified \u003Cem>Legionella pneumophilia\u003C\u002Fem> serogroup 1 and \u003Cem>Legionella spp\u003C\u002Fem>. (hereinafter collectively called \u003Cem>Legionella\u003C\u002Fem>) in the potable water system of the vessels. FDA investigators also observed insanitary conditions related to the potable water systems onboard the vessels. At the conclusion of the inspections, the FDA investigators issued a Form FDA 483, Inspectional Observations, to both vessels.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the potable water onboard the American Star and American Heritage vessels is adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that it has been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth or rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>Additionally, the presence of \u003Cem>Legionella\u003C\u002Fem> in the potable water on the American Star and American Heritage vessels, as evidenced by the laboratory analysis of FDA’s water samples, causes your vessels’ potable water to be adulterated within the meaning of section 402(a)(1) of the Act [21 U.S.C. § 342(a)(1)] in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.\u003C\u002Fp>\n\n\u003Cp>We received your responses to the biofilm swabs and potable water positive results for \u003Cem>Legionella\u003C\u002Fem> and to the Form FDA 483 in regard to the American Star on the following dates: June 2, 2022, June 4, 2022, June 13, 2022, June 28, 2022, July 5, 2022, July 6, 2022, July 8, 2022, July 11, 2022, July 12, 2022, July 14, 2022, July 20, 2022, August 2, 2022, and August 16, 2022. We received your responses in regard to the American Heritage on July 19, 2022, August 1, 2022, August 16, 2022, and August 28, 2022.\u003C\u002Fp>\n\n\u003Cp>After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continued concerns and to provide detailed information describing our findings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Star\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Presence of \u003Cem>Legionella \u003C\u002Fem>Onboard the Vessel\u003C\u002Fp>\n\n\u003Cp>On April 30, 2022, FDA investigators collected ten (10) biofilm swabs and fourteen (14) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered \u003Cem>Legionella\u003C\u002Fem> from:\u003C\u002Fp>\n\n\u003Cp>Biofilm Swabs (60% of samples positive):\u003Cbr>\n• 5 Showerhead pipes in passenger cabins\u003Cbr>\n• Wait station hand sink faucet aerator in the galley\u003C\u002Fp>\n\n\u003Cp>Potable Water (93% of samples positive):\u003Cbr>\n• 7 Showerhead pipes in passenger cabins\u003Cbr>\n• 2 Showerhead pipes in crew rooms\u003Cbr>\n• Wait station hand sink faucet aerator in the galley\u003Cbr>\n• Galley prep sink faucet aerator\u003Cbr>\n• Potable water holding tank\u003Cbr>\n• Post pump \u003Cstrong>(b)(4)\u003C\u002Fstrong> hot water return spigot\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Post-Notification Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not change your procedures regarding potable water after CDC notified you on November 5, 2021, that one of your passengers was diagnosed with Legionnaires’ disease. For example, you did not change your procedures for flushing or disinfection and did not perform environmental sampling. Subsequently, after FDA notified you of its detection of \u003Cem>Legionella\u003C\u002Fem> onboard your vessel (June 2, 2022), you disinfected the vessel’s potable water system on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On June 4, 2022, you provided a letter to each passenger notifying them of the presence of \u003Cem>Legionella\u003C\u002Fem> in the potable water system onboard your vessel and mitigation steps you had taken. Also, you provided a letter notifying passengers who were onboard the vessel previously from May 3, 2022 to June 4, 2022.\u003C\u002Fp>\n\n\u003Cp>During the week of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you conducted water sampling using a field test kit. On June 24, 2022, FDA expressed concerns to you regarding the use of this field test kit and ending passenger notifications based on this testing because your testing was limited to \u003Cem>Legionella pneumophilia\u003C\u002Fem> serogroup 1 and did not include species identified as present on the vessel by FDA’s testing. In addition, FDA expressed concerns with the sensitivity, detection limit, and size of the water samples collected for the field test kit you used. On June 28, 2022, you shared additional sample collection results with FDA, separate from the field test kit, that were analyzed in a laboratory.\u003C\u002Fp>\n\n\u003Cp>FDA expressed concerns with these laboratory results not being representative nor sufficient to determine whether \u003Cem>Legionella\u003C\u002Fem> is still present and your use of these and the field test kit results to justify ending notification of passengers. Specifically, FDA collected 14 bulk water and 10 biofilm swab samples; you collected \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk water and \u003Cstrong>(b)(4)\u003C\u002Fstrong> biofilm swab samples for the laboratory tests. Thirteen of fourteen (92.86%) of FDA’s bulk water samples and 6 of 10 (60%) of FDA’s biofilm swab samples were positive for \u003Cem>Legionella\u003C\u002Fem>. You did not evaluate most of the bulk water and biofilm swab locations that were positive from FDA’s sampling. In addition, one of the biofilm swabs you took was from a \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was negative from FDA’s sampling.\u003C\u002Fp>\n\n\u003Cp>You restarted passenger notifications and provided them from July 9, 2022 to July 30, 2022. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you collected additional samples and notified FDA of negative results on August 16, 2022. On September 20, 2022, FDA submitted additional follow-up questions regarding the vessel’s sampling process, laboratory results, and future disinfection process. To date, we have not received a response.\u003C\u002Fp>\n\n\u003Cp>Further, in FDA’s emails to American Cruise Lines on July 11, 2022 and August 5, 2022, we reminded you that a voluntary corrective action plan to FDA would include not only testing for \u003Cem>Legionella\u003C\u002Fem>, but other documents, such as detailed procedures put in place onboard the vessel to address Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Vessel Inspection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the following insanitary conditions and practices were observed: \u003Cem>Failure to Monitor Potable Water Parameters\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You did not monitor potable water parameters, such as free or total chlorine residual, temperature, and pH on the vessel when docked and not in operation or while in operation. Sample collection of biofilm swabs and potable water samples by FDA investigators on April 30, 2022, documented the following:\u003C\u002Fp>\n\n\u003Cp>Free chlorine and total chlorine residual were measured at 1.5ppm and 2ppm, respectively, in the potable water holding tanks where water is initially stored in the vessel. After the potable water traveled from the potable water holding tanks where initially stored to distal piping onboard the vessel such as showerheads, seven of 10 biofilm swabs and 10 of 14 bulk potable water samples had no free or total chlorine residual. The dissipation in chlorine residual from the potable water holding tanks to distal piping indicates that conditions, such as the presence of biofilm or planktonic microorganisms, led to the immediate use of the residual chlorine in the potable water system on the vessel.\u003C\u002Fp>\n\n\u003Cp>Eight of 10 biofilm swabs from showerhead pipes and a wait station hand sink faucet aerator and 11 of 14 bulk potable water samples had temperature ranges from 83.1°F - 112.6°F, which is ideal for \u003Cem>Legionella\u003C\u002Fem> growth.\u003C\u002Fp>\n\n\u003Cp>pH was measured between 5-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored.&nbsp;Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases &gt;7, with significant loss of efficacy at pH &gt;8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\u003C\u002Fp>\n\n\u003Cp>By monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage \u003Cem>Legionella\u003C\u002Fem> and other waterborne pathogens to grow. If you find that one or more of these parameters is not being met, the next step would be to take corrective actions to get conditions back within an acceptable range for the vessel’s potable water system.\u003C\u002Fp>\n\n\u003Cp>While the vessel \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the potable water system was flushed and filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Stagnant or standing water in a potable water system can increase the risk for growth and spread of \u003Cem>Legionella\u003C\u002Fem> and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the \u003Cem>Legionella\u003C\u002Fem> growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is also essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> (and other waterborne pathogens) to grow.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Monitor Disinfection Effectiveness\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>According to the Port Engineer, cabin outlets were allowed to run for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection when the vessel \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\u003C\u002Fp>\n\n\u003Cp>During the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system. Without verifying the disinfectant level, pH, and temperature during disinfection in a complex potable water system such as a vessel you cannot know whether the disinfection was effective in various areas of the potable water system. In addition, you did not perform environmental sampling of the potable water system, i.e., testing biofilm swabs and bulk potable water for microorganisms such as \u003Cem>Legionella\u003C\u002Fem>, to validate the effectiveness of the disinfection and your frequency of disinfection (\u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Cruise Lines’ Response\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We received your new Water Log on July 12, 2022, which provides for recording water samples from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for temperature, free chlorine, and pH. You changed the Water Log on August 17, 2022, to specify hot or cold water for each location. In addition, you created an additional Water Log, received by FDA on August 17, 2022, to record water samples for temperature, free chlorine, and pH \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the vessel.\u003C\u002Fp>\n\n\u003Cp>You have not provided detailed documentation of your new procedures related to water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. In addition, we have the following concerns regarding your Water Logs:\u003C\u002Fp>\n\n\u003Cp>Neither Water Log indicates your acceptable ranges for temperature and pH.\u003C\u002Fp>\n\n\u003Cp>Both Water Logs specify that free chlorine must be maintained at \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm. It is unclear how you established this level and whether it is the target level in cold only or both hot and cold water. Free chlorine that drops below an appropriately determined target level at a specific location could be indicative that additional corrective actions need to be considered, such as disinfection of the potable water system. Neither Water Log has a section for any corrective action(s) that may have occurred when free chlorine was detected below \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Therefore, it is not clear what you plan to do if this occurs.\u003C\u002Fp>\n\n\u003Cp>Both Water Logs specify \u003Cstrong>(b)(4)\u003C\u002Fstrong> for water collection; a vessel can be an extremely complex water system, and it is essential to consider \u003Cstrong>(b)(4)\u003C\u002Fstrong> for potable water parameters occurs. Also, water collection should focus on the hot water system because \u003Cem>Legionella\u003C\u002Fem> grows best in warm water; nearly all of FDA’s samples were taken from your hot water system.\u003C\u002Fp>\n\n\u003Cp>Also, timing is also essential to consider when monitoring potable water; potable water parameters taken after water has been stored on the vessel for a few days before refilling and\u002For flushing will provide different information compared to potable water parameters taken immediately after refilling and\u002For flushing. For example, a potable water holding tank that has just been flushed, refilled, and immediately sampled for potable water parameters would likely indicate the current parameters of the potable water taken onboard. A potable water tank that has not been flushed and\u002For refilled for a period of time such as a few days would be informative as to what occurs to the potable water after filling onboard and whether acceptable ranges of potable water parameters continue to be met. Your Water Logs do not specify when potable water parameters are to be taken.\u003C\u002Fp>\n\n\u003Cp>We note that both Water Logs refer only to free chlorine and not total chlorine. Vessels collect water from various locations; it is essential for the vessel to know what disinfectant such as chloramine or chlorine is being used by the potable water source being onloaded to the vessel. For example, if you take on water that is disinfected with chloramine, you would need to monitor both free chlorine and total chlorine.\u003C\u002Fp>\n\n\u003Cp>You have not provided additional information regarding how you will address the risk from stagnant water during docking. Further, it is not clear whether your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Logs are for use only during vessel operation or will also be used during docking. As explained previously, it is essential to monitor parameters such as free or total chlorine, temperatures, and pH when water is stagnant to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> to grow.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Heritage\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Presence of Legionella Onboard the Vessel\u003C\u002Fem>\u003Cbr>\nOn June 15, 2022, FDA investigators collected twenty-four (24) biofilm swabs and twenty-nine (29) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered \u003Cem>Legionella\u003C\u002Fem> from:\u003Cbr>\nBiofilm Swabs (8% of samples positive):\u003Cbr>\n• 1 Showerhead pipe in a passenger cabin\u003Cbr>\n• 1 Bathroom faucet aerator in a passenger cabin\u003C\u002Fp>\n\n\u003Cp>Potable Water (7% of samples positive)\u003Cbr>\n• 1 Showerhead pipe in a passenger cabin\u003Cbr>\n• 1 Bathroom faucet aerator in a passenger cabin\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Post-Notification Actions\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On April 30, 2021 and November 30, 2021 , you were notified by CDC of confirmed cases of Legionnaires’ disease. After being notified of two confirmed cases of Legionnaires’ disease with travel onboard the American Heritage, you did not change your procedures for flushing or disinfection and did not perform potable water or environmental sampling. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you disinfected the vessel’s potable water system. Subsequently, on June 15, 2022, FDA collected water and biofilm samples from the vessel. On July 14, 2022, FDA notified you of the positive findings regarding \u003Cem>Legionella\u003C\u002Fem> onboard the vessel. Subsequently, you provided notifications to each passenger on the voyage departing July 16, 2022, of the presence of \u003Cem>Legionella\u003C\u002Fem> in the potable water system. You also provided notifications to passengers onboard the vessel previously that departed on June 18, 2022, June 25, 2022, July 2, 2022, and July 9, 2022.\u003C\u002Fp>\n\n\u003Cp>FDA’s positive samples were collected after your \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection and thus show that your disinfection was not fully effective. The passenger cabin where FDA detected \u003Cem>Legionella\u003C\u002Fem> in the showerhead pipe and bathroom faucet aerator is very distal to the potable water holding tanks and water heaters; distal locations are where routine chlorine levels would be lowest and hyperchlorination would be least effective. You subsequently disinfected the showerhead pipe and sink faucet aerator in the positive passenger cabin and installed a \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the showerhead in that cabin to decrease the risk of exposure to \u003Cem>Legionella\u003C\u002Fem>. However, you have not performed any additional disinfection of the potable water system since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is prior to FDA’s collection of positive samples.\u003C\u002Fp>\n\n\u003Cp>We continue to have concerns with the potential exposure of passengers and crew members to \u003Cem>Legionella\u003C\u002Fem> onboard the American Heritage. We note that you have chosen not to do remediation and disinfect the potable water system after notification that the showerhead pipe and sink faucet aerator in a passenger cabin had biofilm swabs and potable water samples that tested positive for Legionella. FDA’s sampling results demonstrate that the disinfection performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, prior to the initial representative sampling by FDA, was not sufficient to address \u003Cem>Legionella\u003C\u002Fem> onboard the American Heritage. The device on the showerhead in the passenger cabin that assists in limiting exposure from showering does not address the overall concern that \u003Cem>Legionella\u003C\u002Fem> may be present in the vessel’s potable water system. Also, although you indicated that you disinfected the sink faucet aerator, you have not addressed the \u003Cem>Legionella\u003C\u002Fem> found in the biofilms from the pipe and in the sink faucet aerator of the passenger cabin. When \u003Cem>Legionella\u003C\u002Fem> is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine. You need to ensure that the disinfection procedures you use are effective for the removal of biofilms associated with \u003Cem>Legionella\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>As we have informed you previously, a voluntary corrective action plan would include documentation of detailed procedures put in place onboard the vessel for control of Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective. On July 21, 2022, FDA expressed concern that you had not provided a detailed disinfection process to be used in the future for the potable water system. On August 28, 2022, you provided a response which stated that you will do a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the vessel with no less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To date, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of \u003Cem>Legionella\u003C\u002Fem> when water is stagnant.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Vessel Inspection\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the following insanitary conditions and practices were observed:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Monitor Potable Water Parameters\u003C\u002Fem>\u003Cbr>\nYou did not monitor parameters of the potable water, such as free or total chlorine residual, temperatures, and pH on the vessel when docked and not in operation or while in operation.\u003C\u002Fp>\n\n\u003Cp>Sample collection of biofilm swabs and potable water samples by FDA investigators on June 15, 2022, documented the following:\u003C\u002Fp>\n\n\u003Cp>Nineteen of 24 biofilm swabs and 24 of 29 bulk potable water samples had no free or total chlorine residual. Lack of free and\u002For total chlorine indicates that conditions, such as the presence of biofilm or planktonic microorganisms may have led to the immediate use of this residual chlorine in the potable water system onboard the vessel.\u003C\u002Fp>\n\n\u003Cp>Twenty-two of 24 biofilm swabs and 26 of 29 bulk potable water samples had temperature ranges from 81.3°F - 113°F, which is ideal for potential \u003Cem>Legionella\u003C\u002Fem> growth.\u003C\u002Fp>\n\n\u003Cp>pH was measured between 6-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored. Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases &gt;7, with significant loss of efficacy at pH &gt;8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\u003C\u002Fp>\n\n\u003Cp>By monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage \u003Cem>Legionella\u003C\u002Fem> and other waterborne pathogens to grow. If you find that one or more of these parameters (e.g., pH, free or total chlorine, temperature) is not being met, the next step would be to take corrective actions to get conditions back to within an acceptable range for the vessel’s potable water system.\u003C\u002Fp>\n\n\u003Cp>While the vessel was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the potable water system was flushed and filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Stagnant or standing water in a potable water system can increase the risk for growth and spread of \u003Cem>Legionella\u003C\u002Fem> and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the \u003Cem>Legionella\u003C\u002Fem> growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> (and other waterborne pathogens) to grow.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Monitor Disinfection Effectiveness\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The Engineering Manager stated that disinfection was performed once from March 2021 to March 2022 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During disinfection, cabin outlets were allowed to run for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\u003C\u002Fp>\n\n\u003Cp>The disinfection consisted of forcing the potable water tanks to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and then flushing \u003Cstrong>(b)(4)\u003C\u002Fstrong> shower heads and sinks on the vessel. Afterwards, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was adjusted down to \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm to make the water potable again. During the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system.\u003C\u002Fp>\n\n\u003Cp>Further, the disinfection you performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was not sufficient as demonstrated by FDA’s sampling results from June 15, 2022 that showed the presence of \u003Cem>Legionella\u003C\u002Fem> in a passenger cabin. Lack of verification of the disinfectant, pH, and temperature during disinfection in a complex potable water system such as a vessel prevents you from knowing whether the disinfection was effective in various areas of the potable water system. In addition, you did not sample the potable water system for microorganisms such as \u003Cem>Legionella\u003C\u002Fem> to verify the effectiveness of the disinfection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Cruise Lines’ Response\u003C\u002Fstrong>\u003Cbr>\nOn July 19, 2022, we received your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log, which provides for recording water samples for temperature, free chlorine, and pH. You stated that the updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log would reflect water samples from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log would reflect water samples from the 22 same locations for the next 30 days inclusive of the showerhead pipes and sink faucet aerators that were positive for Legionella. On August 1, 2022, FDA received a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log to replace the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log and to be completed \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Aside from the Water Logs, we have not received documentation regarding your procedures for water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. We have similar concerns with regards to these Water Logs as we express earlier in this letter for the Water Logs for the American Star.\u003C\u002Fp>\n\n\u003Cp>Regarding disinfection during \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your August 28 response stated that you will do a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the vessel with no less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of Legionella when water is stagnant. Also, it is not clear whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Logs you provided are for use only when the vessel is in operation or also will be used when the vessel is docked. As explained earlier, it is essential for you to monitor parameters such as pH, free or total chlorine residual, and temperatures during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> (and other waterborne pathogens) to grow. Water that stagnates for extended periods of time may allow for the growth of these biofilms, which can decrease the effectiveness of the disinfectant used. As a reminder, when \u003Cem>Legionella\u003C\u002Fem> is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine.\u003C\u002Fp>\n\n\u003Cp>Note that “Only potable water shall be provided for drinking and culinary purposes by any operator of a conveyance engaged in interstate traffic” (see 21 CFR 1240.80). Potable water is defined as “[w]ater which meets the standards prescribed in the Environmental Protection Agency's Primary Drinking Water Regulations as set forth in 40 CFR part 141 and the [FDA’s] sanitation requirements as set forth in [21 CFR Parts 1240 and 1250]” (see 21 CFR 1240.3).\u003C\u002Fp>\n\n\u003Cp>Finally, we note that you have other vessels in your fleet. Although we are not aware of a case of Legionnaires’ disease being associated with any of those vessels, based on your practices on the American Star and American Heritage, we have concerns about the potable water on your other vessels. Specifically, if adequate practices are not followed regarding potable water on those vessels, there is a potential for waterborne illnesses to occur. It would not be appropriate to wait until there is a confirmed case of Legionnaires’ disease to address the water practices onboard those other vessels. As a reminder, people at increased risk of Legionnaire’s disease include those 50 years of age or older and we understand that the majority of your passengers onboard the American Star and American Heritage exceed this age.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your vessels. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Stephen Rabe, Compliance Officer, via email at: ORAHAFEAST5FirmResponses@fda.hhs.gov or to U.S. Food and Drug Administration, 550 Main Street, Suite 4-930, Cincinnati, OH 45202. If you have any questions about the content of this letter, you may contact Mr. Rabe at 513-322-0660.\u003C\u002Fp>\n\n\u003Cp>Please also send a copy of the reply to Beira Montalvo, Compliance Officer, via email at: Beira.Montalvo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDivision Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast 5\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Notification by CDC is based on travel on a cruise ship during any of the 14 days before symptom onset. Notification does not mean that the vessel is the source of infection.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPaul E. Taiclet\n\nRecipient Title\n\nExecutive Vice President\n\nAmerican Cruise Lines\n\n741 Boston Post Road, Suite 200\n\nGuilford, CT 06437\n\nUnited States\n\nTaiclet@americancruiselines.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nJanuary 24, 2023\n\nWarning Letter 641736\n\nDear Mr. Taiclet:\n\nThe United States Food and Drug Administration (FDA) inspected your American Star and American Heritage vessels from April 30, 2022, through June 17, 2022, and from June 15, 2022, through August 15, 2022, respectively. FDA also conducted an investigation of the American Star and American Heritage vessels in December 2021. The investigation and inspections were initiated by FDA after three of your passengers who traveled in April 2021, September 2021, and September-October 2021 aboard these vessels were diagnosed with Legionnaires’ disease. American Cruise Lines and FDA were notified by the Centers for Disease Control and Prevention (CDC) of the first confirmed case of Legionnaires’ disease at the end of April 2021 (American Heritage), the second at the beginning of November 2021 (American Star), and the third at the end of November 2021 (American Heritage).1\n\nDuring our inspections, FDA investigators collected biofilm swabs and potable water samples from your American Star and American Heritage vessels. Laboratory Analysis of those samples identified Legionella pneumophilia serogroup 1 and Legionella spp. (hereinafter collectively called Legionella) in the potable water system of the vessels. FDA investigators also observed insanitary conditions related to the potable water systems onboard the vessels. At the conclusion of the inspections, the FDA investigators issued a Form FDA 483, Inspectional Observations, to both vessels.\n\nBased on FDA’s inspectional findings, we have determined that the potable water onboard the American Star and American Heritage vessels is adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that it has been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth or rendered injurious to health.\n\nAdditionally, the presence of Legionella in the potable water on the American Star and American Heritage vessels, as evidenced by the laboratory analysis of FDA’s water samples, causes your vessels’ potable water to be adulterated within the meaning of section 402(a)(1) of the Act [21 U.S.C. § 342(a)(1)] in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.\n\nWe received your responses to the biofilm swabs and potable water positive results for Legionella and to the Form FDA 483 in regard to the American Star on the following dates: June 2, 2022, June 4, 2022, June 13, 2022, June 28, 2022, July 5, 2022, July 6, 2022, July 8, 2022, July 11, 2022, July 12, 2022, July 14, 2022, July 20, 2022, August 2, 2022, and August 16, 2022. We received your responses in regard to the American Heritage on July 19, 2022, August 1, 2022, August 16, 2022, and August 28, 2022.\n\nAfter reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continued concerns and to provide detailed information describing our findings.\n\nAmerican Star\n\nPresence of Legionella Onboard the Vessel\n\nOn April 30, 2022, FDA investigators collected ten (10) biofilm swabs and fourteen (14) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered Legionella from:\n\nBiofilm Swabs (60% of samples positive):\n\n• 5 Showerhead pipes in passenger cabins\n\n• Wait station hand sink faucet aerator in the galley\n\nPotable Water (93% of samples positive):\n\n• 7 Showerhead pipes in passenger cabins\n\n• 2 Showerhead pipes in crew rooms\n\n• Wait station hand sink faucet aerator in the galley\n\n• Galley prep sink faucet aerator\n\n• Potable water holding tank\n\n• Post pump (b)(4) hot water return spigot\n\nPost-Notification Actions\n\nYou did not change your procedures regarding potable water after CDC notified you on November 5, 2021, that one of your passengers was diagnosed with Legionnaires’ disease. For example, you did not change your procedures for flushing or disinfection and did not perform environmental sampling. Subsequently, after FDA notified you of its detection of Legionella onboard your vessel (June 2, 2022), you disinfected the vessel’s potable water system on (b)(4). On June 4, 2022, you provided a letter to each passenger notifying them of the presence of Legionella in the potable water system onboard your vessel and mitigation steps you had taken. Also, you provided a letter notifying passengers who were onboard the vessel previously from May 3, 2022 to June 4, 2022.\n\nDuring the week of (b)(4), you conducted water sampling using a field test kit. On June 24, 2022, FDA expressed concerns to you regarding the use of this field test kit and ending passenger notifications based on this testing because your testing was limited to Legionella pneumophilia serogroup 1 and did not include species identified as present on the vessel by FDA’s testing. In addition, FDA expressed concerns with the sensitivity, detection limit, and size of the water samples collected for the field test kit you used. On June 28, 2022, you shared additional sample collection results with FDA, separate from the field test kit, that were analyzed in a laboratory.\n\nFDA expressed concerns with these laboratory results not being representative nor sufficient to determine whether Legionella is still present and your use of these and the field test kit results to justify ending notification of passengers. Specifically, FDA collected 14 bulk water and 10 biofilm swab samples; you collected (b)(4) bulk water and (b)(4) biofilm swab samples for the laboratory tests. Thirteen of fourteen (92.86%) of FDA’s bulk water samples and 6 of 10 (60%) of FDA’s biofilm swab samples were positive for Legionella. You did not evaluate most of the bulk water and biofilm swab locations that were positive from FDA’s sampling. In addition, one of the biofilm swabs you took was from a (b)(4) that was negative from FDA’s sampling.\n\nYou restarted passenger notifications and provided them from July 9, 2022 to July 30, 2022. On (b)(4), you collected additional samples and notified FDA of negative results on August 16, 2022. On September 20, 2022, FDA submitted additional follow-up questions regarding the vessel’s sampling process, laboratory results, and future disinfection process. To date, we have not received a response.\n\nFurther, in FDA’s emails to American Cruise Lines on July 11, 2022 and August 5, 2022, we reminded you that a voluntary corrective action plan to FDA would include not only testing for Legionella, but other documents, such as detailed procedures put in place onboard the vessel to address Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective.\n\nVessel Inspection\n\nDuring the inspection, the following insanitary conditions and practices were observed: Failure to Monitor Potable Water Parameters\n\nYou did not monitor potable water parameters, such as free or total chlorine residual, temperature, and pH on the vessel when docked and not in operation or while in operation. Sample collection of biofilm swabs and potable water samples by FDA investigators on April 30, 2022, documented the following:\n\nFree chlorine and total chlorine residual were measured at 1.5ppm and 2ppm, respectively, in the potable water holding tanks where water is initially stored in the vessel. After the potable water traveled from the potable water holding tanks where initially stored to distal piping onboard the vessel such as showerheads, seven of 10 biofilm swabs and 10 of 14 bulk potable water samples had no free or total chlorine residual. The dissipation in chlorine residual from the potable water holding tanks to distal piping indicates that conditions, such as the presence of biofilm or planktonic microorganisms, led to the immediate use of the residual chlorine in the potable water system on the vessel.\n\nEight of 10 biofilm swabs from showerhead pipes and a wait station hand sink faucet aerator and 11 of 14 bulk potable water samples had temperature ranges from 83.1°F - 112.6°F, which is ideal for Legionella growth.\n\npH was measured between 5-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored. Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases >7, with significant loss of efficacy at pH >8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\n\nBy monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage Legionella and other waterborne pathogens to grow. If you find that one or more of these parameters is not being met, the next step would be to take corrective actions to get conditions back within an acceptable range for the vessel’s potable water system.\n\nWhile the vessel (b)(4), the potable water system was flushed and filled (b)(4). Stagnant or standing water in a potable water system can increase the risk for growth and spread of Legionella and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the Legionella growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is also essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella (and other waterborne pathogens) to grow.\n\nFailure to Monitor Disinfection Effectiveness\n\nAccording to the Port Engineer, cabin outlets were allowed to run for approximately (b)(4) during (b)(4) disinfection when the vessel (b)(4). No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\n\nDuring the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system. Without verifying the disinfectant level, pH, and temperature during disinfection in a complex potable water system such as a vessel you cannot know whether the disinfection was effective in various areas of the potable water system. In addition, you did not perform environmental sampling of the potable water system, i.e., testing biofilm swabs and bulk potable water for microorganisms such as Legionella, to validate the effectiveness of the disinfection and your frequency of disinfection ((b)(4)).\n\nAmerican Cruise Lines’ Response\n\nWe received your new Water Log on July 12, 2022, which provides for recording water samples from (b)(4) for temperature, free chlorine, and pH. You changed the Water Log on August 17, 2022, to specify hot or cold water for each location. In addition, you created an additional Water Log, received by FDA on August 17, 2022, to record water samples for temperature, free chlorine, and pH (b)(4) on (b)(4) from (b)(4) on the vessel.\n\nYou have not provided detailed documentation of your new procedures related to water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. In addition, we have the following concerns regarding your Water Logs:\n\nNeither Water Log indicates your acceptable ranges for temperature and pH.\n\nBoth Water Logs specify that free chlorine must be maintained at (b)(4)ppm. It is unclear how you established this level and whether it is the target level in cold only or both hot and cold water. Free chlorine that drops below an appropriately determined target level at a specific location could be indicative that additional corrective actions need to be considered, such as disinfection of the potable water system. Neither Water Log has a section for any corrective action(s) that may have occurred when free chlorine was detected below (b)(4) ppm. Therefore, it is not clear what you plan to do if this occurs.\n\nBoth Water Logs specify (b)(4) for water collection; a vessel can be an extremely complex water system, and it is essential to consider (b)(4) for potable water parameters occurs. Also, water collection should focus on the hot water system because Legionella grows best in warm water; nearly all of FDA’s samples were taken from your hot water system.\n\nAlso, timing is also essential to consider when monitoring potable water; potable water parameters taken after water has been stored on the vessel for a few days before refilling and\u002For flushing will provide different information compared to potable water parameters taken immediately after refilling and\u002For flushing. For example, a potable water holding tank that has just been flushed, refilled, and immediately sampled for potable water parameters would likely indicate the current parameters of the potable water taken onboard. A potable water tank that has not been flushed and\u002For refilled for a period of time such as a few days would be informative as to what occurs to the potable water after filling onboard and whether acceptable ranges of potable water parameters continue to be met. Your Water Logs do not specify when potable water parameters are to be taken.\n\nWe note that both Water Logs refer only to free chlorine and not total chlorine. Vessels collect water from various locations; it is essential for the vessel to know what disinfectant such as chloramine or chlorine is being used by the potable water source being onloaded to the vessel. For example, if you take on water that is disinfected with chloramine, you would need to monitor both free chlorine and total chlorine.\n\nYou have not provided additional information regarding how you will address the risk from stagnant water during docking. Further, it is not clear whether your (b)(4) and (b)(4) Water Logs are for use only during vessel operation or will also be used during docking. As explained previously, it is essential to monitor parameters such as free or total chlorine, temperatures, and pH when water is stagnant to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella to grow.\n\nAmerican Heritage\n\nPresence of Legionella Onboard the Vessel\n\nOn June 15, 2022, FDA investigators collected twenty-four (24) biofilm swabs and twenty-nine (29) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered Legionella from:\n\nBiofilm Swabs (8% of samples positive):\n\n• 1 Showerhead pipe in a passenger cabin\n\n• 1 Bathroom faucet aerator in a passenger cabin\n\nPotable Water (7% of samples positive)\n\n• 1 Showerhead pipe in a passenger cabin\n\n• 1 Bathroom faucet aerator in a passenger cabin\n\nPost-Notification Actions\n\nOn April 30, 2021 and November 30, 2021 , you were notified by CDC of confirmed cases of Legionnaires’ disease. After being notified of two confirmed cases of Legionnaires’ disease with travel onboard the American Heritage, you did not change your procedures for flushing or disinfection and did not perform potable water or environmental sampling. On (b)(4), you disinfected the vessel’s potable water system. Subsequently, on June 15, 2022, FDA collected water and biofilm samples from the vessel. On July 14, 2022, FDA notified you of the positive findings regarding Legionella onboard the vessel. Subsequently, you provided notifications to each passenger on the voyage departing July 16, 2022, of the presence of Legionella in the potable water system. You also provided notifications to passengers onboard the vessel previously that departed on June 18, 2022, June 25, 2022, July 2, 2022, and July 9, 2022.\n\nFDA’s positive samples were collected after your (b)(4) disinfection and thus show that your disinfection was not fully effective. The passenger cabin where FDA detected Legionella in the showerhead pipe and bathroom faucet aerator is very distal to the potable water holding tanks and water heaters; distal locations are where routine chlorine levels would be lowest and hyperchlorination would be least effective. You subsequently disinfected the showerhead pipe and sink faucet aerator in the positive passenger cabin and installed a (b)(4) on the showerhead in that cabin to decrease the risk of exposure to Legionella. However, you have not performed any additional disinfection of the potable water system since (b)(4), which is prior to FDA’s collection of positive samples.\n\nWe continue to have concerns with the potential exposure of passengers and crew members to Legionella onboard the American Heritage. We note that you have chosen not to do remediation and disinfect the potable water system after notification that the showerhead pipe and sink faucet aerator in a passenger cabin had biofilm swabs and potable water samples that tested positive for Legionella. FDA’s sampling results demonstrate that the disinfection performed on (b)(4), prior to the initial representative sampling by FDA, was not sufficient to address Legionella onboard the American Heritage. The device on the showerhead in the passenger cabin that assists in limiting exposure from showering does not address the overall concern that Legionella may be present in the vessel’s potable water system. Also, although you indicated that you disinfected the sink faucet aerator, you have not addressed the Legionella found in the biofilms from the pipe and in the sink faucet aerator of the passenger cabin. When Legionella is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine. You need to ensure that the disinfection procedures you use are effective for the removal of biofilms associated with Legionella.\n\nAs we have informed you previously, a voluntary corrective action plan would include documentation of detailed procedures put in place onboard the vessel for control of Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective. On July 21, 2022, FDA expressed concern that you had not provided a detailed disinfection process to be used in the future for the potable water system. On August 28, 2022, you provided a response which stated that you will do a “(b)(4)” of the vessel with no less than (b)(4)ppm of (b)(4) for a minimum of (b)(4) when (b)(4). To date, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of Legionella when water is stagnant.\n\nVessel Inspection\n\nDuring the inspection, the following insanitary conditions and practices were observed:\n\nFailure to Monitor Potable Water Parameters\n\nYou did not monitor parameters of the potable water, such as free or total chlorine residual, temperatures, and pH on the vessel when docked and not in operation or while in operation.\n\nSample collection of biofilm swabs and potable water samples by FDA investigators on June 15, 2022, documented the following:\n\nNineteen of 24 biofilm swabs and 24 of 29 bulk potable water samples had no free or total chlorine residual. Lack of free and\u002For total chlorine indicates that conditions, such as the presence of biofilm or planktonic microorganisms may have led to the immediate use of this residual chlorine in the potable water system onboard the vessel.\n\nTwenty-two of 24 biofilm swabs and 26 of 29 bulk potable water samples had temperature ranges from 81.3°F - 113°F, which is ideal for potential Legionella growth.\n\npH was measured between 6-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored. Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases >7, with significant loss of efficacy at pH >8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\n\nBy monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage Legionella and other waterborne pathogens to grow. If you find that one or more of these parameters (e.g., pH, free or total chlorine, temperature) is not being met, the next step would be to take corrective actions to get conditions back to within an acceptable range for the vessel’s potable water system.\n\nWhile the vessel was (b)(4), the potable water system was flushed and filled (b)(4). Stagnant or standing water in a potable water system can increase the risk for growth and spread of Legionella and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the Legionella growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella (and other waterborne pathogens) to grow.\n\nFailure to Monitor Disinfection Effectiveness\n\nThe Engineering Manager stated that disinfection was performed once from March 2021 to March 2022 and (b)(4) during (b)(4) from (b)(4). During disinfection, cabin outlets were allowed to run for approximately (b)(4). No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\n\nThe disinfection consisted of forcing the potable water tanks to a (b)(4) concentration of (b)(4)ppm for (b)(4) and then flushing (b)(4) shower heads and sinks on the vessel. Afterwards, the (b)(4) was adjusted down to (b)(4)ppm to make the water potable again. During the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system.\n\nFurther, the disinfection you performed on (b)(4), was not sufficient as demonstrated by FDA’s sampling results from June 15, 2022 that showed the presence of Legionella in a passenger cabin. Lack of verification of the disinfectant, pH, and temperature during disinfection in a complex potable water system such as a vessel prevents you from knowing whether the disinfection was effective in various areas of the potable water system. In addition, you did not sample the potable water system for microorganisms such as Legionella to verify the effectiveness of the disinfection.\n\nAmerican Cruise Lines’ Response\n\nOn July 19, 2022, we received your new (b)(4) and (b)(4) Water Log, which provides for recording water samples for temperature, free chlorine, and pH. You stated that the updated (b)(4) Water Log would reflect water samples from (b)(4), and the updated (b)(4) Water Log would reflect water samples from the 22 same locations for the next 30 days inclusive of the showerhead pipes and sink faucet aerators that were positive for Legionella. On August 1, 2022, FDA received a new (b)(4) Water Log and a (b)(4) Water Log to replace the (b)(4) Water Log and to be completed (b)(4) from (b)(4).\n\nAside from the Water Logs, we have not received documentation regarding your procedures for water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. We have similar concerns with regards to these Water Logs as we express earlier in this letter for the Water Logs for the American Star.\n\nRegarding disinfection during (b)(4), your August 28 response stated that you will do a “(b)(4)” of the vessel with no less than (b)(4)ppm of (b)(4) for a minimum of (b)(4) when the (b)(4). However, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of Legionella when water is stagnant. Also, it is not clear whether the (b)(4) and (b)(4) Water Logs you provided are for use only when the vessel is in operation or also will be used when the vessel is docked. As explained earlier, it is essential for you to monitor parameters such as pH, free or total chlorine residual, and temperatures during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella (and other waterborne pathogens) to grow. Water that stagnates for extended periods of time may allow for the growth of these biofilms, which can decrease the effectiveness of the disinfectant used. As a reminder, when Legionella is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine.\n\nNote that “Only potable water shall be provided for drinking and culinary purposes by any operator of a conveyance engaged in interstate traffic” (see 21 CFR 1240.80). Potable water is defined as “[w]ater which meets the standards prescribed in the Environmental Protection Agency's Primary Drinking Water Regulations as set forth in 40 CFR part 141 and the [FDA’s] sanitation requirements as set forth in [21 CFR Parts 1240 and 1250]” (see 21 CFR 1240.3).\n\nFinally, we note that you have other vessels in your fleet. Although we are not aware of a case of Legionnaires’ disease being associated with any of those vessels, based on your practices on the American Star and American Heritage, we have concerns about the potable water on your other vessels. Specifically, if adequate practices are not followed regarding potable water on those vessels, there is a potential for waterborne illnesses to occur. It would not be appropriate to wait until there is a confirmed case of Legionnaires’ disease to address the water practices onboard those other vessels. As a reminder, people at increased risk of Legionnaire’s disease include those 50 years of age or older and we understand that the majority of your passengers onboard the American Star and American Heritage exceed this age.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your vessels. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to Stephen Rabe, Compliance Officer, via email at: ORAHAFEAST5FirmResponses@fda.hhs.gov or to U.S. Food and Drug Administration, 550 Main Street, Suite 4-930, Cincinnati, OH 45202. If you have any questions about the content of this letter, you may contact Mr. Rabe at 513-322-0660.\n\nPlease also send a copy of the reply to Beira Montalvo, Compliance Officer, via email at: Beira.Montalvo@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDivision Director\n\nOffice of Human and Animal Food Operations\n\nEast 5\n\n_________________________________\n\n1 Notification by CDC is based on travel on a cruise ship during any of the 14 days before symptom onset. Notification does not mean that the vessel is the source of infection.","American Cruise Lines","american-cruise-lines-641736-01242023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cruise-lines-641736-01242023","2026-10-26T08:07:54.752621+00:00","2023-02-14","641736","Food & Beverages","Division of Human and Animal Food Operations East V","Paul E. Taiclet","2026-08-20T01:15:11.36+00:00","United Parcel Service","2023-01-24",{"id":160,"raw":161,"subject":165,"body_html":167,"body_text":168,"firm_name":169,"letter_id":170,"created_at":171,"fei_number":19,"letter_url":172,"updated_at":173,"action_type":22,"case_status":174,"posted_date":175,"marcs_cms_no":176,"product_type":26,"closeout_date":24,"issuing_office":11,"recipient_name":177,"body_fetched_at":178,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":179,"medical_device_id":19,"response_letter_date":19},3279,[162,163,164,11,165,13,166,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-07T04:00:00Z\">05\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnikkiso-medical-america-inc-613109-05072021\">Nikkiso Medical America, Inc\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnikkiso-co-ltd-613109-07232025\">\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Toshihiko Kai \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nikkiso Medical America, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20-3, Ebisu 4-Chome, Shibuya-ku\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tokyo\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>150-6022\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:T.Kai@nikkiso.co.jp\"> T.Kai@nikkiso.co.jp\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 7, 2021\u003Cbr>\n\u003Cbr>\nRefer to CPT1900751; CMS #613109\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Toshihiko Kai:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the Nikkiso DBB-06 (DBB-06) in the United States without the necessary marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>FDA reviewed on February 5, 2021 Nikkiso’s marketing materials for DBB-06. This review revealed that DBB-06 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The DBB-06 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with a significant change or modification, specifically the introduction of a physiological closed loop controller (PCLC) system (also referred to as PCLC function or functionality in this letter) which is a change or modification in the device that could significantly affect the safety or effectiveness of the device, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s marketing materials for DBB-06 provide evidence that the device is intended for dialysis with a PCLC system, which would constitute a significant change or modification to the device, for which your firm lacks clearance or approval. Examples include:\u003Cbr>\n\u003Cbr>\n• In the online version of your firm’s product brochure found at http:\u002F\u002Fnikkisoamerica.com\u002Fwp-content\u002Fuploads\u002F2011\u002F08\u002FNIKKISO-DBB06-RV09262016-V3.pdf, your firmclaims that the DBB-06 Haemo-Master Blood Volume Monitor (BVM) uses “adaptive feedback” to regulate the “blood volume trend.”\u003C\u002Fp>\n\n\u003Cp>• The website also includes the following statement: “The unique adaptive feedback feature of the BVM allows for automatic changes of fluid removal to achieve desired outcomes.”\u003C\u002Fp>\n\n\u003Cp>Although the DBB-06 device was cleared via the 510(k) pathway under K091978 and K152938, neither K091978 nor K152938 adequately described the PCLC function. For example, there is no mention of PCLC functionality in the 510(k) summary or in the Indications for Use statement for either 510(k). Notably, on page 6 of the 510(k) summary for K091978, the Blood Volume Monitor’s intended use is described as follows: “The healthcare provider may increase or decrease the rate at which fluid is removed from the blood based on the data that blood volume monitor provides.” This description contrasts with your firm’s current marketing materials, which describe PCLC functionality, i.e., the use of “adaptive feedback” to change dialysis therapy parameters (e.g., ultrafiltration rate) automatically with no clinician involvement. As discussed above, the introduction of a PCLC system is considered a change or modification in the device that could significantly affect the safety or effectiveness of the device, and therefore, requires clearance or approval. For example, the introduction of a PCLC system creates new risks, including reduced monitoring and adjustment of dialysis therapy by the clinician due to increased reliance on automation technology to monitor and adjust dialysis therapy.\u003C\u002Fp>\n\n\u003Cp>This is not the first time that FDA has communicated with your firm that the PCLC function was not cleared under either K091978 or K152938 for the device. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please provide a justification for inclusion of this feature with supportive performance data for its safe and effective use. If your intent is to reference the DBB-06 device (K091978 and K152938), we do not believe this function was cleared.” On August 16, 2019, FDA issued your firm an “It has come to our attention” letter advising your firm that FDA believed the “Haemo-Master Blood Volume Monitor as an adaptive feedback controller of the ultrafiltration rate for a patient” was not cleared under the 510(k) pathway. In additional correspondence in 2019, Nikkiso continued to take the position that the PCLC function had been addressed by validation testing included in an Appendix to K091978 and that the PCLC function had been cleared. Nonetheless, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Regardless of whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, along with all the previous communication, illustrates that the firm understands FDA’s position on the regulatory status of the DBB-06 device with the PCLC function.\u003Cbr>\n\u003Cbr>\nBased on the information reviewed by FDA, Nikkiso’s marketing of the DBB-06 device with the PCLC function, which has not been cleared or approved, has resulted, as noted above, in the misbranding and adulteration of the device.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our office requests that Nikkiso America, Inc. immediately cease activities that result in the misbranding or adulteration of the Nikkiso DBB-06, such as the commercial distribution of the device with the PCLC function as discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the identification number CPT1900751 and CMS# 613109 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact Carolyn Y. Neuland, Ph.D. at 301-796-6523.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: US Agent:\u003Cbr>\nDeno Zachary\u003Cbr>\nMIC International\u003Cbr>\n206 East 75th Street, Suite 4\u003Cbr>\nNew York , NY US 10021\u003Cbr>\nPhone: 917 3315789 Ext\u003Cbr>\nEmail: Dzachary@Micinternational.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Toshihiko Kai\n\nRecipient Title\n\nPresident & Chief Executive Officer\n\nNikkiso Medical America, Inc\n\n20-3, Ebisu 4-Chome, Shibuya-ku\n\nTokyo,\n\n150-6022\n\nJapan\n\nT.Kai@nikkiso.co.jp\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nMay 7, 2021\n\nRefer to CPT1900751; CMS #613109\n\nDear Mr. Toshihiko Kai:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the Nikkiso DBB-06 (DBB-06) in the United States without the necessary marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nFDA reviewed on February 5, 2021 Nikkiso’s marketing materials for DBB-06. This review revealed that DBB-06 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The DBB-06 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with a significant change or modification, specifically the introduction of a physiological closed loop controller (PCLC) system (also referred to as PCLC function or functionality in this letter) which is a change or modification in the device that could significantly affect the safety or effectiveness of the device, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3).\n\nSpecifically, your firm’s marketing materials for DBB-06 provide evidence that the device is intended for dialysis with a PCLC system, which would constitute a significant change or modification to the device, for which your firm lacks clearance or approval. Examples include:\n\n• In the online version of your firm’s product brochure found at http:\u002F\u002Fnikkisoamerica.com\u002Fwp-content\u002Fuploads\u002F2011\u002F08\u002FNIKKISO-DBB06-RV09262016-V3.pdf, your firmclaims that the DBB-06 Haemo-Master Blood Volume Monitor (BVM) uses “adaptive feedback” to regulate the “blood volume trend.”\n\n• The website also includes the following statement: “The unique adaptive feedback feature of the BVM allows for automatic changes of fluid removal to achieve desired outcomes.”\n\nAlthough the DBB-06 device was cleared via the 510(k) pathway under K091978 and K152938, neither K091978 nor K152938 adequately described the PCLC function. For example, there is no mention of PCLC functionality in the 510(k) summary or in the Indications for Use statement for either 510(k). Notably, on page 6 of the 510(k) summary for K091978, the Blood Volume Monitor’s intended use is described as follows: “The healthcare provider may increase or decrease the rate at which fluid is removed from the blood based on the data that blood volume monitor provides.” This description contrasts with your firm’s current marketing materials, which describe PCLC functionality, i.e., the use of “adaptive feedback” to change dialysis therapy parameters (e.g., ultrafiltration rate) automatically with no clinician involvement. As discussed above, the introduction of a PCLC system is considered a change or modification in the device that could significantly affect the safety or effectiveness of the device, and therefore, requires clearance or approval. For example, the introduction of a PCLC system creates new risks, including reduced monitoring and adjustment of dialysis therapy by the clinician due to increased reliance on automation technology to monitor and adjust dialysis therapy.\n\nThis is not the first time that FDA has communicated with your firm that the PCLC function was not cleared under either K091978 or K152938 for the device. (b)(4). Please provide a justification for inclusion of this feature with supportive performance data for its safe and effective use. If your intent is to reference the DBB-06 device (K091978 and K152938), we do not believe this function was cleared.” On August 16, 2019, FDA issued your firm an “It has come to our attention” letter advising your firm that FDA believed the “Haemo-Master Blood Volume Monitor as an adaptive feedback controller of the ultrafiltration rate for a patient” was not cleared under the 510(k) pathway. In additional correspondence in 2019, Nikkiso continued to take the position that the PCLC function had been addressed by validation testing included in an Appendix to K091978 and that the PCLC function had been cleared. Nonetheless, (b)(4).\n\nRegardless of whether the (b)(4), along with all the previous communication, illustrates that the firm understands FDA’s position on the regulatory status of the DBB-06 device with the PCLC function.\n\nBased on the information reviewed by FDA, Nikkiso’s marketing of the DBB-06 device with the PCLC function, which has not been cleared or approved, has resulted, as noted above, in the misbranding and adulteration of the device.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur office requests that Nikkiso America, Inc. immediately cease activities that result in the misbranding or adulteration of the Nikkiso DBB-06, such as the commercial distribution of the device with the PCLC function as discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nYour firm’s response should be sent to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the identification number CPT1900751 and CMS# 613109 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact Carolyn Y. Neuland, Ph.D. at 301-796-6523.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC: US Agent:\n\nDeno Zachary\n\nMIC International\n\n206 East 75th Street, Suite 4\n\nNew York , NY US 10021\n\nPhone: 917 3315789 Ext\n\nEmail: Dzachary@Micinternational.com","Nikkiso Medical America, Inc","nikkiso-medical-america-inc-613109-05072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnikkiso-medical-america-inc-613109-05072021","2026-10-26T08:09:33.866363+00:00","Closed Out","2021-07-06","613109","Mr. Toshihiko Kai","2026-08-20T03:00:01.467+00:00","2021-05-07",{"id":181,"raw":182,"subject":80,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":43,"fei_number":19,"letter_url":191,"updated_at":192,"action_type":22,"case_status":23,"posted_date":193,"marcs_cms_no":194,"product_type":133,"closeout_date":19,"issuing_office":186,"recipient_name":195,"body_fetched_at":196,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":197,"medical_device_id":19,"response_letter_date":19},2395,[183,184,185,186,80,13,13,13],"\u003Ctime datetime=\"2022-10-18T13:20:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-06T04:00:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cleaning-solutions-632881-09062022\">American Cleaning Solutions\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ronald C. Ingber\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Cleaning Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3930 Review Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Long Island City\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter CMS #: 632881\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ingber:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, American Cleaning Solutions, FEI 3001587133, at 3930 Review Avenue, Long Island City, Ny from March 7 to March 28, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 29, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP. We acknowledge your commitment to deregistering and your decision to cease manufacturing hand sanitizer drug products permanently.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizer\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> drug products including Secure Gel Hand Rub and Secure Hand Rub, as well as non-drug products including insecticides and industrial cleaners. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture pesticides or other non-pharmaceutical products due to the risk of cross-contamination. Our investigator also observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\u003C\u002Fp>\n\n\u003Cp>Your firm lacks an adequate cleaning and maintenance procedure. Your cleaning procedure states that your production tanks are cleaned with hot water and allowed to air dry. Your procedure does not list or describe the use of cleaning agents, sampling requirements, or testing specifications. During the inspection you stated that you document cleaning activities on the drug product batch records. However, no evidence of cleaning was observed on the batch records of your drug products, and you confirmed that your firm does not have cleaning or equipment use logs.\u003C\u002Fp>\n\n\u003Cp>In addition, your equipment used to manufacture your drug products were observed to be in a state of disrepair. For example, rust-like residue and other substances were observed on the product contact surfaces of your production and mixing vessels. An accumulation of dirt, debris, and grease-like residues was also observed throughout the facility and on production equipment used to manufacture drug products such as your pumps and filling lines.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has not established that your processes used to manufacture hand sanitizer drug products are validated. You also confirmed that equipment qualification has not been performed on this equipment.\u003C\u002Fp>\n\n\u003Cp>Further, your batch records do not accurately or consistently reflect your formulation for hand sanitizer drug products. For example, the formulation for your hand sanitizer drug products calls for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% isopropanol as the active ingredient. However, examples from the batch records of these products manufactured in 2020, included a mixture of both isopropanol and ethanol as active ingredients. However, ethanol was not listed as an ingredient on your hand sanitizer drug product labels. In addition, your labels list “Purified Water USP” as an ingredient. However, your formulation calls for the use of “\u003Cstrong>(b)(4)\u003C\u002Fstrong> water” and you confirmed to our investigators that your firm is unable to manufacture purified water, and that you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> water as an ingredient in the manufacturing of your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming components for identity before using the components to manufacture your drug products. Additionally, you relied on certificates of analysis from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure that your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>You stated to our investigators that you only test raw materials arriving in tankers. However, you were unable to provide evidence that any testing was performed on your incoming raw materials. In addition, you were unable to provide evidence that you have ever qualified the suppliers of your raw materials.\u003C\u002Fp>\n\n\u003Cp>You manufactured drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID- 19)\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine drug components before use to assure adequate quality, including testing for the presence of methanol in ethanol, before use in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Appropriate testing for the identity and strength of the active ingredients was performed and reviewed before release for each batch of drug product (21 CFR 211.165(a)).\u003C\u002Fli>\n\t\u003Cli>Thorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Appropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>501(d) Adulteration Violations - Substitution\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Secure Hand Sanitizer, listed as being manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient Isopropyl Alcohol (IPA). However, you confirmed to our investigator and provided production records of batches of this product which contained the addition of ethanol. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, isopropanol, was substituted wholly or in part with ethanol.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection conducted in 2016, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>While we acknowledge your commitment to cease production of drugs at this facility, we note that you provided a similar commitment in your response to your 2016 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume manufacturing drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 632881 and include FEI: 3001587133.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact Samina Khan, Compliance Officer, at samina.khan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nNerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u002F\u003Cbr>\nNew Jersey District\u003C\u002Fp>\n\n\u003Cp>___________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cem>86 Fed Reg at 56960\u003C\u002Fem>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol- based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because American Cleaning Solutions hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ronald C. Ingber\n\nRecipient Title\n\nPresident\n\nAmerican Cleaning Solutions\n\n3930 Review Ave.\n\nLong Island City, NY 11101\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter CMS #: 632881\n\nSeptember 6, 2022\n\nDear Mr. Ingber:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, American Cleaning Solutions, FEI 3001587133, at 3930 Review Avenue, Long Island City, Ny from March 7 to March 28, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 29, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP. We acknowledge your commitment to deregistering and your decision to cease manufacturing hand sanitizer drug products permanently.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b).\n\nYour firm manufactures over-the-counter (OTC) hand sanitizer1 drug products including Secure Gel Hand Rub and Secure Hand Rub, as well as non-drug products including insecticides and industrial cleaners. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture pesticides or other non-pharmaceutical products due to the risk of cross-contamination. Our investigator also observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\n\nYour firm lacks an adequate cleaning and maintenance procedure. Your cleaning procedure states that your production tanks are cleaned with hot water and allowed to air dry. Your procedure does not list or describe the use of cleaning agents, sampling requirements, or testing specifications. During the inspection you stated that you document cleaning activities on the drug product batch records. However, no evidence of cleaning was observed on the batch records of your drug products, and you confirmed that your firm does not have cleaning or equipment use logs.\n\nIn addition, your equipment used to manufacture your drug products were observed to be in a state of disrepair. For example, rust-like residue and other substances were observed on the product contact surfaces of your production and mixing vessels. An accumulation of dirt, debris, and grease-like residues was also observed throughout the facility and on production equipment used to manufacture drug products such as your pumps and filling lines.\n\nInadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nYour firm has not established that your processes used to manufacture hand sanitizer drug products are validated. You also confirmed that equipment qualification has not been performed on this equipment.\n\nFurther, your batch records do not accurately or consistently reflect your formulation for hand sanitizer drug products. For example, the formulation for your hand sanitizer drug products calls for the use of (b)(4)% isopropanol as the active ingredient. However, examples from the batch records of these products manufactured in 2020, included a mixture of both isopropanol and ethanol as active ingredients. However, ethanol was not listed as an ingredient on your hand sanitizer drug product labels. In addition, your labels list “Purified Water USP” as an ingredient. However, your formulation calls for the use of “(b)(4) water” and you confirmed to our investigators that your firm is unable to manufacture purified water, and that you use (b)(4) water as an ingredient in the manufacturing of your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYou failed to adequately test your incoming components for identity before using the components to manufacture your drug products. Additionally, you relied on certificates of analysis from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure that your incoming components meet appropriate specifications.\n\nYou stated to our investigators that you only test raw materials arriving in tankers. However, you were unable to provide evidence that any testing was performed on your incoming raw materials. In addition, you were unable to provide evidence that you have ever qualified the suppliers of your raw materials.\n\nYou manufactured drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID- 19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nAs a manufacturer, you have a responsibility to sample, test, and examine drug components before use to assure adequate quality, including testing for the presence of methanol in ethanol, before use in production.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAppropriate testing for the identity and strength of the active ingredients was performed and reviewed before release for each batch of drug product (21 CFR 211.165(a)).\n\nThorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\n\nAppropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\n\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of annual product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\n501(d) Adulteration Violations - Substitution\n\nSecure Hand Sanitizer, listed as being manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient Isopropyl Alcohol (IPA). However, you confirmed to our investigator and provided production records of batches of this product which contained the addition of ethanol. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, isopropanol, was substituted wholly or in part with ethanol.\n\nRepeat Observations at Facility\n\nIn a previous inspection conducted in 2016, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nDrug Production Ceased\n\nWhile we acknowledge your commitment to cease production of drugs at this facility, we note that you provided a similar commitment in your response to your 2016 FDA inspection.\n\nIf you plan to resume manufacturing drugs, notify this office before resuming your operations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 632881 and include FEI: 3001587133.\n\nIf you have questions regarding the content of this letter, please contact Samina Khan, Compliance Officer, at samina.khan@fda.hhs.gov.\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations Division I\u002F\n\nNew Jersey District\n\n___________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol- based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because American Cleaning Solutions hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","American Cleaning Solutions","american-cleaning-solutions-632881-09062022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cleaning-solutions-632881-09062022","2026-10-26T08:07:54.694061+00:00","2022-10-18","632881","Mr. Ronald C. Ingber","2026-08-20T01:30:05.513+00:00","2022-09-06",{"id":199,"raw":200,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":210,"fei_number":19,"letter_url":211,"updated_at":212,"action_type":22,"case_status":23,"posted_date":213,"marcs_cms_no":214,"product_type":215,"closeout_date":19,"issuing_office":204,"recipient_name":216,"body_fetched_at":217,"delivery_method":218,"recipient_title":19,"reference_number":19,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},3561,[201,202,203,204,205,13,13,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-22T05:00:00Z\">01\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-global-health-group-llc-610283-01222021\">American Global Health Group, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan Jewett\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Global Health Group, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11808 Northup Way, Suite W105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bellevue\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98005\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 22, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 610283\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jewett:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.aloecure.com in December 2020 and January 2021, and has determined that you take orders there for your AloeCure brand products including: AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme. We also reviewed your Facebook social media page at www.facebook.com\u002Faloecure, which promotes your products and directs users to your website, www.aloecure.com, for purchase.\u003C\u002Fp>\n\n\u003Cp>The claims on your website and Facebook page establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims and Facebook page claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure VeraFlex\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure VeraFlex webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint):\u003C\u002Fp>\n\n\u003Cp>• “Featuring A Clinically Proven Ingredient to Improve . . . Mobility, and Reduce Joint Discomfort”.\u003Cbr>\n• “Increase mobility, reduce stiffness . . .”\u003Cbr>\n• “Our research shows that joint stiffness, soreness and discomfort is caused by inflammation that attacks healthy cartilage and protective tissue. According to leading medical scientists, this inflammation is caused by two inflammatory enzymes released by the body’s own immune system . . . Remarkably, the active ingredients in VeraFlex help to block the production of both these critical enzymes, resulting in a dramatic decrease in discomfort.”\u003Cbr>\n• “[A] recent study in the Journal of Nutrition and Metabolism shows the potential of these ingredients [in VeraFlex] to help the production of new liver, lung, and immune system cells that respond to fight infections”.\u003C\u002Fp>\n\n\u003Cp>On the Facebook page at www.facebook.com\u002Faloecure:\u003C\u002Fp>\n\n\u003Cp>• “AloeCure’s VeraFlex features active ingredients that show improvement in joint stiffness in as few as 3 days and improved joint function within 7 days . . . ”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure Advanced Formula Capsule\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure Advanced Formula Capsule webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule):\u003C\u002Fp>\n\n\u003Cp>• “[D]elivers a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn while reducing inflammatory response . . .”\u003Cbr>\n• “Scientifically proven natural acid buffer reduces stomach acid by up to 100x . . .”\u003C\u002Fp>\n\n\u003Cp>On the Facebook page at www.facebook.com\u002Faloecure:\u003C\u002Fp>\n\n\u003Cp>• “[D]eliver a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn”.\u003Cbr>\n• “[D]elivers fast acid buffering results with plenty of Acemannan, the primary active ingredient in aloe vera known for healing”.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure Pure Aloe Vera Extract\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure Pure Aloe Vera Extract webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice):\u003C\u002Fp>\n\n\u003Cp>• “Aloe Extract will coat your esophagus and calm your stomach. Once it contacts excess stomach acid, this soothing extract will neutralize it instantly”.\u003Cbr>\n• “Buffers Stomach Acid on Contact”.\u003Cbr>\n• “[A]cts as an acid buffer, improving pH regulation and overall digestive function enough to relieve discomfort . . . it's brimming with malic-calcium, a powerful acid blocker that quenches the awful burning sensation in your throat, esophagus, and stomach. It keeps the acid levels balanced to help flare ups from coming back . . . AloeCure also contains polysaccharides including the highest levels of acemannan, Aloe's famous healing property . . . delivers relief to cells scorched by excess acid and inflammation . . . Aloe is an immune system modulator which can improve and manage … inflammation.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure Probiotic &amp; Enzyme\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure Probiotic &amp; Enzyme webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproduct\u002Fprobiotic-enzyme):\u003C\u002Fp>\n\n\u003Cp>• “Each AloeCure Probiotic + Enzyme capsule, provided by American Global Health Group, LLC, contains over two billion beneficial biorganisms . . . mixed in a base of digestive enzymes.”\u003Cbr>\n• “There are varying degrees of enzyme deficiencies. At the extreme end of the spectrum is the inherited condition of cystic fibrosis, in which the enzymes needed to digest proteins, carbohydrates, and fats are either missing or are present in reduced amounts. Other severe conditions that are associated with enzyme deficiencies include pancreatic insufficiency, Celiac disease, and Crohn’s disease”.\u003C\u002Fp>\n\n\u003Cp>On the same webpage, the following claims were made for Amylase, Protease, and Lipase, ingredients in AloeCure Probiotic &amp; Enzyme:\u003C\u002Fp>\n\n\u003Cp>• “A protease deficiency results in an alkaline excess in the blood . . . can cause anxiety and insomnia . . . [A] protease deficiency lays the foundation of arthritis, osteoporosis and other calcium deficient diseases”.\u003Cbr>\n• “When you are low in amylase you are a candidate for abscesses. Amylase is also involved in anti-inflammatory reactions. An Amylase deficiency can result in skin problems such as psoriasis, eczema, hives, allergic reactions, atopic dermatitis, and all types of herpes. Asthma and emphysema may also be exacerbated by an amylase deficiency”.\u003Cbr>\n• “Lipase deficient people have a tendency towards high cholesterol, high triglycerides, . . . and diabetes. Lipase deficient people also have decreased cell permeability, which can cause nutrient deficiencies within cells. Conditions such as vertigo or dizziness aggravated by movement can result from lipase deficiency.”\u003Cbr>\n\u003Cbr>\nAlso, your website at www.aloecure.com contains evidence of intended use in the form of personal testimonials recommending that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples of these personal testimonials include:\u003C\u002Fp>\n\n\u003Cp>AloeCure Pure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule\u002F and https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice\u002F)\u003C\u002Fp>\n\n\u003Cp>• “In 2007 I was introduced to AloeCure®. I've put AloeCure to the test and it works! AloeCure helps naturally balance the stomach pH levels, decrease the acidity feeling and prevent that burning sensation so many complain of due to stress, worry, or an unhealthy lifestyle. AloeCure is an all-natural solution that allows your body to heal itself.”\u003C\u002Fp>\n\n\u003Cp>AloeCure VeraFlex (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint\u002F)\u003C\u002Fp>\n\n\u003Cp>• “I know first-hand the devastation of chronic pain and that restoration IS possible. While in medical school I developed rheumatoid arthritis, causing me to be wheelchair bound, potentially derailing my medical career . . . VeraFlex users can generally expect more flexibility in three days . . . their joint pain alleviated in five days . . . and in just seven days, a tremendous improvement in overall joint function. In my opinion, AloeCure has created the best supplement for joint health on the market and I recommend it to anyone looking for better mobility, reduced pain . . .”\u003Cbr>\n• “I have used VeraFlex since October 2019 for chronic annoying sciatica type pain. I would be driving the car for 20 minutes and I have to shift my position because I really was getting sore in that area and ever since I started the VeraFlex I have not had that situation, it is totally resolved it and I take it once a day every day.”\u003Cbr>\n• “Eight years ago I had an operation which resulted in losing 3 inches on one of my legs and that resulted in Joint pain. And over a period of years the pain got worse. And since I've taken VeraFlex I've had no knee pain at all.”\u003C\u002Fp>\n\n\u003Cp>Additionally, the Blog tab of your website (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F) contains evidence of intended use that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples include the following blog posts:\u003C\u002Fp>\n\n\u003Cp>• The article titled “5 Foods That Neutralize Stomach Acid” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F5-foods-that-decrease-stomach-acid) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “For any who have suffered through a sleepless night due to excess stomach acid or indigestion, an acidic stomach can be a great cause of pain, distress, and discomfort . . . ALOE VERA . . . contains a natural stomach acid buffer called malic-calcium that neutralizes excess acid . . . It contains two active constituents - glycoproteins and polysaccharides. The former helps to reduce inflammation and hinder pain . . . Aloe Vera can soothe the esophagus track, too, and provide relief from irritation . . . Other studies indicate and suggest that Aloe Vera . . . contributes in helping to balance stomach acid.”\u003Cbr>\n• The article titled “Aloe Vera vs. Apple Cider Vinegar” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Faloe-vera-vs-apple-cider-vinegar) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “Aloe Vera supports digestive wellness due to its anti-inflammatory properties. For many people, digestive issues stem from the occurrence of inflammation within the digestive system, the gastrointestinal tract . . . Aloe Vera . . . can offer benefits for an inflamed GI tract.”\u003Cbr>\n• The article titled “The Endless Benefits of Aloe Vera Gel” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Fendless-benefits-aloe-vera) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, and states: “Below we share some of our favorite ways aloe vera juice benefits us inside and out . . . When our bodies have too much inflammation, it can cause a range of problems from asthma and eczema to arthritis and rheumatism. Aloe’s main property is to be soothing as well as moistening which helps to clear inflammation throughout the body. The enzymes present in the plant’s inner gel produce an anti-inflammatory effect on the body . . .”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products AloeCure Probiotic &amp; Enzyme Blend and AloeCure VeraFlex are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, AloeCure Probiotic &amp; Enzyme Blend and AloeCure VeraFlex fail to bear adequate directions for their intended use, and therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct any violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at \u003Cspan>425-302-0413\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director Program Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJonathan Jewett\n\nRecipient Title\n\nChief Executive Officer\n\nAmerican Global Health Group, LLC\n\n11808 Northup Way, Suite W105\n\nBellevue, WA 98005\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nJanuary 22, 2021\n\nIn reply, refer to CMS 610283\n\nWARNING LETTER\n\nDear Mr. Jewett:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.aloecure.com in December 2020 and January 2021, and has determined that you take orders there for your AloeCure brand products including: AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme. We also reviewed your Facebook social media page at www.facebook.com\u002Faloecure, which promotes your products and directs users to your website, www.aloecure.com, for purchase.\n\nThe claims on your website and Facebook page establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims and Facebook page claims that provide evidence that your products are intended for use as drugs include:\n\nAloeCure VeraFlex\n\nOn the AloeCure VeraFlex webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint):\n\n• “Featuring A Clinically Proven Ingredient to Improve . . . Mobility, and Reduce Joint Discomfort”.\n\n• “Increase mobility, reduce stiffness . . .”\n\n• “Our research shows that joint stiffness, soreness and discomfort is caused by inflammation that attacks healthy cartilage and protective tissue. According to leading medical scientists, this inflammation is caused by two inflammatory enzymes released by the body’s own immune system . . . Remarkably, the active ingredients in VeraFlex help to block the production of both these critical enzymes, resulting in a dramatic decrease in discomfort.”\n\n• “[A] recent study in the Journal of Nutrition and Metabolism shows the potential of these ingredients [in VeraFlex] to help the production of new liver, lung, and immune system cells that respond to fight infections”.\n\nOn the Facebook page at www.facebook.com\u002Faloecure:\n\n• “AloeCure’s VeraFlex features active ingredients that show improvement in joint stiffness in as few as 3 days and improved joint function within 7 days . . . ”\n\nAloeCure Advanced Formula Capsule\n\nOn the AloeCure Advanced Formula Capsule webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule):\n\n• “[D]elivers a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn while reducing inflammatory response . . .”\n\n• “Scientifically proven natural acid buffer reduces stomach acid by up to 100x . . .”\n\nOn the Facebook page at www.facebook.com\u002Faloecure:\n\n• “[D]eliver a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn”.\n\n• “[D]elivers fast acid buffering results with plenty of Acemannan, the primary active ingredient in aloe vera known for healing”.\n\nAloeCure Pure Aloe Vera Extract\n\nOn the AloeCure Pure Aloe Vera Extract webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice):\n\n• “Aloe Extract will coat your esophagus and calm your stomach. Once it contacts excess stomach acid, this soothing extract will neutralize it instantly”.\n\n• “Buffers Stomach Acid on Contact”.\n\n• “[A]cts as an acid buffer, improving pH regulation and overall digestive function enough to relieve discomfort . . . it's brimming with malic-calcium, a powerful acid blocker that quenches the awful burning sensation in your throat, esophagus, and stomach. It keeps the acid levels balanced to help flare ups from coming back . . . AloeCure also contains polysaccharides including the highest levels of acemannan, Aloe's famous healing property . . . delivers relief to cells scorched by excess acid and inflammation . . . Aloe is an immune system modulator which can improve and manage … inflammation.”\n\nAloeCure Probiotic & Enzyme\n\nOn the AloeCure Probiotic & Enzyme webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproduct\u002Fprobiotic-enzyme):\n\n• “Each AloeCure Probiotic + Enzyme capsule, provided by American Global Health Group, LLC, contains over two billion beneficial biorganisms . . . mixed in a base of digestive enzymes.”\n\n• “There are varying degrees of enzyme deficiencies. At the extreme end of the spectrum is the inherited condition of cystic fibrosis, in which the enzymes needed to digest proteins, carbohydrates, and fats are either missing or are present in reduced amounts. Other severe conditions that are associated with enzyme deficiencies include pancreatic insufficiency, Celiac disease, and Crohn’s disease”.\n\nOn the same webpage, the following claims were made for Amylase, Protease, and Lipase, ingredients in AloeCure Probiotic & Enzyme:\n\n• “A protease deficiency results in an alkaline excess in the blood . . . can cause anxiety and insomnia . . . [A] protease deficiency lays the foundation of arthritis, osteoporosis and other calcium deficient diseases”.\n\n• “When you are low in amylase you are a candidate for abscesses. Amylase is also involved in anti-inflammatory reactions. An Amylase deficiency can result in skin problems such as psoriasis, eczema, hives, allergic reactions, atopic dermatitis, and all types of herpes. Asthma and emphysema may also be exacerbated by an amylase deficiency”.\n\n• “Lipase deficient people have a tendency towards high cholesterol, high triglycerides, . . . and diabetes. Lipase deficient people also have decreased cell permeability, which can cause nutrient deficiencies within cells. Conditions such as vertigo or dizziness aggravated by movement can result from lipase deficiency.”\n\nAlso, your website at www.aloecure.com contains evidence of intended use in the form of personal testimonials recommending that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples of these personal testimonials include:\n\nAloeCure Pure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule\u002F and https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice\u002F)\n\n• “In 2007 I was introduced to AloeCure®. I've put AloeCure to the test and it works! AloeCure helps naturally balance the stomach pH levels, decrease the acidity feeling and prevent that burning sensation so many complain of due to stress, worry, or an unhealthy lifestyle. AloeCure is an all-natural solution that allows your body to heal itself.”\n\nAloeCure VeraFlex (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint\u002F)\n\n• “I know first-hand the devastation of chronic pain and that restoration IS possible. While in medical school I developed rheumatoid arthritis, causing me to be wheelchair bound, potentially derailing my medical career . . . VeraFlex users can generally expect more flexibility in three days . . . their joint pain alleviated in five days . . . and in just seven days, a tremendous improvement in overall joint function. In my opinion, AloeCure has created the best supplement for joint health on the market and I recommend it to anyone looking for better mobility, reduced pain . . .”\n\n• “I have used VeraFlex since October 2019 for chronic annoying sciatica type pain. I would be driving the car for 20 minutes and I have to shift my position because I really was getting sore in that area and ever since I started the VeraFlex I have not had that situation, it is totally resolved it and I take it once a day every day.”\n\n• “Eight years ago I had an operation which resulted in losing 3 inches on one of my legs and that resulted in Joint pain. And over a period of years the pain got worse. And since I've taken VeraFlex I've had no knee pain at all.”\n\nAdditionally, the Blog tab of your website (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F) contains evidence of intended use that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples include the following blog posts:\n\n• The article titled “5 Foods That Neutralize Stomach Acid” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F5-foods-that-decrease-stomach-acid) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “For any who have suffered through a sleepless night due to excess stomach acid or indigestion, an acidic stomach can be a great cause of pain, distress, and discomfort . . . ALOE VERA . . . contains a natural stomach acid buffer called malic-calcium that neutralizes excess acid . . . It contains two active constituents - glycoproteins and polysaccharides. The former helps to reduce inflammation and hinder pain . . . Aloe Vera can soothe the esophagus track, too, and provide relief from irritation . . . Other studies indicate and suggest that Aloe Vera . . . contributes in helping to balance stomach acid.”\n\n• The article titled “Aloe Vera vs. Apple Cider Vinegar” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Faloe-vera-vs-apple-cider-vinegar) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “Aloe Vera supports digestive wellness due to its anti-inflammatory properties. For many people, digestive issues stem from the occurrence of inflammation within the digestive system, the gastrointestinal tract . . . Aloe Vera . . . can offer benefits for an inflamed GI tract.”\n\n• The article titled “The Endless Benefits of Aloe Vera Gel” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Fendless-benefits-aloe-vera) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, and states: “Below we share some of our favorite ways aloe vera juice benefits us inside and out . . . When our bodies have too much inflammation, it can cause a range of problems from asthma and eczema to arthritis and rheumatism. Aloe’s main property is to be soothing as well as moistening which helps to clear inflammation throughout the body. The enzymes present in the plant’s inner gel produce an anti-inflammatory effect on the body . . .”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products AloeCure Probiotic & Enzyme Blend and AloeCure VeraFlex are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, AloeCure Probiotic & Enzyme Blend and AloeCure VeraFlex fail to bear adequate directions for their intended use, and therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct any violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director Program Division Director","American Global Health Group, LLC","american-global-health-group-llc-610283-01222021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-global-health-group-llc-610283-01222021","2026-10-26T08:07:54.889582+00:00","2021-02-02","610283","DrugsFood & Beverages","Jonathan Jewett","2026-08-20T03:24:57.367+00:00","Overnight Delivery","2021-01-22",{"id":221,"raw":222,"subject":227,"body_html":228,"body_text":229,"firm_name":230,"letter_id":231,"created_at":43,"fei_number":19,"letter_url":232,"updated_at":233,"action_type":22,"case_status":23,"posted_date":234,"marcs_cms_no":235,"product_type":236,"closeout_date":19,"issuing_office":226,"recipient_name":237,"body_fetched_at":238,"delivery_method":239,"recipient_title":19,"reference_number":19,"action_taken_date":234,"medical_device_id":19,"response_letter_date":19},2413,[223,224,225,226,227,13,13,13],"\u003Ctime datetime=\"2022-09-29T19:00:00Z\">09\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-29T04:00:00Z\">09\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-legends-eliquid-642590-09292022\">American Legends Eliquid\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chuck Hawley\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Legends Eliquid\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2115 Main Street, Suite E\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Snellville\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30078\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quickchases@gmail.com\"> quickchases@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 29, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hawley:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that American Legends Eliquid manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States American Legends E Liquid Loki 18MG e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200684, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nChuck Hawley\n\nRecipient Title\n\nOwner\n\nAmerican Legends Eliquid\n\n2115 Main Street, Suite E\n\nSnellville, GA 30078\n\nUnited States\n\nquickchases@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 29, 2022\n\nWARNING LETTER\n\nDear Mr. Hawley:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that American Legends Eliquid manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States American Legends E Liquid Loki 18MG e-liquid product without a marketing authorization order.\n\nThe e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200684, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","American Legends Eliquid","american-legends-eliquid-642590-09292022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-legends-eliquid-642590-09292022","2026-10-26T08:07:54.963824+00:00","2022-09-29","642590","Tobacco","Chuck Hawley","2026-08-20T01:31:45.903+00:00","VIA UPS and Electronic Mail",{"id":241,"raw":242,"subject":247,"body_html":248,"body_text":249,"firm_name":250,"letter_id":251,"created_at":85,"fei_number":19,"letter_url":252,"updated_at":253,"action_type":22,"case_status":23,"posted_date":254,"marcs_cms_no":255,"product_type":153,"closeout_date":19,"issuing_office":246,"recipient_name":256,"body_fetched_at":257,"delivery_method":258,"recipient_title":19,"reference_number":19,"action_taken_date":259,"medical_device_id":19,"response_letter_date":19},362,[243,244,245,246,247,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-08T04:00:00Z\">09\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-food-distributor-inc-715733-09082025\">American Food Distributor Inc. \u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Osman Hajjoul\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Food Distributor Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>36175 Herman St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Romulus\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48174-3302\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 8, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS 715733\u003C\u002Fp>\u003Cp>Dear Mr. Hajjoul\u003C\u002Fp>\u003Cp>On July 2 through July 15, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of American Food Distributor Inc. located at 36175 Herman St, Romulus, MI 48174-3302. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on July 15, 2025.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Tahina, imported from supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Extra Virgin Olive Oil, imported from supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Mallow leaves, imported from supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # \u003Cstrong>(b)(4)\u003C\u002Fstrong> at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to:\u003C\u002Fp>\u003Cp>Food and Drug Administration\u003Cbr>Attention: Joseph DiNardo, Compliance Officer\u003Cbr>300 Pearl St, Suite 100\u003Cbr>Buffalo, NY 14202\u003C\u002Fp>\u003Cp>If you have any questions regarding this letter, or wish to send your response electronically, you may contact Joseph DiNardo via email at joseph.dinardo@fda.hhs.gov. Please reference CMS #715733 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Keith J. Jasukaitis\u003Cbr>Program Division Director\u003Cbr>Division of Northern Border Imports\u003C\u002Fp>\u003Cp>Mr. Osman Hajjoul\u003Cbr>American Food Distributor Inc.\u003Cbr>36175 Herman St\u003Cbr>Romulus, MI 48174-3302\u003Cbr>\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003Cbr>FEI: 3030309113\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Osman Hajjoul\n\nRecipient Title\n\nOwner\n\nAmerican Food Distributor Inc.\n\n36175 Herman St\n\nRomulus, MI 48174-3302\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nSeptember 8, 2025\nWARNING LETTER\nRe: CMS 715733\nDear Mr. Hajjoul\nOn July 2 through July 15, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of American Food Distributor Inc. located at 36175 Herman St, Romulus, MI 48174-3302. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on July 15, 2025.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nTahina, imported from supplier (b)(4)\nExtra Virgin Olive Oil, imported from supplier (b)(4)\nMallow leaves, imported from supplier (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # (b)(4) at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to:\nFood and Drug Administration\nAttention: Joseph DiNardo, Compliance Officer\n300 Pearl St, Suite 100\nBuffalo, NY 14202\nIf you have any questions regarding this letter, or wish to send your response electronically, you may contact Joseph DiNardo via email at joseph.dinardo@fda.hhs.gov. Please reference CMS #715733 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nKeith J. Jasukaitis\nProgram Division Director\nDivision of Northern Border Imports\nMr. Osman Hajjoul\nAmerican Food Distributor Inc.\n36175 Herman St\nRomulus, MI 48174-3302\n(b)(6), (b)(7)(C)\nFEI: 3030309113","American Food Distributor Inc.","american-food-distributor-inc-715733-09082025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-food-distributor-inc-715733-09082025","2026-10-26T08:07:54.841301+00:00","2026-01-27","715733","Mr. Osman Hajjoul","2026-08-19T07:16:14.827+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2025-09-08",{"id":261,"raw":262,"subject":227,"body_html":266,"body_text":267,"firm_name":268,"letter_id":269,"created_at":18,"fei_number":19,"letter_url":270,"updated_at":271,"action_type":22,"case_status":23,"posted_date":272,"marcs_cms_no":273,"product_type":236,"closeout_date":19,"issuing_office":226,"recipient_name":19,"body_fetched_at":274,"delivery_method":239,"recipient_title":19,"reference_number":275,"action_taken_date":276,"medical_device_id":19,"response_letter_date":19},784,[263,264,265,226,227,13,13,13],"\u003Ctime datetime=\"2025-07-11T04:00:00Z\">07\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-10T04:00:00Z\">07\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-vapor-inc-dba-artisan-vapor-company-709628-07102025\">American Vapor Inc., d\u002Fb\u002Fa Artisan Vapor Company \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501219\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>American Vapor Inc., d\u002Fb\u002Fa Artisan Vapor Company \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3108 Old Denton Road, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carrollton\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75007\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 10, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that American Vapor Inc., d\u002Fb\u002Fa Artisan Vapor Company sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Uno Mas X Apple Peach Strawberry 5% Nicotine.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501219, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501219\n\nProduct:\n\nTobacco\n\nRecipient:\n\nAmerican Vapor Inc., d\u002Fb\u002Fa Artisan Vapor Company\n\n3108 Old Denton Road, Suite 110\n\nCarrollton, TX 75007\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJuly 10, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that American Vapor Inc., d\u002Fb\u002Fa Artisan Vapor Company sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Uno Mas X Apple Peach Strawberry 5% Nicotine.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501219, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","American Vapor Inc., d\u002Fb\u002Fa Artisan Vapor Company","american-vapor-inc-dba-artisan-vapor-company-709628-07102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-vapor-inc-dba-artisan-vapor-company-709628-07102025","2026-10-26T08:07:55.109159+00:00","2025-07-11","709628","2026-08-19T16:36:49.482+00:00","ER2501219","2025-07-10",{"id":278,"raw":279,"subject":284,"body_html":285,"body_text":286,"firm_name":287,"letter_id":288,"created_at":289,"fei_number":19,"letter_url":290,"updated_at":291,"action_type":22,"case_status":23,"posted_date":292,"marcs_cms_no":293,"product_type":294,"closeout_date":19,"issuing_office":283,"recipient_name":295,"body_fetched_at":296,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":297,"medical_device_id":19,"response_letter_date":19},1691,[280,281,282,283,284,13,13,13],"\u003Ctime datetime=\"2023-12-14T13:45:00Z\">12\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-30T05:00:00Z\">11\u002F30\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-aquarium-products-664610-11302023\">American Aquarium Products\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved Medically Important Antimicrobials Marketed for Use in Non-food Minor Species","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Devon Trigg\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>American Aquarium Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4990 State Highway 38\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Drain\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97435\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@americanaquariumproducts.com\"> info@americanaquariumproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@americanaquariumproducts.com\"> sales@americanaquariumproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 30, 2023\u003C\u002Fp>\n\n\u003Cp>Re: CMS 664610\u003C\u002Fp>\n\n\u003Cp>Dear Devon Trigg:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm's distribution of veterinary products for use in aquarium fish.\u003C\u002Fp>\n\n\u003Cp>In August 2023, the U.S. Food and Drug Administration (FDA) reviewed your website (https:\u002F\u002Fwww.americanaquariumproducts.com\u002F), where you take orders for AAP Aquatronics Discomed, AAP Aquatronics Myacin, and AAP Aquatronics Spectrogram. The claims on your website establish that these products are intended for use in the cure, mitigation, treatment, or prevention of diseases in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. In addition, these animal drugs are misbranded under section 502(o) of the FD&amp;C Act [21 U.S.C. § 352(o)] because they have not been drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA in accordance with sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)]. As discussed below, introducing or delivering these unapproved and misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>UNAPPROVED NEW ANIMAL DRUGS\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nExamples of claims observed on your website (https:\u002F\u002Fwww.americanaquariumproducts.com\u002F) that establish the intended use of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>AAP Aquatronics Discomed\u003C\u002Fstrong>, Water Soluble Levamisol, NaCl, Piperazine, Magnesium Sulfate and Neomycin Sulfate Activity (pharmaceutical grade), 250 mg, capsules. According to your website: “AAP Discomed is a unique anti-parasitic &amp; secondary internal bacterial infection medication (primarily internal but some external effectiveness) to use to make a medicated fish food for Freshwater and Marine aquariums... Specific Treatment for Cichlids suffering weight loss. * For treatment of Nematodes; Including Camallanus, Capillari, &amp; Eustrongylid. As well, due to the ingredient Neomycin Sulfate, Discomed is also an excellent internal bacterial medication too. * Treats parasitic causes of Color Loss, Weight Loss and Wasting, Darkened Body Color, Skinny Body, &amp; Concaved Abdomen.” Further, the product label states: “Anti-parasitic biotic capsules. Symptoms and Causes: Concaved abdomen, internal worms, skinny body, capillaria, darkened body, hexamita.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>AAP Aquatronics Myacin\u003C\u002Fstrong>, Erythromycin Phosphate, capsules. According to your website: “AAP Myacin is pharmaceutical grade Erythromycin Phosphate. All others including Maracyn &amp; API Erythromycin are Erythromycin sulfate which is less effective and with a lessor spectrum. Treats\u002FPrevents Cloudy or Protruding eyes (including many causes of popeye). Treats\u002FPrevents Mouth &amp; Eye Sores. Treats\u002FPrevents Molly &amp; Tetra Disease (in particular Neon Tetra &amp; FNT Disease) as well as unknown Tetra \"die offs\". Treats\u002FPrevents Reddened Areas or Gills).” Further, the product label states: “colorless antibiotic capsules. General aquatic antibiotic. Symptoms and causes: fin, tail or body rot; bacterial infections; mouth &amp; eye sores; fungal infections; cloudy or protruding eyes; popeye; wasting away; molly and tetra disease.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>AAP Aquatronics Spectrogram\u003C\u002Fstrong>, blended antibiotic capsules. Your website states: “Symptoms and Causes: Abdominal Bloat, Dropsy, Red Body Patches, Bacterial Infections, Hemorrhage, Furunculosis, White Body Slime, Columnaris, Protruding Scales, Fungal Infections.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These products are new animal drugs under section 201(v) of the FD&amp;C Act [21 U.S.C. § 321(v)] because they are for use in nonfood-producing fish, which are minor species as defined by sections 201(nn) and (oo) of the FD&amp;C Act [21 U.S.C. § 321(nn) and (oo)], and are not the subject of a final FDA regulation finding either that the drugs are generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the drug’s labeling, or finding that the exception to the criterion in section 201(v)(1) of the FD&amp;C Act has been met.\u003C\u002Fp>\n\n\u003Cp>To be legally marketed, a new animal drug must be the subject of an approved new animal drug application, a conditionally approved new animal drug application, or a listing on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species (“index listing”) under section 512, 571, or 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. The FDA approval and index listing processes allow FDA to ensure that there is adequate evidence to demonstrate that new animal drugs are safe, properly manufactured, accurately labeled, and meet the relevant effectiveness standard. The animal drugs named above have not been approved, conditionally approved, or index listed.\u003C\u002Fp>\n\n\u003Cp>Animal drugs that lack the required approval or index listing are considered unsafe and adulterated under sections 512(a) and 501(a)(5) of the FD&amp;C Act [21 U.S.C. §§ 360b(a) and 351(a)(5)]. Introduction or delivery for introduction of an adulterated animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>FDA is particularly concerned about your unapproved animal drugs because they raise public health concerns. Available as over-the-counter drugs, they contain antimicrobials that are considered medically important in the treatment of human disease.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Concern about the development of resistance to antimicrobials important in human medicine has led FDA to promote more judicious use of animal drugs containing medically important antimicrobials, including working toward ensuring that these drugs can be used in animals only under the supervision of a licensed veterinarian.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>MISBRANDED NEW ANIMAL DRUGS\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nSections 510(b)(1) and (j)(1) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] require that manufacturers (which includes repackers and relabelers) of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drug products they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&amp;C Act. None of the animal drugs in this letter are drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>You should be aware that if we take enforcement action against any of the drugs named above or other unapproved\u002Funindexed products you market that contain medically important antimicrobials, we may take action against all of your products that violate the FD&amp;C Act at the same time, including but not limited to enjoining the manufacturing and distribution of all of your unapproved\u002Funindexed products.\u003C\u002Fp>\n\n\u003Cp>We have the following comments:\u003C\u002Fp>\n\n\u003Cp>1. You can legally market the products named above if you obtain an index listing, approval, or conditional approval. Information about the processes and requirements for obtaining an index listing and various types of animal drug approval is available on the FDA website at\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fminor-useminor-species and\u003C\u002Fli>\n\t\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fnew-animal-drug-applications\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The index listing process was added to the FD&amp;C Act in 2004 as a streamlined alternative process that addresses the challenges of obtaining FDA approval for drugs for minor species (which are any animal species other than horses, cattle, pigs, dogs, cats, chickens, and turkeys). Drugs intended for use in minor species not used for human or animal food are eligible for index listing. Because the above-named products are intended for use in nonfood-producing fish, you may wish to explore the index listing process. The approval process can also be used for drugs for use in these species.\u003C\u002Fp>\n\n\u003Cp>2. Information on establishment registration and drug listing is available on the FDA website at:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Findustry\u002Ffda-basics-industry\u002Fregistration-and-listing\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Within fifteen (15) working days of receiving this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Dr. Vic Boddie, United States Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by emailing CVMUnapprovedDrugs@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector Division of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> A list of medically important drug classes of antimicrobials can be found in Guidance for Industry (GFI) # 152, “Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,” available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FAnimalVeterinary\u002FGuidanceComplianceEnforcement\u002FGuidanceforIndustry\u002FUCM052519.pdf\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDevon Trigg\n\nAmerican Aquarium Products\n\n4990 State Highway 38\n\nDrain, OR 97435\n\nUnited States\n\ninfo@americanaquariumproducts.com\n\nsales@americanaquariumproducts.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nNovember 30, 2023\n\nRe: CMS 664610\n\nDear Devon Trigg:\n\nThis letter concerns your firm's distribution of veterinary products for use in aquarium fish.\n\nIn August 2023, the U.S. Food and Drug Administration (FDA) reviewed your website (https:\u002F\u002Fwww.americanaquariumproducts.com\u002F), where you take orders for AAP Aquatronics Discomed, AAP Aquatronics Myacin, and AAP Aquatronics Spectrogram. The claims on your website establish that these products are intended for use in the cure, mitigation, treatment, or prevention of diseases in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. In addition, these animal drugs are misbranded under section 502(o) of the FD&C Act [21 U.S.C. § 352(o)] because they have not been drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA in accordance with sections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)]. As discussed below, introducing or delivering these unapproved and misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nUNAPPROVED NEW ANIMAL DRUGS\n\nExamples of claims observed on your website (https:\u002F\u002Fwww.americanaquariumproducts.com\u002F) that establish the intended use of your products as drugs include, but may not be limited to, the following:\n\nAAP Aquatronics Discomed, Water Soluble Levamisol, NaCl, Piperazine, Magnesium Sulfate and Neomycin Sulfate Activity (pharmaceutical grade), 250 mg, capsules. According to your website: “AAP Discomed is a unique anti-parasitic & secondary internal bacterial infection medication (primarily internal but some external effectiveness) to use to make a medicated fish food for Freshwater and Marine aquariums... Specific Treatment for Cichlids suffering weight loss. * For treatment of Nematodes; Including Camallanus, Capillari, & Eustrongylid. As well, due to the ingredient Neomycin Sulfate, Discomed is also an excellent internal bacterial medication too. * Treats parasitic causes of Color Loss, Weight Loss and Wasting, Darkened Body Color, Skinny Body, & Concaved Abdomen.” Further, the product label states: “Anti-parasitic biotic capsules. Symptoms and Causes: Concaved abdomen, internal worms, skinny body, capillaria, darkened body, hexamita.”\n\nAAP Aquatronics Myacin, Erythromycin Phosphate, capsules. According to your website: “AAP Myacin is pharmaceutical grade Erythromycin Phosphate. All others including Maracyn & API Erythromycin are Erythromycin sulfate which is less effective and with a lessor spectrum. Treats\u002FPrevents Cloudy or Protruding eyes (including many causes of popeye). Treats\u002FPrevents Mouth & Eye Sores. Treats\u002FPrevents Molly & Tetra Disease (in particular Neon Tetra & FNT Disease) as well as unknown Tetra \"die offs\". Treats\u002FPrevents Reddened Areas or Gills).” Further, the product label states: “colorless antibiotic capsules. General aquatic antibiotic. Symptoms and causes: fin, tail or body rot; bacterial infections; mouth & eye sores; fungal infections; cloudy or protruding eyes; popeye; wasting away; molly and tetra disease.”\n\nAAP Aquatronics Spectrogram, blended antibiotic capsules. Your website states: “Symptoms and Causes: Abdominal Bloat, Dropsy, Red Body Patches, Bacterial Infections, Hemorrhage, Furunculosis, White Body Slime, Columnaris, Protruding Scales, Fungal Infections.”\n\nThese products are new animal drugs under section 201(v) of the FD&C Act [21 U.S.C. § 321(v)] because they are for use in nonfood-producing fish, which are minor species as defined by sections 201(nn) and (oo) of the FD&C Act [21 U.S.C. § 321(nn) and (oo)], and are not the subject of a final FDA regulation finding either that the drugs are generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the drug’s labeling, or finding that the exception to the criterion in section 201(v)(1) of the FD&C Act has been met.\n\nTo be legally marketed, a new animal drug must be the subject of an approved new animal drug application, a conditionally approved new animal drug application, or a listing on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species (“index listing”) under section 512, 571, or 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. The FDA approval and index listing processes allow FDA to ensure that there is adequate evidence to demonstrate that new animal drugs are safe, properly manufactured, accurately labeled, and meet the relevant effectiveness standard. The animal drugs named above have not been approved, conditionally approved, or index listed.\n\nAnimal drugs that lack the required approval or index listing are considered unsafe and adulterated under sections 512(a) and 501(a)(5) of the FD&C Act [21 U.S.C. §§ 360b(a) and 351(a)(5)]. Introduction or delivery for introduction of an adulterated animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nFDA is particularly concerned about your unapproved animal drugs because they raise public health concerns. Available as over-the-counter drugs, they contain antimicrobials that are considered medically important in the treatment of human disease.1 Concern about the development of resistance to antimicrobials important in human medicine has led FDA to promote more judicious use of animal drugs containing medically important antimicrobials, including working toward ensuring that these drugs can be used in animals only under the supervision of a licensed veterinarian.\n\nMISBRANDED NEW ANIMAL DRUGS\n\nSections 510(b)(1) and (j)(1) of the FD&C Act [21 U.S.C. § 360(b), (j)] require that manufacturers (which includes repackers and relabelers) of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drug products they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&C Act. None of the animal drugs in this letter are drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\n\nYou should be aware that if we take enforcement action against any of the drugs named above or other unapproved\u002Funindexed products you market that contain medically important antimicrobials, we may take action against all of your products that violate the FD&C Act at the same time, including but not limited to enjoining the manufacturing and distribution of all of your unapproved\u002Funindexed products.\n\nWe have the following comments:\n\n1. You can legally market the products named above if you obtain an index listing, approval, or conditional approval. Information about the processes and requirements for obtaining an index listing and various types of animal drug approval is available on the FDA website at\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fminor-useminor-species and\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fnew-animal-drug-applications\n\nThe index listing process was added to the FD&C Act in 2004 as a streamlined alternative process that addresses the challenges of obtaining FDA approval for drugs for minor species (which are any animal species other than horses, cattle, pigs, dogs, cats, chickens, and turkeys). Drugs intended for use in minor species not used for human or animal food are eligible for index listing. Because the above-named products are intended for use in nonfood-producing fish, you may wish to explore the index listing process. The approval process can also be used for drugs for use in these species.\n\n2. Information on establishment registration and drug listing is available on the FDA website at:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Findustry\u002Ffda-basics-industry\u002Fregistration-and-listing\n\nWithin fifteen (15) working days of receiving this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Dr. Vic Boddie, United States Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by emailing CVMUnapprovedDrugs@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector Division of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\n_________________\n\n1 A list of medically important drug classes of antimicrobials can be found in Guidance for Industry (GFI) # 152, “Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,” available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FAnimalVeterinary\u002FGuidanceComplianceEnforcement\u002FGuidanceforIndustry\u002FUCM052519.pdf","American Aquarium Products","american-aquarium-products-664610-11302023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-aquarium-products-664610-11302023","2026-10-26T08:07:54.578064+00:00","2023-12-14","664610","Animal & VeterinaryDrugs","Devon Trigg","2026-08-20T00:26:06.739+00:00","2023-11-30",{"id":299,"raw":300,"subject":304,"body_html":305,"body_text":306,"firm_name":307,"letter_id":308,"created_at":43,"fei_number":19,"letter_url":309,"updated_at":310,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":311,"product_type":312,"closeout_date":19,"issuing_office":303,"recipient_name":313,"body_fetched_at":314,"delivery_method":315,"recipient_title":19,"reference_number":19,"action_taken_date":316,"medical_device_id":19,"response_letter_date":19},2202,[140,301,302,303,304,13,13,13],"\u003Ctime datetime=\"2023-02-10T05:00:00Z\">02\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-chinese-natural-herbs-inc-631597-02102023\">American Chinese Natural Herbs, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations West Division 3","CGMP\u002FManufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Signature Required\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Canh L. Duong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Chinese Natural Herbs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2205 Executive Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Garland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75041\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations West Division 3\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>1201 Main St., Suite 7200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 10, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CMS# 631597\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Duong:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA or we) conducted an inspection of your facility&nbsp;located at 2205 Executive Drive, Garland, TX 75041 from February 15, 2022 through March&nbsp;17, 2022, and we also reviewed labels for your products. Based on inspectional findings, we&nbsp;have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and&nbsp;applicable regulations. You can find the Act and the FDA’s regulations through links on FDA’s&nbsp;home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>We received your written response dated March 29, 2022, written in response to the Form&nbsp;FDA 483, Inspectional Observations, issued to you at the close of the inspection. We have&nbsp;reviewed that document and our comments on your response are listed following each of the&nbsp;significant violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed significant violations of the Current Good&nbsp;Manufacturing Practice (CGMP) regulations for Manufacturing, Packaging, Labeling, or&nbsp;Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations,&nbsp;Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be&nbsp;adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that&nbsp;they have been prepared, packed, or held under conditions that do not meet CGMP&nbsp;requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the required specifications for each component used in the&nbsp;manufacture of a dietary supplement, as required by 21 CFR 111.70(b). Specifically, you&nbsp;did not establish specifications for the components used for your dietary supplement&nbsp;products. For example, you have not established component specifications for the identity&nbsp;of the following dietary ingredients:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Thorough Wax Extract used in Hawthorn Plus, Super Dandelion Capsules, and&nbsp;Thorough Wax Extract product;\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> American Ginseng Extract used in Thorough Wax Extract;\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Oyster Extract used in King Kong and Thorough Wax Extract;\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Ginger Root used in Happy Smile Herb Blend;\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Prunella Vulgaris used in Stomach Miracle;\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Mulberry Leaf used in Stomach Miracle, Wooly, and Vital; and&nbsp;Bitter Almond Extract used in Almond Plus.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated March 29, 2022. You state that you are obtaining&nbsp;monographs for ingredients from “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and that you are&nbsp;identifying tests and testing equipment such as HPLC; however, we are unable to evaluate&nbsp;the adequacy of your corrective actions because you did not provide documentation to show&nbsp;that your firm has established component specifications.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish product specifications for the identity, purity, strength, and&nbsp;composition of the finished batch of the dietary supplement, and for limits on those types&nbsp;of contamination that may adulterate, or that may lead to adulteration of, the finished&nbsp;batch of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you&nbsp;provided a product list with approximately 50 different types of products in different tablet&nbsp;or capsule numbers. You provided a sheet with a list of ingredients and weights for&nbsp;approximately 12 of your products. Your “specification sheets” only indicate the&nbsp;ingredients and weights.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated March 29, 2022, and it is inadequate. With regards&nbsp;to your response for finished product identity specifications, your proposed corrective action&nbsp;of using organoleptic attributes (feel and color) along with microscopic photos of the powder&nbsp;within your capsules does not provide sufficient detail for your firm to be able confirm the&nbsp;identity of the finished product, and it does not ensure that you can distinguish one product&nbsp;from any other mix of powdered substances.\u003C\u002Fp>\n\n\u003Cp>3. You failed to establish MMRs for your products that include all elements required by 21&nbsp;CFR 111.210. Specifically, the MMR for your products Stomach Miracle, Thorough Wax&nbsp;Extract, and Almond Plus, failed to include the information required by 21 CFR 111.210,&nbsp;such as:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The name of the dietary supplement to be manufactured and the strength,&nbsp;concentration, weight, or measure of each dietary ingredient for each batch size, as&nbsp;required by 21 CFR 111.210(a);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;A complete list of components to be used, as required by 21 CFR 111.210(b);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> An accurate statement of the weight or measure of each component to be used, as&nbsp;required by 21 CFR 111.210(c);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The identity and weight or measure of each dietary ingredient that will be declared on&nbsp;the Supplement Facts label and the identity of each ingredient that will be declared on&nbsp;the ingredients list of the dietary supplement, as required by 21 CFR 111.210(d);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> A statement of any intentional overage amount of a dietary ingredient, as required by&nbsp;21 CFR 111.210(e);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> A description of packaging and a representative label, or a cross-reference to the&nbsp;physical location of the actual or representative label, as required by 21 CFR&nbsp;111.210(g);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Written instructions, as required by 21 CFR 111.210(h), including the following:\u003C\u002Fp>\n\n\u003Cp>o Specifications for each point, step, or stage in the manufacturing process where&nbsp;control is necessary to ensure the quality of the dietary supplement and that the&nbsp;dietary supplement is packaged and labeled as specified in the master&nbsp;manufacturing record as required by 21 CFR 111.210(h)(1);\u003Cbr>\no Procedures for sampling and a cross-reference to procedures for tests or&nbsp;examinations as required by 21 CFR 111.210(h)(2);\u003Cbr>\no Specific actions necessary to perform and verify points, steps, or stages in the&nbsp;manufacturing process where control is necessary to ensure the quality of the&nbsp;dietary supplement and that the dietary supplement is packaged and labeled as&nbsp;specified in the master manufacturing record, as required by 21 CFR&nbsp;111.210(h)(3).\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>▪\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Such specific actions must include verifying the weight or measure of any&nbsp;component and verifying the addition of any component, as required by 21 CFR&nbsp;111.210(h)(3)(i); and\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>▪\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> For manual operations, such specific actions must include, as required by 21&nbsp;CFR 111.210(h)(3)(ii):\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> One person weighing or measuring a component and another person&nbsp;verifying the weight or measure, as required by 21 CFR 111.210(h)(3)(ii)(A);\u003Cbr>\nand\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> One person adding the component and another person verifying the&nbsp;addition, as required by 21 CFR 111.210(h)(3)(ii)(B).\u003C\u002Fp>\n\n\u003Cp>o Special notations and precautions to be followed, as required by 21 CFR&nbsp;111.210(h)(4); and\u003Cbr>\no Corrective action plans for use when a specification is not met, as required by 21&nbsp;CFR 111.210(h)(5).\u003C\u002Fp>\n\n\u003Cp>4. You failed to prepare a batch production record every time you manufactured a batch of&nbsp;dietary supplement as required by 21 CFR 111.255(a). Specifically, during the inspection,&nbsp;your firm did not have batch production records (BPRs) for all products that had been&nbsp;manufactured, such as Almond Plus and Stomach Miracle.\u003C\u002Fp>\n\n\u003Cp>5. Your BPRs for Stomach Miracle, Thorough Wax Extract, and Almond Plus did not include&nbsp;complete information as required by 21 CFR 111.260. Specifically, your BPRs lack:\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The unique identifier that you assigned to each component (or, when applicable, to a&nbsp;product that you receive from a supplier for packaging or labeling as a dietary&nbsp;supplement), packaging, and label used, as required by 21 CFR 111.260(d);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> A statement of the actual yield and a statement of the percentage of theoretical yield&nbsp;at appropriate phases of processing as required by 21 CFR 111.260(f);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The actual results obtained during any monitoring operation as required by 21 CFR&nbsp;111.260(g);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The results of any testing or examination performed during the batch production, or a&nbsp;cross-reference to such results as required by 21 CFR 111.260(h);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Documentation that the finished dietary supplement meets specifications established&nbsp;in accordance with Sec. 111.70(e) and (g) as required by 21 CFR 111.260(i);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Documentation, at the time of performance, of the manufacture of the batch, including:\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The date on which each step of the master manufacturing record was performed; and&nbsp;The initials of the persons performing each step, including: The initials of the person&nbsp;responsible for weighing or measuring each component used in the batch; The initials&nbsp;of the person responsible for verifying the weight or measure of each component used&nbsp;in the batch; The initials of the person responsible for adding the component to the&nbsp;batch; and The initials of the person responsible for verifying the addition of&nbsp;components to the batch results as required by 21 CFR 111.260 (j);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Documentation, at the time of performance, of packaging and labeling operations,&nbsp;including: The unique identifier that you assigned to packaging and labels used, the&nbsp;quantity of the packaging and labels used, and, when label reconciliation is required,&nbsp;reconciliation of any discrepancies between issuance and use of labels; An actual or&nbsp;representative label, or a cross-reference to the physical location of the actual or&nbsp;representative label specified in the master manufacturing record; and The results of&nbsp;any tests or examinations conducted on packaged and labeled dietary supplements&nbsp;(including repackaged or relabeled dietary supplements), or a cross-reference to the&nbsp;physical location of such results as required by 21 CFR 111.260(k);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Documentation at the time of performance that quality control personnel: Reviewed&nbsp;the batch production record, including: Review of any monitoring operation required&nbsp;under subpart E of this part; and Review of the results of any tests and examinations,&nbsp;including tests and examinations conducted on components, in-process materials,&nbsp;finished batches of dietary supplements, and packaged and labeled dietary&nbsp;supplements; Approved or rejected any reprocessing or repackaging; and Approved&nbsp;and released, or rejected, the batch for distribution, including any reprocessed batch;&nbsp;and Approved and released, or rejected, the packaged and labeled dietary&nbsp;supplement, including any repackaged or relabeled dietary supplement, as required&nbsp;by 21 CFR 111.260(l);\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Documentation at the time of performance of any required material review and&nbsp;disposition decision, as required by 21 CFR 111.260 (m); and\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Documentation at the time of performance of any reprocessing as required by 21 CFR&nbsp;111.260(n).\u003C\u002Fp>\n\n\u003Cp>In your response from March 29, 2022, you state that you are planning to implement&nbsp;electronic batch production records. You did not provide an example or documents showing&nbsp;your implementation of electronic batch production records, so we are unable to evaluate the&nbsp;adequacy of your corrective actions.\u003Cbr>\n\u003Cbr>\n7. You failed to establish and follow written procedures to fulfill the requirements of Subpart&nbsp;O (Product Complaints), as required by 21 CFR 111.553. Specifically, you provided the&nbsp;investigator with a “Return Policy for product Complaints.” The policy states that you&nbsp;refund or exchange the product, that you refer to the “Batch Production Record” and that&nbsp;your quality control personnel reexamine the batch “to ensure [whether] the batch was&nbsp;contaminated.” It also states that if multiple reports and complaints are received “in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;time span,” that the batch will be sent to a laboratory for testing. Your product complaint&nbsp;procedures failed to include that a qualified person will review all product complaints (not&nbsp;only on the basis of returned products) and will investigate any product complaint that&nbsp;involves a possible failure of a dietary supplement to meet any of its specifications, or any&nbsp;other requirements of this part, including those specifications and other requirements that,&nbsp;if not met, may result in a risk of illness or injury, not only when you have multiple reports&nbsp;or complaints, as required by 21 CFR 111.560(a).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to establish and follow written procedures for the responsibilities of the&nbsp;quality control operations, including written procedures for conducting a material review&nbsp;and making a disposition decision as required by 21 CFR 111.103. Specifically, your firm&nbsp;did not establish written procedures that included procedures to follow for conducting a&nbsp;material review and make a disposition decision for each lot of finished dietary\u003Cbr>\nsupplement products manufactured and distributed under your own label name, American&nbsp;Chinese Natural Herbs.\u003C\u002Fp>\n\n\u003Cp>Your firm’s March 29, 2022, response stated that you are in the process of developing new&nbsp;standard operating procedures however, we are unable to evaluate the adequacy of your&nbsp;corrective actions because you did not provide examples of those new standard operating&nbsp;procedures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed product labels collected during the inspection and have determined&nbsp;that your Almond Plus (300 Pills), Almond Plus (600 pills), Stomach Miracle (120 capsules&nbsp;and 270 capsules), LIV-97, Yellow Dragon, King Kong, Vital, Happy Smile Herb Blend,&nbsp;Hawthorn Plus, Thorough Wax Extract, Woolly, and Super Dandelion Capsules products are&nbsp;misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with&nbsp;the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Almond Plus (300 pills) product is misbranded within the meaning of section&nbsp;403(q)(5)(F) of the Act [21 U.S.C. § 343 (q)(5)(F)] in that the presentation of the nutrition&nbsp;information on the labeling of your product does not comply with 21 CFR 101.36(a). For&nbsp;example, your Almond Plus (300 pills) product label fails to present the nutrition&nbsp;information in the form of a supplement facts label.\u003C\u002Fp>\n\n\u003Cp>2. Your Almond Plus (300 pills) product is misbranded within the meaning of 403(s)(2)(B) of&nbsp;the Act [21 U.S.C. § 343 (s)(2)(B)] because it does not include a statement of identity as&nbsp;a “dietary supplement” as required by 21 CFR 101.3(g).\u003Cbr>\n\u003Cbr>\n3. Your Almond Plus (300 pills and 600 pills), Stomach Miracle (120 capsules and 270&nbsp;capsules), LIV-97, Yellow Dragon, King Kong, Vital, Happy Smile Herb Blend, Hawthorn&nbsp;Plus, Thorough Wax Extract, Woolly, and Super Dandelion Capsules products are&nbsp;misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in&nbsp;that the label fails to declare the common or usual name of each ingredient used as&nbsp;required by 21 CFR 101.4 and 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Almond Plus (300 pills and 600 pills):\u003Cbr>\no Declares red date and melissa but fails to declare the standardized common&nbsp;names jujube and lemon balm, respectively, as listed in the reference Herbs of&nbsp;Commerce (HOC).\u003Cbr>\no Declares mimosa, but this is not the common or usual name of a dietary ingredient.\u003Cbr>\no Sand is not in HOC; therefore, the Latin binomial must be declared in accordance&nbsp;with 21 CFR 101.4(h)(2).\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Happy Smile Herb Blend:\u003Cbr>\no Declares glehniae, patriniae, longanae, ophiopogonis, polygalae, and astragail,&nbsp;but the standardized common names must be stated in English as glehnia,&nbsp;patrinia, longan, ophiopogon, polygala, and astragalus, respectively.\u003Cbr>\no Declares Ganoderma lucidum, Poria cocos, Zizphy spinosae, Nelumbinis, red&nbsp;date, and Coicis, but fails to declare the standardized common names reishi, poria,&nbsp;jujube, sacred lotus, jujube, and Job’s tears, respectively, as listed in HOC.\u003Cbr>\no Declares concha pteriae and atralodis, but these are not the common or usual&nbsp;names of dietary ingredients.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Hawthorn Plus:\u003Cbr>\no Declares nut grass, thorough wax, tree of heaven, and Indian bread, but fails to&nbsp;declare the standardized common names Cyperus, bupleurum, Chinese tree-ofheaven or Indian tree-of-heaven, and poria, respectively, as listed in HOC.\u003Cbr>\no Batavia and sand are not in HOC; therefore, the Latin binomial must be declared&nbsp;in accordance with 21 CFR 101.4(h)(2).\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> King Kong:\u003Cbr>\no Declares Rubi but this is not the common or usual name of a dietary ingredient.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> LIV-97:\u003Cbr>\no Declares artemissa [sic], thorough wax, tree of heaven, neroli, tang kuei, and&nbsp;oldenlandia, but fails to declare the standardized common names sweet&nbsp;wormwood, bupleurum, Chinese tree-of-heaven or Indian tree-of-heaven, bitter&nbsp;orange, dong quai, and hedyotis, respectively, as listed in HOC.\u003Cbr>\no Declares dragons blood but fails to declare the standardized common name&nbsp;dragon’s blood croton which is indicated by the Latin binomial listed in the finished&nbsp;product specification sheet provided during the inspection.\u003Cbr>\no Batavia and sand are not in HOC; therefore, the Latin binomial must be declared&nbsp;in accordance with 21 CFR 101.4(h)(2).\u003Cbr>\no Declares cyperi but the standardized common name must be stated in English as&nbsp;cyperus.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Stomach Miracle:\u003Cbr>\no Declares Prunella vulgaris, Psoralea coryliflia, Verbena officinalis, Xanthium&nbsp;sibiricum, Eclipta prostrata, Mesoma [sic] chinensis, Curcuma longa L., Agrimonia&nbsp;Pilosa, Zea mays, and Ziziphus jujuba, but fails to declare the standardized&nbsp;common names heal all, psoralea, European vervain, xanthium, eclipta, mesona,&nbsp;turmeric, agrimony, corn, and jujube, respectively, as listed in HOC.\u003Cbr>\no Declares Oytrea densekamellosa [sic] but fails to declare the common or usual&nbsp;name oyster.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Super Dandelion Capsules\u003Cbr>\no Declares tang kuei, red peony, thorough wax, and tree of heaven, but fails to&nbsp;declare the standardized common names dong quai, Chinese peony, bupleurum,&nbsp;and Chinese tree-of-heaven or Indian tree-of-heaven, respectively, as listed in&nbsp;HOC.\u003Cbr>\no Declares origanum, silver, red, and liquidambaris, but these are not the common&nbsp;or usual names of dietary ingredients.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Thorough Wax Extract:\u003Cbr>\no Your product is manufactured into capsules, but the product label fails to list the&nbsp;ingredients used to form the capsules.\u003Cbr>\no Declares thorough wax and tang kuei, but fails to declare the standardized&nbsp;common names bupleurum, dong quai, respectively, as listed in HOC.\u003Cbr>\no Declares water lavage[sic], mimosa, origanum, silver, and liquidambaris, but these&nbsp;are not the common or usual names of dietary ingredients.\u003Cbr>\no Regarding the botanical ingredient “water lavage [sic] extract”, please provide the&nbsp;Latin Binomial (Genus and species) of the water lovage extract ingredient, the&nbsp;identity specification for the ingredient, a Certificate of Analysis from the supplier,&nbsp;and testing that can verify the identity of the ingredient you used in the manufacture&nbsp;of the Thorough Wax Extract dietary supplement. Some synonyms to Water&nbsp;Lovage are Water Hemlock or Hemlock Water Dropwort. These synonyms&nbsp;correspond to Oenanthe crocata L., which is a poisonous plant of the Apiaceae&nbsp;family.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Vital:\u003Cbr>\no Declares Polygonum aviculare L, Prunus japonica, Plumeria rubra L, Luffa&nbsp;cylindrica, Rubia cordifolia, and red date, but fails to declare the standardized&nbsp;common names knotweed, Japanese bush cherry, frangipani, luffa, Indian&nbsp;madder, and jujube, respectively, as listed in HOC.\u003Cbr>\no Declares mimosa, plantage, and acanthopanacis, but these are not the common&nbsp;or usual names of dietary ingredients.\u003Cbr>\n\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Wooly:\u003Cbr>\no Declares woolly grass and shave grass but fails to declare the standardized&nbsp;common names imperata and giant horsetail, respectively, as listed in HOC.\u003Cbr>\no Declares plantage and cocklebur, but these are not the common or usual names&nbsp;of dietary ingredients.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Yellow Dragon:\u003Cbr>\no White man is not in HOC; therefore, the Latin binomial must be declared in&nbsp;accordance with 21 CFR 101.4(h)(2).\u003Cbr>\no Declares celadine, dogwood, and peony, but these are not the common or usual&nbsp;names of dietary ingredients.\u003Cbr>\no Declares Indian bread but fails to declare the standardized common names poria&nbsp;as listed in HOC.\u003Cbr>\no Your product is manufactured into capsules, but the product label fails to list the&nbsp;ingredients used to form the capsules.\u003C\u002Fp>\n\n\u003Cp>4. Your Almond Plus (300 pills and 600 pills), Happy Smile Herb Blend, Hawthorn Plus,&nbsp;Stomach Miracle (120 capsules and 270 capsules), King Kong, LIV-97, Vital, Super&nbsp;Dandelion Plus, Thorough Wax Extract, Woolly, and Yellow Dragon products are&nbsp;misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. §&nbsp;343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves)&nbsp;from which each botanical dietary ingredient in the product is derived, as required by 21&nbsp;CFR 101.36(d)(1) and 21 CFR 101.4(h)(1). For example:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Happy Smile Herb Blend, Hawthorn Plus, Stomach Miracle (120 capsules and 270&nbsp;capsules), Super Dandelion Capsules, and Vital:\u003Cbr>\no Not all ingredients indicate the plant part used. The label must list the English name&nbsp;of the plant part; for example, root instead of radix. Furthermore, herb (herba) does&nbsp;not describe the plant part; if the entire plant is used, indicate this by stating “whole&nbsp;plant.”\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Almond Plus (300 pills and 600 pills):\u003Cbr>\no Red date, bitter almond, and wild yam do not indicate the plant part used.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> King Kong:\u003Cbr>\no Asparagus extract, aged red ginseng extract, Dried Seal Extract, and Achyranthes&nbsp;Extract ingredients do not indicate the plant part used.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> LIV-97:\u003Cbr>\no Artemissa [sic], Jasmine, dragons blood, Neroli, Tree of Heaven, Oldenlandia,&nbsp;Honey Suckle [sic] ingredients do not indicate the plant part.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Thorough Wax Extract:\u003Cbr>\no Thorough Wax Extract, Water Lavage [sic] Extract, American Ginseng Extract, and&nbsp;Origanum Extract do not indicate the plant part used.\u003Cbr>\n\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Woolly:\u003Cbr>\no Woolly grass, bitter orange, and shave grass do not indicate the plant part used.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Yellow Dragon:\u003Cbr>\no Sea dragon extract, Indian bread extract, achyranthes extract, and water plantain&nbsp;extract do not indicate the plant part used.\u003C\u002Fp>\n\n\u003Cp>5. Your Happy Smile Herb Blend products, Stomach Miracle (120 capsules and 270&nbsp;capsules), and Vital products are misbranded within the meaning of section 403(f) of the&nbsp;Act [21 U.S.C. § 343(f)] because the product labels contain information in two languages&nbsp;but do not repeat all the required information in both languages. As required by 21 CFR&nbsp;101.15(c), if a product label contains any representation in a foreign language or foreign\u003Cbr>\ncharacters, all words, statements, and other information required by or under authority of&nbsp;the Act to appear on the label must appear in the foreign language.\u003C\u002Fp>\n\n\u003Cp>6. Your Happy Smile Herb Blend and Stomach Miracle (120 capsules and 270 capsules),&nbsp;and Vital products are misbranded within the meaning of section 403(a)(1) of the Act [21&nbsp;U.S.C. § 343(a)(1)] because the labels are false and misleading. Specifically:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your Happy Smile Herb Blend product label states each capsule contains 500 mg and&nbsp;the serving size is 3 capsules with the amount per serving as 1,500 mg, but the sum&nbsp;of the dietary ingredients listed in the Supplement Facts is 765 mg,. Therefore,&nbsp;according to list in the Supplement Facts panel, the amount per capsule would be 255&nbsp;mg, which does not match the 500 mg listed on the label.\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your Stomach Miracle (120 capsules and 270 capsules), product labels state each&nbsp;capsule contains 500 mg and the serving size is 3 capsules with the amount per&nbsp;serving as 1,500 mg, but the sum of the dietary ingredients listed in the Supplement&nbsp;Facts is 1150 mg. Therefore, according to list in the Supplement Facts panel, the&nbsp;amount per capsule would be 383 mg, which does not match the 500 mg listed on the&nbsp;label.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your Vital product label states each capsule contains 500 mg and the serving size is&nbsp;3 capsules with the amount per serving as 1,500 mg, but the sum of the dietary&nbsp;ingredients listed in the Supplement Facts is 1210 mg. Therefore, according to list in&nbsp;the Supplement Facts panel, the amount per capsule would be 403 mg, which does&nbsp;not match the 500 mg listed on the label.\u003C\u002Fp>\n\n\u003Cp>7. Your Almond Plus (300 pills and 600 pills), King Kong, LIV-97, Thorough Wax Extract,&nbsp;and Yellow Dragon products are misbranded within the meaning of section 403(q)(1)(A)&nbsp;of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is&nbsp;incorrect. Serving size for a dietary supplement is the maximum amount consumed per&nbsp;eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and&nbsp;21 CFR 101.12(b) Table 2. Specifically:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your Almond Plus (300 pills and 600 pills) product label fails to list the serving size.\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your King Kong product label suggests consumers take 3-5 pills twice daily, but the&nbsp;serving size is 3 pills. The serving size should be 5 pills.\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your LIV-97 product label suggests consumers take 8-12 pills twice daily, but the&nbsp;serving size is 3 pills. The serving size should be 12 pills.\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your Thorough Wax Extract product label directs consumers to take 3-6 capsules 2&nbsp;times daily, but the serving size is 3 capsules. The serving size should be 6 capsules.\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> Your Yellow Dragon product label suggests consumers take 2-5 capsules twice daily,&nbsp;but the serving size is 2 capsules. The serving size should be 5 capsules.\u003C\u002Fp>\n\n\u003Cp>8. Your Almond Plus (300 pills and 600 pills), Hawthorn Plus, LIV-97, Super Dandelion&nbsp;Capsules, Thorough Wax Extract, Woolly, and Yellow Dragon products are misbranded&nbsp;within the meaning of section 403(s)(2)(A)(ii) of the Act [21 U.S.C. § 343 (s)(2)(A)(ii)] in&nbsp;that the product label fails to include the quantitative amount by weight per serving size&nbsp;of each dietary ingredient or fails to include the total quantitative amount by weight per\u003Cbr>\nserving size of all dietary ingredients in a proprietary blend as required by 21 CFR 101.36.\u003C\u002Fp>\n\n\u003Cp>9. Your LIV-97, Stomach Miracle (120 capsules and 270 capsules), Thorough Wax Extract,&nbsp;and Yellow Dragon products are misbranded within the meaning of Section 403(r)(6) of&nbsp;the Act [21 U.S.C. § 343(r)(6)] because the label makes structure function claims but fails&nbsp;to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b).&nbsp;For example: Your product labels do not bear a symbol next to all structure\u002Ffunction claims&nbsp;linking the claims to the FDA disclaimer.\u003C\u002Fp>\n\n\u003Cp>10. Your Stomach Miracle (120 capsules and 270 capsules) and Happy Smile Herb Blend&nbsp;products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. §&nbsp;343(w)] in that the finished product labels fail to declare the major food allergen oyster.&nbsp;Section 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean&nbsp;shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that\u003Cbr>\ncontains protein derived from one of these foods, with the exception of highly refined oils&nbsp;as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not&nbsp;a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains,&nbsp;a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The word “Contains” followed by the name of the food source from which the major&nbsp;food allergen is derived, is printed immediately after or adjacent to the list of&nbsp;ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> The common or usual name of the major food allergen in the list of ingredients is&nbsp;followed in parentheses by the name of the food source from which the major food&nbsp;allergen is derived [e.g. “Whey (Milk)”], except the name of the food source is not&nbsp;required when either the common or usual name of the ingredient uses the name of&nbsp;the food source, or the name of the food source appears else-where in the ingredient&nbsp;list (unless the name of the food source that appears elsewhere in the ingredient list&nbsp;appears as part of the name of an ingredient that is not a major food allergen), section&nbsp;403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003Cbr>\n\u003Cbr>\nThis letter is not intended to be an all-inclusive statement of violations that may exist in&nbsp;connection with your products. You are responsible for investigating and determining the&nbsp;causes of any violations and for preventing their recurrence or the occurrence of other&nbsp;violations. It is your responsibility to ensure that your firm complies with all requirements of&nbsp;federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them.&nbsp;Failure to adequately address this matter may result in legal action including, without&nbsp;limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>We offer the following comments:\u003C\u002Fp>\n\n\u003Cp>1. Your Stomach Miracle (120 capsules and 270 capsules) and Vital product labels bear the&nbsp;statement of identity as “Herbal Food Supplement.” While “Herbal Supplement” is an&nbsp;appropriate statement of identity, the term “Food Supplement” is not appropriate because&nbsp;it does not identify or describe the dietary ingredients or combination of ingredients that&nbsp;the product supplies. Your Hawthorn Plus product label misspells the dietary ingredient&nbsp;betelnut and your Yellow Dragon label misspells the dietary ingredient teasel.\u003C\u002Fp>\n\n\u003Cp>2. Your Happy Smile Herb Blend, Stomach Miracle (120 capsules and 270 capsules), Super&nbsp;Dandelion Capsules, Vital, and Woolly product labels list Other Ingredients: Gelatin&nbsp;(capsule) within the Supplement Facts label. The ingredients list should be located&nbsp;outside and directly below the Supplement Facts label in accordance with 21 CFR&nbsp;101.4(g).\u003C\u002Fp>\n\n\u003Cp>3. Your Happy Smile Herb Blend, Hawthorn Plus, Stomach Miracle (120 capsules and 270&nbsp;capsules), Super Dandelion Capsules, Vital, and Woolly product labels fail to indent the&nbsp;dietary ingredients contained in the proprietary blend under the term “Proprietary Blend”&nbsp;as required by 21 CFR 101.36(c)(2).\u003C\u002Fp>\n\n\u003Cp>4. Your Thorough Wax Extract product label’s information panel includes nutrition&nbsp;information intermingled with information that is considered intervening material. An&nbsp;example of intervening material is “Product contains no sugar, starch, ….” All information&nbsp;appearing on the information panel of the product label should appear in one place&nbsp;without other intervening material [21 CFR 101.2(e)].\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific&nbsp;steps you have taken to address any violations. Include an explanation of each step being&nbsp;taken to prevent the recurrence of violations, as well as copies of related documentation. If&nbsp;you cannot complete corrective actions within 15 working days, state the reason for the delay&nbsp;and the time within which you will do so. If you believe that your products are not in violation&nbsp;of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n\u003Cbr>\nPlease send your written response to the U.S. Food and Drug Administration, Attention: Chad&nbsp;J. Whitwell, Compliance Officer, at the following email: Chad.Whitwell@fda.hhs.gov&nbsp;(preferred) or you may also mail a hard copy addressed to Chad J. Whitwell, Compliance&nbsp;Officer, U.S. Food and Drug Administration at 1201 Main St, Suite 7200, Dallas, TX 75202.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Mr. Whitwell at 214-253-5328 or by email.\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\n&nbsp;Edmundo Garcia, Jr.\u003Cbr>\n&nbsp;Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –&nbsp;West Division 3&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Overnight Delivery\n\nSignature Required\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Canh L. Duong\n\nRecipient Title\n\nOwner\n\nAmerican Chinese Natural Herbs, Inc.\n\n2205 Executive Drive\n\nGarland, TX 75041\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations West Division 3\n\n1201 Main St., Suite 7200\n\nDallas, TX 75202\n\nUnited States\n\nWARNING LETTER\n\nFebruary 10, 2023\n\nCMS# 631597\n\nDear Dr. Duong:\n\nThe U.S. Food and Drug Administration (FDA or we) conducted an inspection of your facility located at 2205 Executive Drive, Garland, TX 75041 from February 15, 2022 through March 17, 2022, and we also reviewed labels for your products. Based on inspectional findings, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and the FDA’s regulations through links on FDA’s home page at www.fda.gov.\n\nWe received your written response dated March 29, 2022, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We have reviewed that document and our comments on your response are listed following each of the significant violations.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility revealed significant violations of the Current Good Manufacturing Practice (CGMP) regulations for Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations, Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of CGMP requirements are as follows:\n\n1. You failed to establish the required specifications for each component used in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b). Specifically, you did not establish specifications for the components used for your dietary supplement products. For example, you have not established component specifications for the identity of the following dietary ingredients:\n\n• Thorough Wax Extract used in Hawthorn Plus, Super Dandelion Capsules, and Thorough Wax Extract product;\n\n• American Ginseng Extract used in Thorough Wax Extract;\n\n• Oyster Extract used in King Kong and Thorough Wax Extract;\n\n• Ginger Root used in Happy Smile Herb Blend;\n\n• Prunella Vulgaris used in Stomach Miracle;\n\n• Mulberry Leaf used in Stomach Miracle, Wooly, and Vital; and Bitter Almond Extract used in Almond Plus.\n\nWe have reviewed your response dated March 29, 2022. You state that you are obtaining monographs for ingredients from “(b)(4)” and that you are identifying tests and testing equipment such as HPLC; however, we are unable to evaluate the adequacy of your corrective actions because you did not provide documentation to show that your firm has established component specifications.\n\n2. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you provided a product list with approximately 50 different types of products in different tablet or capsule numbers. You provided a sheet with a list of ingredients and weights for approximately 12 of your products. Your “specification sheets” only indicate the ingredients and weights.\n\nWe have reviewed your response dated March 29, 2022, and it is inadequate. With regards to your response for finished product identity specifications, your proposed corrective action of using organoleptic attributes (feel and color) along with microscopic photos of the powder within your capsules does not provide sufficient detail for your firm to be able confirm the identity of the finished product, and it does not ensure that you can distinguish one product from any other mix of powdered substances.\n\n3. You failed to establish MMRs for your products that include all elements required by 21 CFR 111.210. Specifically, the MMR for your products Stomach Miracle, Thorough Wax Extract, and Almond Plus, failed to include the information required by 21 CFR 111.210, such as:\n\n• The name of the dietary supplement to be manufactured and the strength, concentration, weight, or measure of each dietary ingredient for each batch size, as required by 21 CFR 111.210(a);\n\n• A complete list of components to be used, as required by 21 CFR 111.210(b);\n\n• An accurate statement of the weight or measure of each component to be used, as required by 21 CFR 111.210(c);\n\n• The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement, as required by 21 CFR 111.210(d);\n\n• A statement of any intentional overage amount of a dietary ingredient, as required by 21 CFR 111.210(e);\n\n• A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label, as required by 21 CFR 111.210(g);\n\n• Written instructions, as required by 21 CFR 111.210(h), including the following:\n\no Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record as required by 21 CFR 111.210(h)(1);\n\no Procedures for sampling and a cross-reference to procedures for tests or examinations as required by 21 CFR 111.210(h)(2);\n\no Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.210(h)(3).\n\n▪ Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component, as required by 21 CFR 111.210(h)(3)(i); and\n\n▪ For manual operations, such specific actions must include, as required by 21 CFR 111.210(h)(3)(ii):\n\n• One person weighing or measuring a component and another person verifying the weight or measure, as required by 21 CFR 111.210(h)(3)(ii)(A);\n\nand\n\n• One person adding the component and another person verifying the addition, as required by 21 CFR 111.210(h)(3)(ii)(B).\n\no Special notations and precautions to be followed, as required by 21 CFR 111.210(h)(4); and\n\no Corrective action plans for use when a specification is not met, as required by 21 CFR 111.210(h)(5).\n\n4. You failed to prepare a batch production record every time you manufactured a batch of dietary supplement as required by 21 CFR 111.255(a). Specifically, during the inspection, your firm did not have batch production records (BPRs) for all products that had been manufactured, such as Almond Plus and Stomach Miracle.\n\n5. Your BPRs for Stomach Miracle, Thorough Wax Extract, and Almond Plus did not include complete information as required by 21 CFR 111.260. Specifically, your BPRs lack:\n\n• The unique identifier that you assigned to each component (or, when applicable, to a product that you receive from a supplier for packaging or labeling as a dietary supplement), packaging, and label used, as required by 21 CFR 111.260(d);\n\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing as required by 21 CFR 111.260(f);\n\n• The actual results obtained during any monitoring operation as required by 21 CFR 111.260(g);\n\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results as required by 21 CFR 111.260(h);\n\n• Documentation that the finished dietary supplement meets specifications established in accordance with Sec. 111.70(e) and (g) as required by 21 CFR 111.260(i);\n\n• Documentation, at the time of performance, of the manufacture of the batch, including:\n\n• The date on which each step of the master manufacturing record was performed; and The initials of the persons performing each step, including: The initials of the person responsible for weighing or measuring each component used in the batch; The initials of the person responsible for verifying the weight or measure of each component used in the batch; The initials of the person responsible for adding the component to the batch; and The initials of the person responsible for verifying the addition of components to the batch results as required by 21 CFR 111.260 (j);\n\n• Documentation, at the time of performance, of packaging and labeling operations, including: The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels; An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record; and The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results as required by 21 CFR 111.260(k);\n\n• Documentation at the time of performance that quality control personnel: Reviewed the batch production record, including: Review of any monitoring operation required under subpart E of this part; and Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements; Approved or rejected any reprocessing or repackaging; and Approved and released, or rejected, the batch for distribution, including any reprocessed batch; and Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement, as required by 21 CFR 111.260(l);\n\n• Documentation at the time of performance of any required material review and disposition decision, as required by 21 CFR 111.260 (m); and\n\n• Documentation at the time of performance of any reprocessing as required by 21 CFR 111.260(n).\n\nIn your response from March 29, 2022, you state that you are planning to implement electronic batch production records. You did not provide an example or documents showing your implementation of electronic batch production records, so we are unable to evaluate the adequacy of your corrective actions.\n\n7. You failed to establish and follow written procedures to fulfill the requirements of Subpart O (Product Complaints), as required by 21 CFR 111.553. Specifically, you provided the investigator with a “Return Policy for product Complaints.” The policy states that you refund or exchange the product, that you refer to the “Batch Production Record” and that your quality control personnel reexamine the batch “to ensure [whether] the batch was contaminated.” It also states that if multiple reports and complaints are received “in a (b)(4) time span,” that the batch will be sent to a laboratory for testing. Your product complaint procedures failed to include that a qualified person will review all product complaints (not only on the basis of returned products) and will investigate any product complaint that involves a possible failure of a dietary supplement to meet any of its specifications, or any other requirements of this part, including those specifications and other requirements that, if not met, may result in a risk of illness or injury, not only when you have multiple reports or complaints, as required by 21 CFR 111.560(a).\n\n8. Your firm failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision as required by 21 CFR 111.103. Specifically, your firm did not establish written procedures that included procedures to follow for conducting a material review and make a disposition decision for each lot of finished dietary\n\nsupplement products manufactured and distributed under your own label name, American Chinese Natural Herbs.\n\nYour firm’s March 29, 2022, response stated that you are in the process of developing new standard operating procedures however, we are unable to evaluate the adequacy of your corrective actions because you did not provide examples of those new standard operating procedures.\n\nMisbranded Dietary Supplements\n\nIn addition, we reviewed product labels collected during the inspection and have determined that your Almond Plus (300 Pills), Almond Plus (600 pills), Stomach Miracle (120 capsules and 270 capsules), LIV-97, Yellow Dragon, King Kong, Vital, Happy Smile Herb Blend, Hawthorn Plus, Thorough Wax Extract, Woolly, and Super Dandelion Capsules products are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Almond Plus (300 pills) product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343 (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36(a). For example, your Almond Plus (300 pills) product label fails to present the nutrition information in the form of a supplement facts label.\n\n2. Your Almond Plus (300 pills) product is misbranded within the meaning of 403(s)(2)(B) of the Act [21 U.S.C. § 343 (s)(2)(B)] because it does not include a statement of identity as a “dietary supplement” as required by 21 CFR 101.3(g).\n\n3. Your Almond Plus (300 pills and 600 pills), Stomach Miracle (120 capsules and 270 capsules), LIV-97, Yellow Dragon, King Kong, Vital, Happy Smile Herb Blend, Hawthorn Plus, Thorough Wax Extract, Woolly, and Super Dandelion Capsules products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the label fails to declare the common or usual name of each ingredient used as required by 21 CFR 101.4 and 21 CFR 101.36. For example:\n\n• Almond Plus (300 pills and 600 pills):\n\no Declares red date and melissa but fails to declare the standardized common names jujube and lemon balm, respectively, as listed in the reference Herbs of Commerce (HOC).\n\no Declares mimosa, but this is not the common or usual name of a dietary ingredient.\n\no Sand is not in HOC; therefore, the Latin binomial must be declared in accordance with 21 CFR 101.4(h)(2).\n\n• Happy Smile Herb Blend:\n\no Declares glehniae, patriniae, longanae, ophiopogonis, polygalae, and astragail, but the standardized common names must be stated in English as glehnia, patrinia, longan, ophiopogon, polygala, and astragalus, respectively.\n\no Declares Ganoderma lucidum, Poria cocos, Zizphy spinosae, Nelumbinis, red date, and Coicis, but fails to declare the standardized common names reishi, poria, jujube, sacred lotus, jujube, and Job’s tears, respectively, as listed in HOC.\n\no Declares concha pteriae and atralodis, but these are not the common or usual names of dietary ingredients.\n\n• Hawthorn Plus:\n\no Declares nut grass, thorough wax, tree of heaven, and Indian bread, but fails to declare the standardized common names Cyperus, bupleurum, Chinese tree-ofheaven or Indian tree-of-heaven, and poria, respectively, as listed in HOC.\n\no Batavia and sand are not in HOC; therefore, the Latin binomial must be declared in accordance with 21 CFR 101.4(h)(2).\n\n• King Kong:\n\no Declares Rubi but this is not the common or usual name of a dietary ingredient.\n\n• LIV-97:\n\no Declares artemissa [sic], thorough wax, tree of heaven, neroli, tang kuei, and oldenlandia, but fails to declare the standardized common names sweet wormwood, bupleurum, Chinese tree-of-heaven or Indian tree-of-heaven, bitter orange, dong quai, and hedyotis, respectively, as listed in HOC.\n\no Declares dragons blood but fails to declare the standardized common name dragon’s blood croton which is indicated by the Latin binomial listed in the finished product specification sheet provided during the inspection.\n\no Batavia and sand are not in HOC; therefore, the Latin binomial must be declared in accordance with 21 CFR 101.4(h)(2).\n\no Declares cyperi but the standardized common name must be stated in English as cyperus.\n\n• Stomach Miracle:\n\no Declares Prunella vulgaris, Psoralea coryliflia, Verbena officinalis, Xanthium sibiricum, Eclipta prostrata, Mesoma [sic] chinensis, Curcuma longa L., Agrimonia Pilosa, Zea mays, and Ziziphus jujuba, but fails to declare the standardized common names heal all, psoralea, European vervain, xanthium, eclipta, mesona, turmeric, agrimony, corn, and jujube, respectively, as listed in HOC.\n\no Declares Oytrea densekamellosa [sic] but fails to declare the common or usual name oyster.\n\n• Super Dandelion Capsules\n\no Declares tang kuei, red peony, thorough wax, and tree of heaven, but fails to declare the standardized common names dong quai, Chinese peony, bupleurum, and Chinese tree-of-heaven or Indian tree-of-heaven, respectively, as listed in HOC.\n\no Declares origanum, silver, red, and liquidambaris, but these are not the common or usual names of dietary ingredients.\n\n• Thorough Wax Extract:\n\no Your product is manufactured into capsules, but the product label fails to list the ingredients used to form the capsules.\n\no Declares thorough wax and tang kuei, but fails to declare the standardized common names bupleurum, dong quai, respectively, as listed in HOC.\n\no Declares water lavage[sic], mimosa, origanum, silver, and liquidambaris, but these are not the common or usual names of dietary ingredients.\n\no Regarding the botanical ingredient “water lavage [sic] extract”, please provide the Latin Binomial (Genus and species) of the water lovage extract ingredient, the identity specification for the ingredient, a Certificate of Analysis from the supplier, and testing that can verify the identity of the ingredient you used in the manufacture of the Thorough Wax Extract dietary supplement. Some synonyms to Water Lovage are Water Hemlock or Hemlock Water Dropwort. These synonyms correspond to Oenanthe crocata L., which is a poisonous plant of the Apiaceae family.\n\n• Vital:\n\no Declares Polygonum aviculare L, Prunus japonica, Plumeria rubra L, Luffa cylindrica, Rubia cordifolia, and red date, but fails to declare the standardized common names knotweed, Japanese bush cherry, frangipani, luffa, Indian madder, and jujube, respectively, as listed in HOC.\n\no Declares mimosa, plantage, and acanthopanacis, but these are not the common or usual names of dietary ingredients.\n\n• Wooly:\n\no Declares woolly grass and shave grass but fails to declare the standardized common names imperata and giant horsetail, respectively, as listed in HOC.\n\no Declares plantage and cocklebur, but these are not the common or usual names of dietary ingredients.\n\n• Yellow Dragon:\n\no White man is not in HOC; therefore, the Latin binomial must be declared in accordance with 21 CFR 101.4(h)(2).\n\no Declares celadine, dogwood, and peony, but these are not the common or usual names of dietary ingredients.\n\no Declares Indian bread but fails to declare the standardized common names poria as listed in HOC.\n\no Your product is manufactured into capsules, but the product label fails to list the ingredients used to form the capsules.\n\n4. Your Almond Plus (300 pills and 600 pills), Happy Smile Herb Blend, Hawthorn Plus, Stomach Miracle (120 capsules and 270 capsules), King Kong, LIV-97, Vital, Super Dandelion Plus, Thorough Wax Extract, Woolly, and Yellow Dragon products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.36(d)(1) and 21 CFR 101.4(h)(1). For example:\n\n• Happy Smile Herb Blend, Hawthorn Plus, Stomach Miracle (120 capsules and 270 capsules), Super Dandelion Capsules, and Vital:\n\no Not all ingredients indicate the plant part used. The label must list the English name of the plant part; for example, root instead of radix. Furthermore, herb (herba) does not describe the plant part; if the entire plant is used, indicate this by stating “whole plant.”\n\n• Almond Plus (300 pills and 600 pills):\n\no Red date, bitter almond, and wild yam do not indicate the plant part used.\n\n• King Kong:\n\no Asparagus extract, aged red ginseng extract, Dried Seal Extract, and Achyranthes Extract ingredients do not indicate the plant part used.\n\n• LIV-97:\n\no Artemissa [sic], Jasmine, dragons blood, Neroli, Tree of Heaven, Oldenlandia, Honey Suckle [sic] ingredients do not indicate the plant part.\n\n• Thorough Wax Extract:\n\no Thorough Wax Extract, Water Lavage [sic] Extract, American Ginseng Extract, and Origanum Extract do not indicate the plant part used.\n\n• Woolly:\n\no Woolly grass, bitter orange, and shave grass do not indicate the plant part used.\n\n• Yellow Dragon:\n\no Sea dragon extract, Indian bread extract, achyranthes extract, and water plantain extract do not indicate the plant part used.\n\n5. Your Happy Smile Herb Blend products, Stomach Miracle (120 capsules and 270 capsules), and Vital products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. § 343(f)] because the product labels contain information in two languages but do not repeat all the required information in both languages. As required by 21 CFR 101.15(c), if a product label contains any representation in a foreign language or foreign\n\ncharacters, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language.\n\n6. Your Happy Smile Herb Blend and Stomach Miracle (120 capsules and 270 capsules), and Vital products are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] because the labels are false and misleading. Specifically:\n\n• Your Happy Smile Herb Blend product label states each capsule contains 500 mg and the serving size is 3 capsules with the amount per serving as 1,500 mg, but the sum of the dietary ingredients listed in the Supplement Facts is 765 mg,. Therefore, according to list in the Supplement Facts panel, the amount per capsule would be 255 mg, which does not match the 500 mg listed on the label.\n\n• Your Stomach Miracle (120 capsules and 270 capsules), product labels state each capsule contains 500 mg and the serving size is 3 capsules with the amount per serving as 1,500 mg, but the sum of the dietary ingredients listed in the Supplement Facts is 1150 mg. Therefore, according to list in the Supplement Facts panel, the amount per capsule would be 383 mg, which does not match the 500 mg listed on the label.\n\n• Your Vital product label states each capsule contains 500 mg and the serving size is 3 capsules with the amount per serving as 1,500 mg, but the sum of the dietary ingredients listed in the Supplement Facts is 1210 mg. Therefore, according to list in the Supplement Facts panel, the amount per capsule would be 403 mg, which does not match the 500 mg listed on the label.\n\n7. Your Almond Plus (300 pills and 600 pills), King Kong, LIV-97, Thorough Wax Extract, and Yellow Dragon products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\n\n• Your Almond Plus (300 pills and 600 pills) product label fails to list the serving size.\n\n• Your King Kong product label suggests consumers take 3-5 pills twice daily, but the serving size is 3 pills. The serving size should be 5 pills.\n\n• Your LIV-97 product label suggests consumers take 8-12 pills twice daily, but the serving size is 3 pills. The serving size should be 12 pills.\n\n• Your Thorough Wax Extract product label directs consumers to take 3-6 capsules 2 times daily, but the serving size is 3 capsules. The serving size should be 6 capsules.\n\n• Your Yellow Dragon product label suggests consumers take 2-5 capsules twice daily, but the serving size is 2 capsules. The serving size should be 5 capsules.\n\n8. Your Almond Plus (300 pills and 600 pills), Hawthorn Plus, LIV-97, Super Dandelion Capsules, Thorough Wax Extract, Woolly, and Yellow Dragon products are misbranded within the meaning of section 403(s)(2)(A)(ii) of the Act [21 U.S.C. § 343 (s)(2)(A)(ii)] in that the product label fails to include the quantitative amount by weight per serving size of each dietary ingredient or fails to include the total quantitative amount by weight per\n\nserving size of all dietary ingredients in a proprietary blend as required by 21 CFR 101.36.\n\n9. Your LIV-97, Stomach Miracle (120 capsules and 270 capsules), Thorough Wax Extract, and Yellow Dragon products are misbranded within the meaning of Section 403(r)(6) of the Act [21 U.S.C. § 343(r)(6)] because the label makes structure function claims but fails to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b). For example: Your product labels do not bear a symbol next to all structure\u002Ffunction claims linking the claims to the FDA disclaimer.\n\n10. Your Stomach Miracle (120 capsules and 270 capsules) and Happy Smile Herb Blend products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)] in that the finished product labels fail to declare the major food allergen oyster. Section 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that\n\ncontains protein derived from one of these foods, with the exception of highly refined oils as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\n• The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\n\n• The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived [e.g. “Whey (Milk)”], except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source, or the name of the food source appears else-where in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nWe offer the following comments:\n\n1. Your Stomach Miracle (120 capsules and 270 capsules) and Vital product labels bear the statement of identity as “Herbal Food Supplement.” While “Herbal Supplement” is an appropriate statement of identity, the term “Food Supplement” is not appropriate because it does not identify or describe the dietary ingredients or combination of ingredients that the product supplies. Your Hawthorn Plus product label misspells the dietary ingredient betelnut and your Yellow Dragon label misspells the dietary ingredient teasel.\n\n2. Your Happy Smile Herb Blend, Stomach Miracle (120 capsules and 270 capsules), Super Dandelion Capsules, Vital, and Woolly product labels list Other Ingredients: Gelatin (capsule) within the Supplement Facts label. The ingredients list should be located outside and directly below the Supplement Facts label in accordance with 21 CFR 101.4(g).\n\n3. Your Happy Smile Herb Blend, Hawthorn Plus, Stomach Miracle (120 capsules and 270 capsules), Super Dandelion Capsules, Vital, and Woolly product labels fail to indent the dietary ingredients contained in the proprietary blend under the term “Proprietary Blend” as required by 21 CFR 101.36(c)(2).\n\n4. Your Thorough Wax Extract product label’s information panel includes nutrition information intermingled with information that is considered intervening material. An example of intervening material is “Product contains no sugar, starch, ….” All information appearing on the information panel of the product label should appear in one place without other intervening material [21 CFR 101.2(e)].\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your written response to the U.S. Food and Drug Administration, Attention: Chad J. Whitwell, Compliance Officer, at the following email: Chad.Whitwell@fda.hhs.gov (preferred) or you may also mail a hard copy addressed to Chad J. Whitwell, Compliance Officer, U.S. Food and Drug Administration at 1201 Main St, Suite 7200, Dallas, TX 75202.\n\nIf you have questions regarding any issues in this letter, please contact Mr. Whitwell at 214-253-5328 or by email.\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 3","American Chinese Natural Herbs, Inc.","american-chinese-natural-herbs-inc-631597-02102023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-chinese-natural-herbs-inc-631597-02102023","2026-10-26T08:07:54.635323+00:00","631597","Dietary SupplementsDrugs","Dr. Canh L. Duong","2026-08-20T01:15:06.539+00:00","UPS Overnight Delivery Signature Required","2023-02-10",{"id":318,"raw":319,"subject":323,"body_html":324,"body_text":325,"firm_name":326,"letter_id":327,"created_at":43,"fei_number":19,"letter_url":328,"updated_at":329,"action_type":22,"case_status":23,"posted_date":330,"marcs_cms_no":331,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":332,"body_fetched_at":333,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":334,"medical_device_id":19,"response_letter_date":19},2127,[320,321,322,11,323,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-27T05:00:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022\">North American Diagnostics, LLC\u003C\u002Fa>","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Elizabeth A. Lashinsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>618 Ridgewood Ave., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holly Hill\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32117\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ealash52@gmail.com\"> ealash52@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 643203\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDecember 27, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lashinsky:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong> Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70.\u003C\u002Fstrong> Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fstrong> Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80.\u003C\u002Fstrong> Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong> Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a).\u003C\u002Fstrong> Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong> Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b).\u003C\u002Fstrong> Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\u003Cbr>\n\u003Cbr>\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to\u003C\u002Fstrong> COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 643203\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nBlake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-%20emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nElizabeth A. Lashinsky\n\nRecipient Title\n\nOwner\n\nNorth American Diagnostics, LLC\n\n618 Ridgewood Ave., Suite 100\n\nHolly Hill, FL 32117\n\nUnited States\n\nealash52@gmail.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 643203\n\nDecember 27, 2022\n\nDear Ms. Lashinsky:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\n\nOur inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\n\nThis inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a). Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\n\n2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70. Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\n\n3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\n\n4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80. Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\n\n5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\n\n6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a). Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\n\n7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\n\n8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b). Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\n\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\n\nWe reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\n\nYour firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 643203 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n______________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","North American Diagnostics, LLC","north-american-diagnostics-llc-643203-12272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022","2026-10-26T08:09:34.512211+00:00","2023-04-18","643203","Elizabeth A. Lashinsky","2026-08-20T01:09:41.813+00:00","2022-12-27",{"id":336,"raw":337,"subject":227,"body_html":341,"body_text":342,"firm_name":343,"letter_id":344,"created_at":171,"fei_number":19,"letter_url":345,"updated_at":346,"action_type":22,"case_status":23,"posted_date":347,"marcs_cms_no":348,"product_type":236,"closeout_date":19,"issuing_office":226,"recipient_name":349,"body_fetched_at":350,"delivery_method":239,"recipient_title":19,"reference_number":351,"action_taken_date":347,"medical_device_id":19,"response_letter_date":19},3104,[338,339,340,226,227,13,13,13],"\u003Ctime datetime=\"2021-10-07T13:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-07T04:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-american-vapes-shreveport-618050-10072021\">Great American Vapes Shreveport\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2100247\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Raymond Odom\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great American Vapes Shreveport\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>934 East 70th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shreveport\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>71106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tony@greatamericanvapes.com\"> tony@greatamericanvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Odom:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Great American Vapes LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Great American VAPES Almond 3 mg 30 ml and Great American VAPES Big Top Cotton Candy 3 mg 30 ml e-liquid products.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). &nbsp;In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 25,500 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003726, on September 9, 2020. &nbsp;However, FDA issued a negative action for STN PM0003726 in the form of a Marketing Denial Order determination on August 26, 2021, which covers 8,607 products. &nbsp;As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003726 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. &nbsp;All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. &nbsp;Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100247, in your response and direct your response to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2100247\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRaymond Odom\n\nRecipient Title\n\nOwner\n\nGreat American Vapes Shreveport\n\n934 East 70th Street\n\nShreveport, LA 71106\n\nUnited States\n\ntony@greatamericanvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDear Mr. Odom:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Great American Vapes LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Great American VAPES Almond 3 mg 30 ml and Great American VAPES Big Top Cotton Candy 3 mg 30 ml e-liquid products.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 25,500 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003726, on September 9, 2020. However, FDA issued a negative action for STN PM0003726 in the form of a Marketing Denial Order determination on August 26, 2021, which covers 8,607 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003726 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100247, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Great American Vapes Shreveport","great-american-vapes-shreveport-618050-10072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-american-vapes-shreveport-618050-10072021","2026-10-26T08:08:49.333426+00:00","2021-10-07","618050","Raymond Odom","2026-08-20T02:32:55.658+00:00","ER2100247",{"id":353,"raw":354,"subject":227,"body_html":358,"body_text":359,"firm_name":360,"letter_id":361,"created_at":210,"fei_number":19,"letter_url":362,"updated_at":363,"action_type":22,"case_status":23,"posted_date":364,"marcs_cms_no":365,"product_type":236,"closeout_date":19,"issuing_office":226,"recipient_name":366,"body_fetched_at":367,"delivery_method":239,"recipient_title":19,"reference_number":19,"action_taken_date":364,"medical_device_id":19,"response_letter_date":19},3566,[355,356,357,226,227,13,13,13],"\u003Ctime datetime=\"2021-01-29T14:00:00Z\">01\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-29T05:00:00Z\">01\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-legends-e-liquid-lllp-612929-01292021\">American Legends E-Liquid, LLLP\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Connie Hawley and Chuck W. Hawley\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>American Legends E-Liquid, LLLP\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2115 Main Street East, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Snellville\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30078\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:americanlegendseliquid.contact@gmail.com\"> americanlegendseliquid.contact@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quickchases@gmail.com\"> quickchases@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>January 29, 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Connie Hawley and Chuck W. Hawley:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Famerican-legends-e-liquid.myshopify.com\u003C\u002Fspan> \u003Cspan>and determined that the e-liquid products\u003Cb> \u003C\u002Fb>listed there are manufactured and offered for sale or distribution to customers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. §&nbsp;321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. §&nbsp;387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; \u003Ci>See\u003C\u002Fi> Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Cu>\u003Cspan>\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect.&nbsp; A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Our review of the website https:\u002F\u002Famerican-legends-e-liquid.myshopify.com\u003C\u002Fspan> \u003Cspan>revealed that you manufacture and offer for sale or distribution\u003Cb> \u003C\u002Fb>to customers in the United States e-liquid products without a marketing authorization order including: Avalon and Bazoo.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act.&nbsp; In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Conclusion and Requested Actions\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your firm is a registered manufacturer with over 600 products listed with FDA.&nbsp; It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations.\u003C\u002Fspan>&nbsp; \u003Cspan>Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction.&nbsp; However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.&nbsp; Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.&nbsp; You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please note your reference number, \u003Cspan>RW2101479\u003C\u002Fspan>, in your response and direct your response via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa> and to the following address: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301)&nbsp;796-9235 \u003Cspan>or via email at\u003C\u002Fspan> \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa>.&nbsp; &nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann Simoneau, J.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance and Enforcement \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Tobacco Products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>VIA UPS and Electronic Mail\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>cc:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>American Legends E-Liquid \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Attn: Chuck W. Hawley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>3554 Highway 20 SE \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Conyers, GA 30013\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>American Legends E-Liquid LLLP\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Chuck W. Hawley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>1931 Goode Road\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Conyers, GA, 30094\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>American Legends E-Liquid LLLP\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Joshua J. Melson \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>420 Oglesby Bridge Rd. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Conyers, GA, 30094\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Shopify, Inc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>abuse@shopify.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>MarkMonitor, Inc.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abusecomplaints@markmonitor.com \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nConnie Hawley and Chuck W. Hawley\n\nAmerican Legends E-Liquid, LLLP\n\n2115 Main Street East, Suite C\n\nSnellville, GA 30078\n\nUnited States\n\namericanlegendseliquid.contact@gmail.com\n\nquickchases@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 29, 2021\n\nWARNING LETTER\n\nDear Connie Hawley and Chuck W. Hawley:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Famerican-legends-e-liquid.myshopify.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Famerican-legends-e-liquid.myshopify.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Avalon and Bazoo.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 600 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101479, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nAmerican Legends E-Liquid\n\nAttn: Chuck W. Hawley\n\n3554 Highway 20 SE\n\nConyers, GA 30013\n\nAmerican Legends E-Liquid LLLP\n\nChuck W. Hawley\n\n1931 Goode Road\n\nConyers, GA, 30094\n\nAmerican Legends E-Liquid LLLP\n\nJoshua J. Melson\n\n420 Oglesby Bridge Rd.\n\nConyers, GA, 30094\n\nShopify, Inc.\n\nabuse@shopify.com\n\nMarkMonitor, Inc.\n\nabusecomplaints@markmonitor.com","American Legends E-Liquid, LLLP","american-legends-e-liquid-lllp-612929-01292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-legends-e-liquid-lllp-612929-01292021","2026-10-26T08:07:54.932539+00:00","2021-01-29","612929","Connie Hawley and Chuck W. Hawley","2026-08-20T03:25:25.186+00:00",{"id":369,"raw":370,"subject":376,"body_html":377,"body_text":378,"firm_name":379,"letter_id":380,"created_at":64,"fei_number":19,"letter_url":381,"updated_at":382,"action_type":22,"case_status":23,"posted_date":383,"marcs_cms_no":384,"product_type":385,"closeout_date":19,"issuing_office":374,"recipient_name":386,"body_fetched_at":387,"delivery_method":388,"recipient_title":19,"reference_number":19,"action_taken_date":389,"medical_device_id":19,"response_letter_date":19},2854,[371,372,373,374,375,13,13,13],"\u003Ctime datetime=\"2022-02-22T14:20:00Z\">02\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-02T05:00:00Z\">02\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022\">Smart Surgical, Inc dba Burst Biologics\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher D. Jones\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Smart Surgical, Inc dba Burst Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3501 W. Elder St., Ste. 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boise\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83705\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2022\u003C\u002Fp>\n\n\u003Cp>[OBPO 21-614361]\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jones:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Burst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\n\n\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\u003C\u002Fp>\n\n\u003Cp>a. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\u003C\u002Fp>\n\n\u003Cp>b. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes that up to and including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is &lt;1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)].\u003C\u002Fstrong> Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a \u003Cem>Paenibacillus\u003C\u002Fem> species, \u003Cem>Bacillus\u003C\u002Fem> non-anthracis, \u003Cem>Kocuria rhizophila\u003C\u002Fem>,&nbsp;\u003Cem>Staphylococcus hominis\u003C\u002Fem>, and \u003Cem>Micrococcus luteus\u003C\u002Fem>) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP &lt;71&gt;, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\u003Cbr>\n\u003Cbr>\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>cc\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher D. Jones\n\nRecipient Title\n\nChief Executive Officer\n\nSmart Surgical, Inc dba Burst Biologics\n\n3501 W. Elder St., Ste. 104\n\nBoise, ID 83705\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2022\n\n[OBPO 21-614361]\n\nDear Mr. Jones:\n\nDuring an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBurst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\n\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in (b)(4), an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\n\n2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\n\na. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\n\nb. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate1. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for (b)(4) days.\n\n3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\n\na. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately (b)(4) units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\n\nb. Your environmental monitoring procedure describes that up to and including (b)(4) colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is \u003C1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and (b)(4) for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)]. Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a Paenibacillus species, Bacillus non-anthracis, Kocuria rhizophila, Staphylococcus hominis, and Micrococcus luteus) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv.\n\nIn addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP \u003C71>, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\n\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\ncc\n\n(b)(6)\n\n_______________________________\n\n1 We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.","Smart Surgical, Inc dba Burst Biologics","smart-surgical-inc-dba-burst-biologics-614361-02022022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022","2026-10-26T08:09:59.293166+00:00","2022-02-22","614361","Biologics","Mr. Christopher D. Jones","2026-08-20T02:09:59.584+00:00","VIA UNITED PARCEL SERVICE","2022-02-02",{"id":391,"raw":392,"subject":227,"body_html":396,"body_text":397,"firm_name":398,"letter_id":399,"created_at":171,"fei_number":19,"letter_url":400,"updated_at":401,"action_type":22,"case_status":174,"posted_date":347,"marcs_cms_no":402,"product_type":236,"closeout_date":403,"issuing_office":226,"recipient_name":349,"body_fetched_at":404,"delivery_method":239,"recipient_title":19,"reference_number":405,"action_taken_date":347,"medical_device_id":19,"response_letter_date":19},3118,[338,339,393,226,394,13,395,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-american-vapes-bossier-city-617946-10072021\">Great American Vapes Bossier City\u003C\u002Fa>","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-american-ventures-llc-dba-great-american-vapes-617946-12072023\">\u003Ctime datetime=\"2024-09-13T04:00:00Z\">09\u002F13\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2100235\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Raymond Odom\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great American Vapes Bossier City\u003C\u002Fdd>\n\n                      \u003Cdd>Great American Ventures LLC\u003C\u002Fdd>\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4126 East Texas Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bossier City\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>71111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tony@greatamericanvapes.com\"> tony@greatamericanvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Odom:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Great American Ventures LLC d\u002Fb\u002Fa Great American Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Great American VAPES Ambrosia 6mg 120ml, Great American VAPES Apple Pie 6mg 120ml, and Great American VAPES Cucumber 6mg 120ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). &nbsp;In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 25,500 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003726, on September 9, 2020. However, FDA issued a negative action for STN PM0003726 in the form of a Marketing Denial Order determination on August 26, 2021, which covers 8,607 products. &nbsp;As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003726 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. &nbsp;All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. &nbsp;Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100235, in your response and direct your response to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2100235\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRaymond Odom\n\nRecipient Title\n\nOwner\n\nGreat American Vapes Bossier City\n\nGreat American Ventures LLC\n\n4126 East Texas Street\n\nSuite 200\n\nBossier City, LA 71111\n\nUnited States\n\ntony@greatamericanvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDear Mr. Odom:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Great American Ventures LLC d\u002Fb\u002Fa Great American Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Great American VAPES Ambrosia 6mg 120ml, Great American VAPES Apple Pie 6mg 120ml, and Great American VAPES Cucumber 6mg 120ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 25,500 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003726, on September 9, 2020. However, FDA issued a negative action for STN PM0003726 in the form of a Marketing Denial Order determination on August 26, 2021, which covers 8,607 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003726 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100235, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Great American Vapes Bossier City","great-american-vapes-bossier-city-617946-10072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-american-vapes-bossier-city-617946-10072021","2026-10-26T08:08:49.278354+00:00","617946","2024-09-13","2026-08-20T02:32:50.143+00:00","ER2100235",28,{"510k":408,"classification":409,"enforcement":410,"event":411,"event_backfill":412,"pma":413,"warning_letter":414},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]